Long-term antipsychotic polypharmacy prescribing in secondary mental health care: detection, predictors and outcomes. by Kadra-Scalzo, Giouliana
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Long-term antipsychotic polypharmacy prescribing in secondary mental health care:











Long-term antipsychotic polypharmacy 
prescribing in secondary mental health care: 
detection, predictors and outcomes. 
 
 
Giouliana Kadra-Scalzo  




Department of Psychological Medicine,  
Institute of Psychiatry, Psychology and Neuroscience,  
King’s College London  




Background: Investigating long-term antipsychotic polypharmacy is key to 
unpacking the associations between serious mental illnesses (SMI) and 
detrimental outcomes, such as premature death and frequent hospital 
readmissions, observed in this population. However, existing research is 
sparse and hampered by methodological problems such as examining small 
and homogeneous samples and residual confounding.    
 
Objectives:  
1) To identify cases on long-term antipsychotic polypharmacy (≥ 6 months) 
prescribing in South London and Maudsley electronic health records (EHR); 
2) To identify factors that predict long-term antipsychotic polypharmacy 
prescribing for SMI patients in secondary mental health care;  
3) To investigate whether outcomes such as hospital readmission and 
mortality are associated with long-term antipsychotic polypharmacy 
prescribing in secondary mental health care.  
 
Methods: Antipsychotic medication information was derived from the Clinical 
Record Interactive Search (CRIS), a de-identified electronic patient records 
system, for the period between 2007 and 2014. Data on mortality were 
extracted using existing linkages between CRIS and death certification (Office 
of National Statistics). Information about antipsychotic co-prescribing was 
extracted using a bespoke algorithm. Multivariable logistic models were built 
to investigate predictors of antipsychotic polypharmacy. To investigate the 
impact of antipsychotic polypharmacy on hospital readmission and all-cause 
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mortality, I constructed multivariable Cox proportion hazard models. To test 
the association between long-term antipsychotic polypharmacy and cause-
specific mortality I used competing risk regression.   
 
Implications: On a clinical level, this thesis provides an insight into factors 
that can predict clinical decision-making regarding antipsychotic 
polypharmacy prescribing in real-life clinical settings. On a patient level, the 
findings highlight patient burden associated with this antipsychotic regimen. In 
the wider treatment, service and policy context, the lack of patient benefit from 
antipsychotic polypharmacy highlights the need for programmes that target 
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CHAPTER 1:  BACKGROUND  
 20 
1.1 Serious mental illnesses and detrimental health outcomes  
The International Classification of Diseases, 10th edition (ICD-10) diagnoses 
of schizophrenia (F20.x), schizoaffective disorder (F25.x) and bipolar disorder 
(F31.x) are referred to as Serious Mental Illnesses (SMIs) due to their 
profound impact on individual’s cognitive, affective, behavioural and physical 
state (Stahl 2013). In addition to having a significant effect on patients’ day-to-
day functioning, SMI diagnoses have also been associated with a number of 
detrimental health outcomes. For example, hospital readmission rates into 
mental health services are high amongst this population (Weiden & Olfson 
1995; Schennach et al. 2012). Furthermore, individuals with SMI have an 
increased risk for physical health problems (Brown et al. 2000); for example, 
the prevalence of metabolic problems has been estimated to be 
approximately twice that of the general population (Reynolds & Kirk 2010). In 
addition, SMI diagnoses have been associated with an increased risk of dying 
prematurely from both natural (e.g. cardiovascular disease, respiratory 
disease) and unnatural (e.g. suicide, violence) causes, in comparison to the 
general population (Osby et al. 2000; Joukama et al. 2001; Joukama et al. 
2006; Auquier et al. 2006; Chang et al. 2011). Natural causes of death are 
among the leading cause of mortality in SMI population, with a particularly 
increased risk for cardiovascular disease (Raedler 2010). Although factors 
such as suicide, accidents, violence and poor lifestyle choices (Brown et al. 
2000; Auquier et al. 2006; Osborn et al. 2014) partially explain some of the 
above disparities, the underlying mechanisms remain unclear.  
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1.2 Antipsychotic medication   
Antipsychotic medications have been the mainstay of treatment for SMI since 
the 1950s, for both acute episodes and maintenance management (Taylor et 
al. 2009). Although antipsychotics have complex psychopharmacological 
mechanisms and differ in their therapeutic actions (e.g. efficacy, tolerability) 
and side effects, they have been loosely categorized in two groups: first- 
generation (FGAs) (i.e. typical; older) and second-generation (SGAs)(i.e. 
atypical; newer) antipsychotics (British National Formulary 2015) based on 
broad psychopharmacological properties and their chronological origin.  
 
Currently in the UK there are fourteen first-generation and eight second-
generation antipsychotics available on prescription. The British National 
Formulary (BNF) (British National Formulary 2015) provides prescription 
guidance, including minimum and maximum recommended prescribing dose. 
Antipsychotic medications have been described as having ‘the most complex 
pharmacological mechanisms of any drug class within the field of clinical 
psychopharmacology’ (Stahl 2013, p.130). Although, the detailed 
psychopharmacological mechanisms of antipsychotic treatment are beyond 
the scope of this thesis, briefly first-generation antipsychotics are primarily 
dopamine D2 receptor antagonists and target predominantly positive 
symptoms (Stahl 2013). FGAs have been associated with acute 
extrapyramidal side effects and hyperprolactinemia. SGAs refer to a group of 
antipsychotics that were introduced starting with clozapine (which was the first 
of the SGAs). They also target positive symptoms; however in contrast to 
FGAs, they have a serotonin-dopamine receptor antagonist action and have 
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been associated with lower levels of extrapyramidal side effects and 
hyperprolactinemia (Stahl 2013). However, SGAs have been associated with 
greater weight gain and metabolic problems, such as diabetes and 
dyslipidaemia (Stahl 2013; Daumit et al. 2008; Correll et al. 2009). 
Consequently patients with SMI frequently have physical health comorbidities 
(Auquier et al. 2006; Raedler 2010; Suzuki et al. 2014; Pramyothin & 
Khaodhiar 2010). In addition research has also indicated that SMI patients 
have an increased risk for comorbid diagnoses such as substance use, 
depression and personality disorder (Kreyenbuhl et al. 2007; Ganguly et al. 
2004). As a result this population could experience psychotropic and/or 
physical health medication polypharmacy for comorbid physical and other 
(than SMI) mental health problems (Kreyenbuhl et al. 2007; Ganguly et al. 
2004; Auquier et al. 2006; Raedler 2010; Suzuki et al. 2014; Pramyothin & 
Khaodhiar 2010). Studies on psychotropic and physical health medication 
polypharmacy are discussed in more detail in the Discussion section 9.7.    
 
1.3 Antipsychotic medication and detrimental health outcomes   
Antipsychotic medication prescribing has been one factor proposed to explain 
the health disparities observed between individuals diagnosed with a serious 
mental illness and the general population.  In addition to the aforementioned 
side effects, some antipsychotics have been associated with increased 
mortality (Montout et al. 2002). For example, although research has been 
sparse, there is some evidence to suggest that FGAs are associated with a 
higher mortality rate from natural causes and suicide in comparison to 
patients who have not received antipsychotic medication (Kiviniemi et al. 
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2013; Joukama et al. 2006). Research examining SGAs has been more 
ambiguous. Olanzapine has been associated with an increased risk for 
natural causes of death such as cardiovascular disease (Raedler 2010) in 
comparison to other antipsychotics. However, clozapine has been associated 
with a decreased risk of premature death from both natural and unnatural 
causes in comparison to patients taking other antipsychotics (Hayes et al. 
2014) and reduced risk of all-cause mortality compared to patients not taking 
antipsychotic medication (Kiviniemi et al. 2013). In addition, clozapine has 
been associated with reduced rehospitalisation (Valevski et al. 2012; Nielsen 
et al. 2012; Gee & Howes 2016). Further evidence has suggested that there is 
a variation in risk across different antipsychotic regimens. For example, 
patients prescribed two or more antipsychotics simultaneously (antipsychotic 
polypharmacy) have been found to have an increased risk for physical health 
problems (Ganguly et al. 2004; Brown et al. 2000; Kuo et al. 2011; Correll et 
al. 2007) and mortality (Waddington et al. 1998; Joukama et al. 2006) in 
comparison to patients prescribed monotherapy.  
 
1.4 Treatment guidelines  
Existing prescribing guidelines (NICE & NCCMH 2013; APA 2010) have been 
a pivotal reference point in clinical decision-making, by advocating evidence-
based approaches to medication prescription for SMIs. These guidelines are 
mostly derived from randomised controlled trials of antipsychotic medication, 
which are recognized as the ‘gold standard’ for establishing antipsychotic 
efficacy, although these may have limited statistical power to investigate rare 
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outcomes, relatively short duration of follow-up and limited generalizability for 
assessing risk.  
 
Current guidelines (NICE & NCCMH 2013) for the management of SMIs 
recommend that a patient is trialled on a single antipsychotic after a careful 
consideration of antipsychotic side effects, medical history and baseline 
physical examination, such as weight, waist circumference, pulse and blood 
pressure, blood glucose, blood lipid profile, prolactin levels and assessment of 
lifestyle factors (e.g. diet and physical activity). A patient whose illness has not 
responded to “the sequential use of adequate doses of at least two different 
antipsychotic drugs (at least one of the drugs should be a non-clozapine 
second-generation antipsychotic)” (NICE 2006, section 1.5.7.2) should be 
offered clozapine. If a non-response to an optimized clozapine treatment is 
further noted, NICE (NICE & NCCMH 2013) recommends that a clozapine 
augmentation should be initiated with another antipsychotic (i.e. clozapine 
polypharmacy). An adequate trial of an antipsychotic is defined as lasting for a 
minimum of 8 to10 weeks (Morrissette & Stahl 2014; Taylor et al. 2011; 
Correll et al. 2009; Paton et al. 2008). According to these guidelines, it is only 
as a last resort that two non-clozapine antipsychotics should be prescribed 
concurrently, a situation also referred to as antipsychotic polypharmacy. 
However, observational studies (Suokas et al. 2012; Sim et al. 2004) 
investigating medication prescribing in clinical settings have highlighted that 
randomised controlled trials poorly reflect ‘real-life’ clinical practice and 
decision-making, as they operate in an idealized environment and investigate 
medication administration in restricted populations and over limited time 
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spans. Furthermore, contrary to existing guidelines that recommend 
antipsychotic polypharmacy as the last alternative in treatment for 
schizophrenia (NICE & NCCMH 2013), polypharmacy is often introduced prior 
to the recommended trialling of two separate antipsychotics and clozapine 
(Lochmann van Bennekom et al. 2013).  
 
1.5 Antipsychotic polypharmacy prevalence  
Aside from clozapine polypharmacy, which has modest evidence of 
effectiveness, albeit mostly derived from open-label trials (Freudenreich & 
Goff 2002; Taylor et al. 2011), there is currently no evidence to indicate that 
antipsychotic polypharmacy is more effective as treatment than a single 
antipsychotic (i.e. monotherapy). However, contrary to existing guidelines and 
recommendations, observational studies have estimated that in real-life 
clinical practice, polypharmacy prevalence varies between 10-30% (Gallego 
et al. 2012; Freudenreich & Goff 2002) with a global median estimated at 
19.6% (Gallego et al. 2012). Antipsychotic polypharmacy prevalence 
significantly differs across countries, with US, Europe and Oceania having a 
higher prevalence in comparison to Asia (Gallego et al. 2012). In the UK, 
amongst the SMI population, polypharmacy prevalence has been estimated at 
38% in inpatient populations and 16% in individuals living in the community 
(Mace & Taylor 2015; Patel et al. 2014).  
 
1.6 Clinical rationale for antipsychotic polypharmacy prescribing  
The disparity between clinical recommendations and practice has brought 
considerable attention to antipsychotic polypharmacy. Research examining 
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the clinical rationale behind its prescribing has indicated that polypharmacy is 
frequently prescribed for the following reasons:  
i) to manage clinical symptoms after the failure of previous 
monotherapy including clozapine (Lochmann van Bennekom et 
al. 2013; Barnes & Paton 2011b);  
ii) when switching from one drug to another (Barnes & Paton 
2011b);  
iii) to deal with side effects of monotherapy such as extrapyramidal 
side effects (Barnes & Paton 2011b; Grech & Taylor 2012; Miller 
& Craig 2002);  
iv) to target particular symptoms such as aggression and negative 
symptoms, or to target residual clinical symptoms (Grech & 
Taylor 2012);  
v) to achieve more rapid response (Miller & Craig 2002; Barnes & 
Paton 2011a);  
vi) to avoid high dosing with one antipsychotic (Barnes & Paton 
2011b; Langan 2010);  
vii) when a combination that has been planned for the short term is 
continued as the patient has become ‘stuck in switching’ (this 
term has been used to indicate that polypharmacy is a 
consequence of a planned cross-titration, where following 
mental health deterioration due to medication switching, the 
patient has remained on two or more antipsychotics) (Barnes & 
Paton 2011b).  
viii) as a result of a patient declining clozapine 
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1.7 Measuring antipsychotic polypharmacy   
To date, there have been substantial differences in measuring antipsychotic 
polypharmacy, ranging from studies that have specified no temporal 
parameters for concurrent antipsychotic use (Misawa et al. 2011; Sim, Su, 
Chan, et al. 2004; Janssen et al. 2005), to studies that have specified 
concomitant prescribing for at least 28 days (Jaffe & Levine 2003), 6 weeks 
(Taylor et al. 2002; Broekema et al. 2007), 60 days (Suokas et al. 2012; 
Ganguly et al. 2004), and 90 or more days (Barbui et al. 2006; Kreyenbuhl et 
al. 2007). Consequently, comparing findings between studies has been very 
difficult. Furthermore, although existing guidelines [e.g. Maudsley Prescribing 
Guidelines (Taylor et al. 2009)] recommend a trial with a minimum duration of 
8-10 weeks in order to establish antipsychotic efficacy and observe treatment 
effect (Morrissette & Stahl 2014; Taylor et al. 2011; Correll et al. 2009; Paton 
et al. 2008), there has been a considerable paucity of research examining 
antipsychotic polypharmacy of longer duration and where a polypharmacy 
regimen is prescribed as a regular treatment.  
 
One of the most significant limitations to measuring polypharmacy of shorter 
duration has been the difficulty in distinguishing between polypharmacy that is 
intended as a regular treatment regimen and medication that is administered 
as required, otherwise known as pro re nata (PRN). Evidence from a UK audit 
(Paton et al. 2008) indicated that approximately 75.8% of antipsychotic 
polypharmacy prescriptions include PRN medication. Furthermore PRN 
medication has been cited as the prime cause for the high prevalence of 
polypharmacy and high-dose prescribing (Paton et al. 2008; Milton et al. 
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1998; Mace & Taylor 2015). An additional problem encountered by studies 
examining polypharmacy over short periods of time is the likely detection of 
antipsychotic cross-titration; otherwise known as ‘switching’. Switching 
between one antipsychotic to another involves short-periods of concomitant 
antipsychotic use, which is usually resolved within 10 weeks (Lochmann van 
Bennekom et al. 2013; Correll et al. 2009). Thus, including cross-titration as 
part of polypharmacy would yield an inflated prevalence and would not reflect 
regimens that are intended as regular long-term treatments. Lastly, 
antipsychotic polypharmacy has been largely examined amongst inpatient 
populations, where it is very prevalent, partly due to PRN medication and 
medication cross-titration (Jaffe & Levine 2003; Centorrino et al. 2004; 
Gallego et al. 2012; Broekema et al. 2007). Therefore, it is imperative to 
examine antipsychotic prescribing beyond an inpatient population.  
 
1.8 Conclusions 
Antipsychotic medication prescribing has been proposed as one of the 
contributing factors to the health disparities observed between patients with 
SMI and the general population (Montout et al. 2002; Kiviniemi et al. 2013; 
Raedler 2010). However, research has also suggested that there are 
significant variations across antipsychotic treatment regimens and negative 
outcomes (Galling et al. 2017). These findings are even more disconcerting in 
view of evidence that this regimen remains common in clinical practice across 
services, countries and time (Gallego et al. 2012; Paton et al. 2008) and 
despite a lack of empirical support and explicit recommendations against its 
use by existing guidelines (APA 2010; NICE & NCCMH 2013). Existing 
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research that has tried to examine antipsychotic polypharmacy prescribing in 
real-life clinical settings has been plagued by inconsistencies with defining 
and measuring this regimen, thus making it almost impossible to draw any 
definitive conclusions regarding the predictors and long-term consequence of 
this regimen (Boaz et al. 2013; Katona et al. 2014; Tiihonen et al. 2012; 
Waddington et al. 1998). In chapter 2, I review existing literature in detail 
examining long-term antipsychotic polypharmacy. 
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CHAPTER 2:  LITERATURE REVIEW  
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2.1 Aim  
The aim of this review was to examine all observational studies that have 
investigated predictors and outcomes of long-term antipsychotic 
polypharmacy; and to draw conclusions taking into account methodological 
limitations.  
 
2.2 Background  
There are four previous papers that have reviewed literature on antipsychotic 
polypharmacy (Langan & Shajahan 2010; Lochmann van Bennekom et al. 
2013; Correll & Gallego 2012; Weinmann et al. 2009), including one very 
recent systematic review and meta-analysis that focused specifically on 
antipsychotic augmentation and its efficacy (Galling et al. 2017). However, to 
date there has been no review examining literature on predictors and 
consequences of long-term antipsychotic polypharmacy. Examining long-term 
concomitant antipsychotic prescribing is important for several reasons. 
Kreyenbul and colleagues (Kreyenbuhl et al. 2006) reported that cross-
sectional definitions of antipsychotic polypharmacy do not accurately reflect or 
identify patients receiving regular long-term polypharmacy and omit between 
32 and 89 percent of this population. This is mainly due to cross-sectional 
methods identifying a high proportion of false positive cases (i.e. PRN 
medication and medications cross-titration) that are primarily consisting of 
short-term polypharmacy and a population with entirely different 
characteristics. Furthermore, studies looking for co-prescription of 
antipsychotic medications over short-periods (e.g. one day census) also risk 
omitting cases of polypharmacy where concomitant medications are 
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mentioned separately (e.g. in separate documents few days apart), although 
the prescriptions overlap in time (Harrington 2002). As a result, we currently 
have a poor understanding of whether certain groups are more likely to 
receive antipsychotic polypharmacy.  
 
Furthermore, we have been unable to estimate accurately the potential 
consequences of this medication regimen. This is especially important when 
we take into consideration existing literature indicating that patients with SMI 
diagnoses who use antipsychotic medications have a high risk for mental 
health hospital readmissions (Weiden & Olfson 1995; Schennach et al. 2012), 
physical health problems and death (Reininghaus et al. 2015; Joukama et al. 
2001; Saha et al. 2007), more specifically natural causes of death such as 
sudden cardiac death (Ray et al. 2009; Koponen et al. 2008; Osby et al. 
2000). Antipsychotic polypharmacy has been found to increase particularly 
the risk of sudden cardiac death (Joukama et al. 2006; Waddington et al. 
1998; Procyshyn et al. 2001; Centorrino et al. 2004) as compared to 
monotherapy. However, existing literature reviews have all included the 
examinations of studies of unspecified or short duration polypharmacy 
(typically an antipsychotic polypharmacy duration of 10 weeks or more is 
required, in order to be able to exclude cross-titration) (Langan & Shajahan 
2010; Lochmann van Bennekom et al. 2013; Correll & Gallego 2012; 
Weinmann et al. 2009). Consequently, research has potentially been subject 
to misclassification. In addition, confounding by indication is also an important 
issue to consider if we are to provide evidence to conclude that the observed 
associations can be attributed to polypharmacy prescribing alone. 
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Confounding by indication here refers to a type of confounding where patients 
prescribed antipsychotic polypharmacy are inherently different from those who 
are prescribed only one antipsychotic. 
 
In this literature review, I aimed to examine observational studies, as opposed 
to randomised control trials. Randomised controlled trials focus on 
establishing drug efficacy i.e. the performance of a medication under ideal 
circumstances. Observational studies however, have the potential to 
investigate effectiveness, which is the performance of a medication under 
real-world circumstances (Singal et al. 2014). Furthermore, antipsychotic 
polypharmacy randomised controlled trials are generally sparse due to 
difficulty in prescribing the same combination and dose of antipsychotics to a 
larger number of patients. Antipsychotic co-prescription is often done after 
careful consideration of a number of different factors such as patient’s age, 
health and lifestyle (NICE & NCCMH 2013). Furthermore, at present little is 
known about the exact mechanisms and interactions between different 
antipsychotics, therefore there is potentially increased risk for side effects 
(Auquier et al. 2006; Raedler 2010; Suzuki et al. 2014; Pramyothin & 
Khaodhiar 2010). As a result, clinical trials are often difficult to plan and 
implement. Although there have been some clinical trials investigating 
polypharmacy, they have predominantly considered clozapine augmentation 
(Freudenreich & Goff 2002; Lochmann van Bennekom et al. 2013). 
Furthermore, due to limited time of follow-up, such studies are not able to 
investigate rarer outcomes such as death. In addition, randomised controlled 
trial population samples are often carefully selected and matched on a 
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number of factors, thus making it impossible to establish predictors of this 
regimen in real-life clinical settings. Lastly, observation studies provide a 
unique opportunity to obtain a true representation of real-world clinical 
practice, patterns and outcomes, in contrast to randomised clinical trials.  
 
 
2.3 Methods   
 
2.3.1 Search strategy  
Relevant publications were ascertained by entering the following search terms 
into PubMed and Ovid (Embase; PsycINFO; Ovid Medliner; International 
Pharmaceutical Abstracts) engines: ‘serious mental illness’ OR 
‘schizophrenia’ OR ‘schizoaffective’ OR ‘bipolar’ AND ‘antipsychotic’ AND 
‘polypharmacy’ OR  ‘combination’ OR ‘polytherapy’ OR ‘concomitant’ OR 
‘addition’ OR cotreatment’ OR ‘adjunctive’ OR ‘concurrent’ OR ‘simultaneous’.    
 
2.3.2 Inclusion criteria  
I considered all cross-sectional and longitudinal observational studies of 
antipsychotic polypharmacy that were published in English, irrespective of 
their publication date, country of origin, and that operationalized the definition 
of ‘long-term polypharmacy’ by restricting the review to studies that explicitly 
ascertained and considered polypharmacy duration of at least 60 days. Most 
of the existing research in this field has rarely examined a minimum duration 
of polypharmacy of more than 60 days, therefore choosing studies with an 
antipsychotic duration over 60 days would have significantly limited the 
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number of studies I can review. Furthermore, polypharmacy of 60 days should 
be able to exclude most cases of cross-titration (see above and Chapter 1 
section 1.7). Therefore, it was considered an adequate definition of long-term 
polypharmacy for the purpose of this review. Studies that did not specify the 
duration of polypharmacy, but which investigated patients discharged from 
hospital on two or more antipsychotics, were included. The main rationale for 
this is that this group was unlikely to be undergoing cross-titration, as this is 
normally completed prior to discharge. Furthermore, the concomitant 
prescribing was very likely to have commenced some time before discharge 
and therefore, polypharmacy would reflect an intended regular treatment. 
Studies that did not include information on the length of concomitant 
prescribing were not considered, as they were most likely to include shorter 
forms of polypharmacy (e.g. PRN medication; cross-titration), based on 
examining existing literature in this field. The only exception to this rule was 
one meta-analysis (Gallego et al. 2012); although this did not only focus on 
antipsychotic polypharmacy duration of 60 or more days, it did exclude 
studies that did not provide specific information on the definition of 
polypharmacy. This meta-analysis included seven of the studies referenced in 
Table 2.1. (Barbui et al. 2006; Biancosino et al. 2005; Clark et al. 2002; Faries 
et al. 2005; Ganguly et al. 2004; Morrato et al. 2007; Kreyenbuhl et al. 2007). 
Systematic literature reviews that had not conducted a meta-analysis, and 
randomized controlled trials, were not included in this review.  
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2.4 Results  
 
2.4.1 Overview 
The search terms described above detected 883 papers. Out of those 739 
were excluded based on their title and abstract (this was mainly due to not 
investigating long-term antipsychotic polypharmacy) or because they were a 
duplicate. I excluded a further 126 as they did not satisfy the inclusion criteria, 
leaving a total of 18 research papers.  
 
Overall, six studies were based on data derived from insurance medical 
databases, four had derived data from national registers, seven had used 
data derived from clinical records, and one was a meta-analysis.  
 
The results section of this chapter catalogues these studies; whereas their 
interpretation, strengths and limitations will be discussed in the discussion 
section of this chapter (see page 66). 
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Table 2.1 summarises published research that has investigated prevalence, 
predictors or consequences of concomitant antipsychotic prescribing for 60 or 
more days, in patients with SMI. The table includes information about the 
primary author, year and country the study was carried out in. In addition, the 
sample size, data source (e.g. medication prescription database, clinical 
records), study design, inclusion criteria and definition of antipsychotic 
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2.4.2 Predictors of antipsychotic polypharmacy    
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Age has been extensively investigated by previous studies; however evidence 
appears mixed. One large US cohort study (Ortiz et al. 2016)(N=86,034) 
reported that patients aged between 35 and 44 years are more likely to be 
prescribed antipsychotic polypharmacy, as compared to patients aged 18-24 
years (OR=1.09, 95% CI: 1.01- 1.19). However, evidence from a meta-
regression including 147 studies and 1,418,163 patients indicated that age did 
not seem to be associated with antipsychotic polypharmacy prescribing 
(Spearman’s rho r=-0.09; p=0.31) (Gallego et al. 2012). This finding was 
further supported by an Italian cohort study [(Santone et al. 2011); (t=-0.929; 
p>0.05)] examining mental health records of inpatients with SMI. A large 
Finnish register based study (Suokas et al. 2012) further drew a distinction 
between chronic and recent-onset schizophrenia outpatients and indicated 
that although age was not associated with antipsychotic polypharmacy in 
chronic schizophrenia, older age was associated with lower risk for 
polypharmacy in recent-onset schizophrenia outpatients (Suokas et al. 2012). 
A large US cohort study (Morrato et al. 2007) investigating patients eligible for 
mental health insurance (Medicaid) in five states, also reported that younger 
patients were at an increased risk for polypharmacy. Similarly, another large 
US study (n=45,571) investigating veterans clinical records, indicated that 
patients were more likely to receive polypharmacy as opposed to 
monotherapy if they were younger [(Kreyenbuhl et al. 2007); OR=0.99, 95% 





Evidence regarding the role of gender in predicting antipsychotic 
polypharmacy prescribing has also been mixed. Four large cohort studies 
reported that being male is associated with increased risk for antipsychotic 
polypharmacy prescribing (Santone et al. 2011; Morrato et al. 2007; Suokas 
et al. 2012; Ganguly et al. 2004). The first mentioned study above (Santone et 
al. 2011) examined a nationwide psychiatric inpatient sample in Italy 
(n=1,022) and found that males were more likely to receive antipsychotic 
polypharmacy (as opposed to antipsychotic monotherapy) than females (x2= 
4.99; p =0.026). The second study (Morrato et al. 2007) examined medical 
insurance records for 55,481 patients across five US states and found that 
men were more likely to receive a polypharmacy prescription (OR=1.26; 95% 
CI: 1.14-1.39). The third study similarly examined medical insurance records 
in two US states (Ganguly et al. 2004) and reported an association (OR=1.15; 
95% CI: 1.02- 1.29; p=0.0197) between male gender and polypharmacy. A 
fourth study (Suokas et al. 2012) examined 16,083 schizophrenia outpatients 
in Finland using a national health register and similarly found that males were 
more like to be prescribed antipsychotic polypharmacy (OR=1.25; 95% CI: 
1.13-1.4). However, three studies also found no evidence to indicate that 
gender had an effect on the likelihood to receive polypharmacy prescription. 
Ortiz et al. (Ortiz et al. 2016) examined 86,034 inpatients at discharge, 
nationally across the US and found that males were no more likely to receive 
polypharmacy than female patients (OR=1.00, 95% CI: 0.95- 1.05). Similarly, 
a large Veterans Affairs US study also reported no difference in risk between 
being prescribed antipsychotic polypharmacy or monotherapy across the 
 56 
genders (OR=1.1, 95% CI: 0.92-1.19)(Kreyenbuhl et al. 2007). Evidence from 
a large meta-analysis (Gallego et al. 2012) investigating 1,418,163 patients 




Three large studies (Morrato et al. 2007; Gallego et al. 2012; Kreyenbuhl et al. 
2007) investigated the association between ethnicity and antipsychotic 
polypharmacy prescribing. Morratto and colleagues (Morrato et al. 2007) 
investigated 55,481 patients from the Medicaid insurance database in US and 
found that the risk for polypharmacy prescribing is higher in patients from 
Asian ethnic background as compared to patients from white ethnicities 
(OR=1.55; 95% CI: 1.17- 2.04). In contrast Kreynbhul (Kreyenbuhl et al. 2007) 
investigated 45,571 patients from the Veterans Health Administration records 
and detected a lower risk for patients from African American background, as 
compared to whites (OR=0.81; 95%CI: 0.75-0.87). In their meta-analysis, 
Gallego and colleagues (Gallego et al. 2012) included information from 147 
studies across the continents, examining a total of 1,418,163 patients and 
found no evidence of an association between antipsychotic polypharmacy 
prescribing and white ethnicity.  
 
Marital status  
Three studies investigated antipsychotic polypharmacy prescribing and 
marital status (Santone et al. 2011; Kreyenbuhl et al. 2007; Biancosino et al. 
2005). A small Italian study (Biancosino et al. 2005)(n=354) investigated the 
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clinical records of an inpatient sample, and found that marital status did not 
predict antipsychotic polypharmacy prescribing (p=0.44). A second Italian 
study (Santone et al. 2011) examining a larger sample (n=1,022) of inpatients 
in a different region, found that single patients were more likely to be 
prescribed antipsychotic polypharmacy than monotherapy (x2= 11.18; 
p=0.048). Furthermore, findings from a large US study (Kreyenbuhl et al. 
2007) examining veterans mental health clinical records, similarly indicated 
that married patients were less likely to receive polypharmacy than 
monotherapy (OR=0.84; 95%CI: 0.78- 0.90). 
 
Employment/ social deprivation  
Employment status has been the only socioeconomic factor that previous 
research has investigated. There were no studies that have investigated the 
association between social deprivation and antipsychotic polypharmacy. In 
total three studies investigated employment status and antipsychotic 
polypharmacy prescribing (Barbui et al. 2006; Biancosino et al. 2005; Santone 
et al. 2011). The first study (Santone et al. 2011) examined 1,022 inpatient in 
an Italian hospital and reported no difference in occupational status between 
patients prescribed polypharmacy and monotherapy (x2= 9.52; p>0.05). 
Similarly, a study conducted across four European countries (UK, Italy, 
Netherland and Germany)(Barbui et al. 2006), including 375 individuals also 
reported no association between employment status and polypharmacy 
(OR=2.46; 95% CI: 0.67- 9.04). However, in their study, Biancosino and 
colleagues (Biancosino et al. 2005) investigated the clinical records of 354 
inpatients and found evidence indicating that not being employed was 
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associated with increased risk for polypharmacy (OR=3.10; 95% CI: 1.06- 
9.09). 
 
Comorbid diagnosis  
Three large cohort studies examined comorbid diagnoses and their 
association with antipsychotic polypharmacy. The first study (Ganguly et al. 
2004) examined the medical insurance records for 31,435 patients with 
schizophrenia and reported that comorbid alcohol (OR=0.58; 95%CI: 0.36- 
0.93; P=0.0237) and comorbid personality disorder (OR=0.71; 95%CI: 0.55- 
0.92; P=0.0082) were associated with lower risk for long-term antipsychotic 
polypharmacy. Another US study examining medical insurance across five US 
states (Morrato et al. 2007) for 55,481 patients found that substance abuse 
was not associated with increased likelihood for polypharmacy prescription 
(OR=0.91; 95% CI: 0.82- 1.02). A third large US study (Kreyenbuhl et al. 
2007) examining the mental health records for 45,571 patients found that 
patients with comorbid depression (OR=0.83; 95%CI: 0.78-0.90); and 
comorbid substance use (OR=0.90; 95% CI: 0.83- 0.97) were less likely to 
receive polypharmacy. 
 
Clinical symptoms  
Overall, there was mixed evidence regarding the role of clinical symptoms in 
antipsychotic polypharmacy prescribing. In their meta-analysis encompassing 
1,418,163 patients, Gallego and colleagues (Gallego et al. 2012) reported 
total psychopathology and positive and negative mental health symptoms [as 
measured by Positive and Negative Syndrome Scale (PANSS); Brief 
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Psychiatric Rating Scale (BPRS)] and functioning [as assessed by  Global 
Assessment of Functioning (GAF) and Clinical Global Impression (CGI)] were 
not associated with antipsychotic polypharmacy (please refer to Table 2.2 for 
the individual results). A small study (Barbui et al. 2006) that investigated 375 
patients over 4 countries also found no association between BPRS negative 
symptoms and polypharmacy (OR=0.86; 95% CI: 0.72- 1.02). On the other 
hand, one study (Moilanen et al. 2016) found that polypharmacy was 
associated with poorer remission of clinical symptoms (as measured by 
PANSS) (p=0.003), poor clinical outcomes (as measured by Clinical Global 
Impression) (p=0.002) and impaired functioning (as measured by The Social 
and occupational Functioning Assessment Scale) (p= 0.002). One further 
study also indicated that BPRS positive symptoms on admission predicted 
antipsychotic polypharmacy at discharge (Biancosino et al. 2005) (OR=1.06; 
95% CI: 1.01- 1.12).  
 
Previous inpatient stay  
There were four studies that have investigated the association between 
inpatient admission and long-term antipsychotic polypharmacy prescribing 
(Gallego et al. 2012; Ganguly et al. 2004; Kreyenbuhl et al. 2007; Ortiz et al. 
2016). Overall, existing studies consistently indicated that a pervious inpatient 
stay increases the risk for antipsychotic polypharmacy prescribing.  Evidence 
from a large meta-analysis (Gallego et al. 2012) indicated that patients who 
have had previous inpatient stay are more likely to receive polypharmacy than 
other patients (p<0.001). This was further supported by a large US study 
investigating medical claims database for 31,435 patients (Ganguly et al. 
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2004), which reported that psychiatric inpatient episodes in the previous six 
months were associated with increased risk for polypharmacy (OR=1.42; 
95%CI: 1.17-1.73; P=0.0004). Another, large US Medicaid study (Ortiz et al. 
2016) also reported that this risk was particularly elevated for inpatient stay of 
90 or more days (as compared to an inpatient stay of 7 or less 
days)(OR=5.53, 95% CI: 5.01- 6.11). The fourth study investigated US 
electronic health records from the Department of Veterans Affairs and found 
that patients with more previous psychiatric admissions were more likely to 
receive antipsychotic polypharmacy than monotherapy (OR=1.63; 95% CI: 
1.52- 1.74)(Kreyenbuhl et al. 2007). 
 
Previous outpatient visit  
Two large US studies investigated the effect of outpatient contact on 
polypharmacy prescribing (Kreyenbuhl et al. 2007; Ganguly et al. 2004). 
Findings were consistent in reporting that as compared to monotherapy, 
patients were more likely to receive antipsychotic polypharmacy if they had 
more outpatient visits [(Ganguly et al. 2004)(OR=1.03; 95% CI: 1.01- 1.05; 
P=0.0061); (Kreyenbuhl et al. 2007)(OR=1.00; 95% CI: 1.002-1.003)]. 
 
Previous community treatment orders (CTOs)  
CTOs are part of the UK Mental Health Act. They are indicators of treatment 
non-adherence, due to being frequently imposed to ensure patients comply 
with their treatment once discharged back in the community. I found no 
previous research that has investigated the role of previous receipt of CTOs 
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or medication non-adherence on long-term antipsychotic polypharmacy 
prescribing.  
 
Previous use of antipsychotic medication 
Previous antipsychotic use was associated with increased risk for 
polypharmacy prescribing (Barbui et al. 2006; Suokas et al. 2012; Ganguly et 
al. 2004). Antipsychotic polypharmacy risk also increased with the number of 
additional antipsychotics previously prescribed [(Barbui et al. 
2006)(OR=144.4; 95% CI: 31.9- 654.4)]. The risk was further sustained for 
both patients with chronic and recent onset schizophrenia (Suokas et al. 
2012).  
 
One meta-analysis and two large US cohort study considered the effect of 
clozapine prescribing in predicting long-term antipsychotic polypharmacy 
prescribing. Evidence from the meta-analysis indicated that there was no 
association (Gallego et al. 2012) between receiving clozapine and 
antipsychotic polypharmacy prescribing (p=0.24). Morrato et al. (Morrato et al. 
2007) examined mental health claims for 55,481 patients in five US states and 
similarly found that clozapine was not associated with increased risk for 
polypharmacy (OR=1.59; 95% CI: 0.96- 2.64). However, one study also 
examining Medicaid insurance claims in two US states (Ganguly et al. 2004) 
reported that clozapine independently predicts long-term antipsychotic 
polypharmacy prescribing (OR=11.77; 95% CI: 9.23- 15.01; P<0.001). In the 
context of existing recommendations and guidelines, it is expected that 
clozapine would predict antipsychotic polypharmacy prescribing. However, it 
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is possible that the aforementioned results reflect differences in prescribing 
cultures across different treatment facilities and across countries 
 
There was only one study that investigated the role of long-acting injectable 
(LAI) antipsychotics in polypharmacy prescribing. In their meta- analysis, 
Gallego and colleagues (Gallego et al. 2012) indicated that patients who have 
received long-acting injectable antipsychotic (LAI) were more likely to receive 
polypharmacy (r=0.26; p=0.04). 
 
2.4.3 Outcomes of antipsychotic polypharmacy    
Table 2.3 summarises studies extracted from Table 2.1. that have 
investigated mortality and readmission outcomes of long-term antipsychotic 
polypharmacy, in patients with SMI. The table includes information about the 
primary author and year, main results and confounders that were adjusted for 
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Scope of previous research investigating outcomes associated with 
long-term antipsychotic polypharmacy prescribing 
In total, I identified three studies that satisfied the inclusion criteria outlined 
above. Two studies considered the risk for death in patients with SMI (Katona 
et al. 2014; Baandrup et al. 2010), and two looked at the risk for hospital 
readmission following a polypharmacy prescription (Boaz et al. 2013; Katona 
et al. 2014).  
 
Secondary mental health hospital readmission  
Studies investigating hospital readmissions amongst patients receiving long-
term antipsychotic polypharmacy have been sparse. In total, two studies 
examining this were identified and overall, results were mixed. Katona and 
colleagues (Katona et al. 2014) investigated a large cohort (n=5,480) of 
Hungarian insurance records and indicated that although polypharmacy was 
associated with more treatment discontinuation (as measured by stopping or 
switching antipsychotic medications; and an indicator of antipsychotic 
effectiveness), it was associated with lower rehospitalisation, in comparison to 
antipsychotic monotherapy (HR=1.69; p<0.001). However, Boaz and 
colleagues (Boaz et al. 2013) also investigated insurance records from the US 
state of Florida (n=3,563) and found that polypharmacy at discharge was not 
associated with future hospital readmissions (HR=1.02; 95% CI: 0.90- 1.14); 
rather readmission was associated with patients being insufficiently stable at 
the point of initial discharge (although the authors did not formally assess 




I identified two large observational studies (Baandrup et al. 2010; Katona et 
al. 2014) that investigated long-term antipsychotic polypharmacy prescribing 
and mortality. A Danish study compared 2,130 patients prescribed 
polypharmacy to age and sex matched patients prescribed monotherapy 
(Baandrup et al. 2010). The risk for natural cause of death did not increase 
when prescribed two or more antipsychotics, as compared to a single 
antipsychotic. A large Hungarian study (Katona et al. 2014) found that 
although antipsychotic polypharmacy had a shorter time to all-cause 
treatment discontinuation compared to monotherapy, monotherapy was 
associated with increased overall mortality in comparison to antipsychotic 
polypharmacy (HR=1.62; p=0.01).
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2.5 Discussion    
Despite considerable variation across studies, the reviewed literature 
indicated that factors such as younger age, single marital status, comorbid 
mental health diagnosis and prior service use (inpatient; outpatient and 
medication use) are plausible predictors of long-term antipsychotic 
polypharmacy prescribing in secondary mental health care. However, 
antipsychotic polypharmacy associations with other factors such as gender, 
ethnicity, employment, clinical symptoms, and specific antipsychotic 
treatments including clozapine and LAI remain unclear. In relation to 
outcomes of long-term antipsychotic polypharmacy, studies investigating 
mortality and hospital readmission were sparse and findings mixed. In order to 
draw any meaningful conclusions from the studies that have been reviewed, it 
is imperative to consider the findings alongside their methodological 
limitations.  
 
2.5.1 General methodological limitations  
Overall, a large proportion of studies investigating predictors and outcomes of 
antipsychotic polypharmacy have used register-based or medical insurance 
databases (Baandrup et al. 2010; Boaz et al. 2013; Katona et al. 2014; 
Ganguly et al. 2004; Morrato et al. 2007; Ortiz et al. 2016; Suokas et al. 
2012). Although these studies contain data for large populations, thus 
increasing statistical power to detect associations, they lack contextual 
information, thus examining a limited number of factors and possible 
confounders. Confounding refers to a factor that is associated with both the 
exposure and outcome but does not lie on the causal pathway. On the other 
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hand, studies that have used information rich clinical records (Biancosino et 
al. 2005; Barbui et al. 2006; Moilanen et al. 2016; Santone et al. 2011) have 
been able to examine a wider number of factors in relation to polypharmacy. 
However, analysing clinical records (where researchers often read records 
and code it by hand according to a defined set of coding rules) is very time 
and labour intensive, and therefore less feasible on a large scale. This has 
resulted in investigating smaller and more homogeneous sample than ideal 
(e.g. inpatients), which limits the generalizability of findings (Biancosino et al. 
2005; Barbui et al. 2006; Moilanen et al. 2016; Santone et al. 2011). 
Furthermore, although I classified studies that considered antipsychotic 
polypharmacy of 60 or more days, as long-term, these cannot definitely 
exclude antipsychotic cross-titration (which can take up to 10 weeks, see 
Chapter 1 section 1.7). Therefore, such studies may be prone to 
polypharmacy misclassification (Ganguly et al. 2004; Boaz et al. 2013; Katona 
et al. 2014; Morrato et al. 2007; Suokas et al. 2012). 
 
2.5.2 Factor-specific methodological limitations  
Age  
Three large studies, two investigating clinical records (Kreyenbuhl et al. 2007; 
Suokas et al. 2012) and one medical insurance databases (Morrato et al. 
2007) reported that younger adults are more likely to receive polypharmacy. 
Overall, these are good quality studies, adjusting for an array of possible 
confounders and encompassing large population samples, therefore 
increasing statistical power to detect associations. However, it is important to 
bear in mind that studies examining specific populations such as the Veteran 
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Affairs Psychosis Registry (Kreyenbuhl et al. 2007) and claims from medical 
health insurance (Morrato et al. 2007) may not be entirely representative of 
patients receiving secondary mental health care. Therefore, this could be a 
potential source of selection bias. Similarly, one study examining a large 
sample of US medical insurance claims reported an increased risk for older 
patients and antipsychotic polypharmacy (Ortiz et al. 2016). This study 
examined exclusively inpatients at discharge and therefore, may not be 
generalizable to patients in different treatment setting (e.g. outpatients). Three 
studies indicated that there is no association between age and antipsychotic 
polypharmacy (Santone et al. 2011; Suokas et al. 2012), including one very 
large meta-analysis encompassing 147 studies across the continents, with a 
total of over a million patients (Gallego et al. 2012). Although this study was 
unable to examine multiple predictors, it included research across the globe, 
with a sufficient power to detect possible associations. Furthermore, this 
finding was supported by a smaller Italian study (Santone et al. 2011) 
examining information-rich clinical records and a large Finnish register-based 
study (Suokas et al. 2012). However, it is important to highlight that the 
aforementioned three studies did not adjust for a number of possible 
confounders such as symptom severity, therefore findings are possibly 
subject to residual confounding. On reflection, some of the highlighted 
methodological limitations may partly explain some of the observed 
heterogeneity across evidence in this field.  However, it is also possible that 
the above findings reflect the varying prescribing practice across facilities and 
countries. Further research is desirable to test the effect of age on a more 




Two cross sectional studies from Italy and Finland and one large US cohort 
study reported that males have an increased likelihood of receiving 
antipsychotic polypharmacy (Santone et al. 2011; Suokas et al. 2012; Morrato 
et al. 2007). This is a heterogeneous group of studies investigating inpatient 
(Santone et al. 2011) and outpatient (Suokas et al. 2012) populations, in 
different countries (Italy; Finland and US), which may indicate that this finding 
is reasonably generalizable. However, aside from one study (Morrato et al. 
2007), which adjusted for possible confounders, it is possible that the above 
findings are subject to residual confounding. On the other hand, two very 
large US medical insurance register studies (Ortiz et al. 2016; Ganguly et al. 
2004); one US veteran record study (Kreyenbuhl et al. 2007)  and one meta-
analysis (Gallego et al. 2012) reported that gender is not associated with a 
risk for antipsychotic polypharmacy prescribing. Although, the latter three 
studies (Ortiz et al. 2016; Ganguly et al. 2004; Kreyenbuhl et al. 2007) had the 
advantage of adjusting for multiple potential confounders and examining 
larger populations, therefore having more statistical power to detect an effect, 
they examined specific population samples (e.g. medical insurance claims; 
veterans), therefore potentially reducing generalizability. Given the extensive 
methodological heterogeneity across the aforementioned studies, we cannot 
draw any definitive conclusions on whether gender predicts long-term 
antipsychotic polypharmacy prescribing. An important caveat worth 
considering here is that it is possible that prescribing cultures vary across 
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different countries and that differences observed across studies may in fact 
represent true differences across countries.  
 
Ethnicity  
Two large US cohort studies (Kreyenbuhl et al. 2007; Morrato et al. 2007) and 
one meta-analysis (Gallego et al. 2012) investigated the association between 
ethnicity and antipsychotic polypharmacy. Although Gallego et al. (Gallego et 
al. 2012) reported no association between white ethnicity and polypharmacy, 
this study did not consider any other ethnicities. Therefore, an association 
cannot be ruled out. Furthermore, heterogeneous classifications of ethnicity 
across the former two studies has made it very difficult to compare existing 
findings. In addition, as discussed in the previous section, although both US 
studies have adjusted for a number of confounders, they have focused on 
distinct population samples, thus comparison of findings may not be 
appropriate.  
 
Marital status  
One small cohort study that was unable to adjust for potential confounders 
reported that marital status does not predict antipsychotic polypharmacy 
(Biancosino et al. 2005) and two large studies from Italy and US (Santone et 
al. 2011; Kreyenbuhl et al. 2007), one of which (Kreyenbuhl et al. 2007) 
adjusted for an array of possible confounders, reported that single patients 
were more likely to be prescribed polypharmacy in comparison to 
monotherapy. It is possible that the study conducted by Biancosino et al. 
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(Biancosino et al. 2005) did not have sufficient statistical power to detect an 
effect (n=358) and may have suffered from residual confounding.  
 
Employment/ social deprivation  
In total three studies (Santone et al. 2011; Barbui et al. 2006; Biancosino et al. 
2005) examined employment and antipsychotic polypharmacy. All but one 
(Biancosino et al. 2005) reported no association between employment and 
polypharmacy regimen. Although, the study by Biancosino et al. (Biancosino 
et al. 2005) examined the smallest population, this was a prospective study, 
examining an array of possible predictors from information-rich clinical 
records, and adjusting for a number of possible confounders. All three studies 
investigated inpatient populations in Italy; however Barbui et al. (Barbui et al. 
2006) conducted their study across an additional three countries. The later 
study also specifically focused on unstable patients, therefore possibly limiting 
the generalizability of their findings to the wider inpatient population. In 
conclusion, based on this evidence it is difficult to determine whether 
employment in fact predicts long-term antipsychotic polypharmacy 
prescribing.  
 
Comorbid diagnoses  
Comorbid diagnosis such as personality disorder (Ganguly et al. 2004); 
depression (Kreyenbuhl et al. 2007); alcohol use (Ganguly et al. 2004), and 
substance use (Ganguly et al. 2004; Kreyenbuhl et al. 2007) have been 
associated with lower risk for long-term antipsychotic polypharmacy. One 
study found that substance abuse was not associated with antipsychotic 
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polypharmacy prescribing (Morrato et al. 2007). Both studies that investigated 
substance abuse, reported findings from US medical insurance records, and 
investigated polypharmacy of 60 or more days duration. However, records 
were derived from different US states, Georgia and California in Ganguly et al. 
(Ganguly et al. 2004) study and California, Nebraska, Oregon, Utah, and 
Wyoming in Morratto et al. (Morrato et al. 2007) study. Although the latter 
study encompassed a larger and potentially more diverse population, it is 
possible that differences in findings reflect differences in the populations that 
were examined. As previously discussed, it is likely that patients eligible for 
medical insurance in the US are inherently different to other non-eligible 
patients seen by secondary mental health services. It is also likely that eligible 
populations differ across states, and have different socio-demographic and 
clinical composition. Therefore findings need to be interpreted and compared 
with caution. Furthermore, despite the above studies including large patient 
samples and adjusting for a number of possible confounders, it is difficult to 
determine whether these findings are generalizable to populations across 
different states and outside the US. Further research is needed to replicate 
the results outside the US and across more diverse population samples.  
 
Clinical symptoms  
Findings regarding the role of clinical symptoms in predicting long-term 
antipsychotic polypharmacy prescribing have been mixed. In total, four 
longitudinal cohort studies investigated clinical symptoms and antipsychotic 
polypharmacy (Barbui et al. 2006; Gallego et al. 2012; Biancosino et al. 2005; 
Moilanen et al. 2016), adjusting for multiple confounders in their analysis. Two 
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studies reported that polypharmacy was not associated with overall or 
individual psychopathology symptoms (Barbui et al. 2006; Gallego et al. 
2012), and two studies reported that polypharmacy was associated with 
positive symptoms (Biancosino et al. 2005), poor functioning, remission, and 
clinical outcomes (Moilanen et al. 2016). However, only two of the 
aforementioned studies specifically measured the clinical symptoms prior to 
the occurrence of antipsychotic polypharmacy (Barbui et al. 2006; Biancosino 
et al. 2005). Given the heterogeneity across their findings it is also important 
to acknowledge that the two studies focused on different clinical populations 
such as clinically unstable patients (Barbui et al. 2006) and inpatients 
(Biancosino et al. 2005). As a result, it is difficult to determine the role of 
clinical symptoms in predicting antipsychotic polypharmacy prescribing.   
 
Previous service use   
Existing evidence from large cohort studies consistently reported that 
antipsychotic polypharmacy is associated with more frequent previous 
hospital admissions (Kreyenbuhl et al. 2007; Gallego et al. 2012; Ganguly et 
al. 2004; Ortiz et al. 2016) and higher number of previous outpatient contact 
(Ganguly et al. 2004; Kreyenbuhl et al. 2007). The majority of this research 
has been conducted in the US, therefore a caveat to consider is that there has 
been a general paucity of research from other countries such as the UK. As a 
result, findings need to be generalised to other populations with caution.   
 
Although studies conducted to date indicate that the number of previous 
antipsychotic drugs is associated with increased risk for polypharmacy (Barbui 
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et al. 2006; Suokas et al. 2012; Ganguly et al. 2004), evidence regarding the 
use of individual antipsychotics such as clozapine has been mixed. Three 
studies investigated clozapine use and antipsychotic polypharmacy (Gallego 
et al. 2012; Ganguly et al. 2004; Morrato et al. 2007); however only one 
(Morrato et al. 2007) examined clozapine as a predictor of polypharmacy, thus 
specifying that clozapine prescription had to occur prior to polypharmacy. 
Therefore, at present it is difficult to determine whether clozapine prescribing 
predicts long-term antipsychotic polypharmacy. Furthermore, out of the 
literature that qualified for this review, only one reported findings on long-
acting injectable (LAI) antipsychotics (Gallego et al. 2012), although they were 
unable to distinguish between this factor being a characteristic or a predictor 
of antipsychotic polypharmacy. Therefore, it is difficult to determine whether 
LAI predicts antipsychotic polypharmacy prescription.  
 
An important caveat to consider in relation to the aforementioned research is 
that existing studies have also sporadically investigated the effect of previous 
antipsychotic polypharmacy episodes on the risk for future antipsychotic 
polypharmacy prescribing (Barbui et al. 2006). More specifically, it is possible 
that previous antipsychotic polypharmacy episodes influence future service 
use, therefore studies that have not examined initiation of antipsychotic 
polypharmacy, may interpret factors as predictors of polypharmacy, where in 
fact they could be consequences of past polypharmacy episodes. This could 




Mortality and readmission  
In total two studies investigated hospital readmission (Boaz et al. 2013; 
Katona et al. 2014) and two studies investigated mortality (Baandrup et al. 
2010; Katona et al. 2014) in relation to long-term antipsychotic polypharmacy 
prescribing. There were several important methodological consideration that 
need to be accounted for in view of the heterogeneity of the findings 
discussed in the Results section of this chapter.  
 
Two out of the three studies (Katona et al. 2014; Boaz et al. 2013) included 
exclusively information on populations eligible for medical insurance. As 
discussed in the previous section, it is possible that such samples do not 
provide a true reflection of patients with SMI seen by secondary mental health 
care. Therefore, their results need to be generalised with caution.  Lastly, as a 
result of investigating database (Baandrup et al. 2010) and insurance records 
(Katona et al. 2014; Boaz et al. 2013), which often contain limited contextual 
information, which might be used as a source of potential confounders in 
multivariable models, it is possible that the above results are subject to 
residual confounding. More specifically, an important confounder that has not 
been considered by any of the aforementioned studies is antipsychotic dose. 
Approximately 20% of UK patients (Paton et al. 2008; Harrington 2002) and 
28% internationally (Barbui et al. 2006) are prescribed high doses of 
antipsychotics. High-dose prescribing is especially prevalent in inpatient 
settings [estimated at around 55% (Grech & Taylor 2012)], where prevalence 
of polypharmacy is also high. In fact, existing research suggests that high 
dose prescribing is often associated with antipsychotic polypharmacy in both 
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inpatients and outpatients (Barnes & Paton 2011a; Barbui et al. 2006; Paton 
et al. 2008; Tungaraza et al. 2010), with PRN medication significantly 
contributing to this (Paton et al. 2008; Milton et al. 1998; Harrington 2002). 
High dose antipsychotic regimens have been associated with a considerable 
side-effect burden such as increased risk for extra-pyramidal side effects 
(Centorrino et al. 2004), hyperprolactinemia; QTc prolongation and sedation 
(Auquier et al. 2006; Raedler 2010; Suzuki et al. 2014). Another factor that 
has been generally poorly adjusted for, and not accounted for by the 
aforementioned studies, is smoking, which is especially prevalent amongst 
patients with SMI (Brown et al. 2000) and has a well established detrimental 
effect on physical health and mortality (Goff et al. 2005; Brown & Mitchell 
2012).  
 
Mortality studies that have not been included  
There were several important studies that could not be included in this review 
because they did not specify the duration of antipsychotic polypharmacy that 
was examined. Therefore, it is very likely that those studies included cases of 
both short and long-term antipsychotic polypharmacy.  
 
Three cohort studies investigating mortality in patients with SMI reported that 
the use of antipsychotic polypharmacy is associated with increased risk for 
overall death (Kiviniemi et al. 2013; Joukama et al. 2006; Waddington et al. 
1998). The first of these, a large Finnish study, also reported an association 
between death from suicide and FGA-only polypharmacy, and SGA-only 
polypharmacy, in comparison to patients not taking antipsychotics. 
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Furthermore, the same study reported that cardiovascular death was also 
associated with FGA-only polypharmacy. Although, this was a large cohort 
study, that was representative of the population it examined, the analysis was 
not adjusted for factors such as antipsychotic dose, thus potentially suffering 
from residual confounding. Similarly, Joukamma et al. (Joukama et al. 2006), 
also a large, representative Finnish study, adjusted for a multitude of socio-
demographic, socioeconomic, physical health and lifestyle factors; however, 
they did not control for the effect of antipsychotic dose. Waddington et al. 
(Waddington et al. 1998) examined 88 inpatients in Ireland. Although the 
study reported descriptive information about antipsychotic dose, they did not 
include it as a covariate in the Cox analysis. Aside from the first study 
(Kiviniemi et al. 2013), both Waddington et al. (Waddington et al. 1998) and 
Joukamma (Joukama et al. 2006) have examined small and homogeneous 
patient samples, therefore potentially reducing the generalizability of their 
findings.  
 
Only one of the studies that was not included in this review reported no 
association between death and antipsychotic polypharmacy as compared to 
antipsychotic monotherapy (Tiihonen et al. 2012). This was a large Finnish 
study using a linked national database. However, this study was unable to 
examine inpatients, due to no access to inpatient records, therefore findings 
are only representative of the Finnish outpatient population. Furthermore, 
similarly to the studies above, dose was not included as a covariate in 
calculating the risk of death, therefore results are potentially subject to 
residual confounding.  
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2.5.3 Conclusion  
This review of literature on predictors and outcomes of long-term 
antipsychotic polypharmacy prescribing revealed several important findings. 
Although there has been considerable previous research that has investigated 
factors that characterise and predict antipsychotic polypharmacy, previous 
studies have been limited by investigating a limited number of factors in the 
same study, mostly due to unavailability of diverse contextual information. 
Therefore, findings on different predictors have been derived mainly from 
studies using different methodologies and populations samples. In addition, 
the aforementioned research has investigated a limited number of potential 
confounders, thus risking residual confounding. Furthermore, although there 
have been some large cohort studies, generalizability of findings has been 
difficult beyond the populations that were examined, due to samples focusing 
on specific population groups (e.g. inpatients; medical insurance claimants). 
Therefore it remains unclear whether key patient factors such as gender, 
ethnicity, social deprivation and clinical symptoms, predict antipsychotic 
polypharmacy prescribing in other patient populations. Despite the above 
limitations, this review provided some support for the hypothesis that factors 
such as previous inpatient and outpatient use predict the prescribing of long-
term antipsychotic polypharmacy.    
 
In relation to outcomes of antipsychotic polypharmacy, a large proportion of 
studies investigating polypharmacy and mortality did not qualify for this 
review, as a result of not specifying the duration of the concomitant 
antipsychotic use that was investigated. Consequently, only three studies 
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could be reviewed in detail. Overall, studies were limited by investigating 
relatively small samples and possible residual confounding, due to not 
adjusting for key factors such as antipsychotic dose and smoking. As a result, 
it is difficult to determine whether antipsychotic polypharmacy is associated 
with a change in the risk of death and hospital readmission.  
 
There has been an extensive number of studies coming from US, Italy and 
Finland. However, there has been a considerable paucity of evidence from UK 
based studies. Therefore, it remains unclear whether the above findings can 
be generalised to the UK population. Although general guidelines, especially 
concerning antipsychotic polypharmacy, are similar across countries (e.g. 
APA and NICE), it is possible that different countries differ in their medication 
prescribing culture (Howes et al. 2012).  
 
In conclusion, there is a clear need for large cohort studies that are 
representative of the population seen by secondary mental health care, and 
that have access to diverse contextual information. The above will ensure that 
the studies are: 1) able to simultaneously measure a diverse number of 
possible predictors and outcomes in the same sample of patients; 2) measure 
a range of possible confounders, and thus test the robustness of the findings; 
3) have sufficient power to detect an association with rare outcomes such as 
death; 4) have sufficient statistical power to adjust for multiple confounders 
simultaneously in the analysis; 5) provide findings which are generalizable 
across a diverse range of patients (e.g. inpatients and outpatients). 
Furthermore, there is a clear need for UK-based research that examines 
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possible predictors and outcomes in NHS settings. Lastly, there is a clear 
need for a better method of identifying long-term antipsychotic polypharmacy 
prescribing on a large scale. This type of concurrent antipsychotic 
administration can be difficult to detect in contrast to its other subtypes with 
more transient nature (i.e. PRN medication; cross-titration). Smaller studies 
that have manually examined clinical records have been better at specifying 
and identifying long-term antipsychotic polypharmacy. However, this latter 
process is very time and labour intensive and not possible on large scale. 
Therefore, there is a need to develop a method that can detect polypharmacy 
fast, on a large scale, and which has the potential to be used across different 
datasets with a similar set-up.
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CHAPTER 3:  THESIS RATIONALE AND OBJECTIVES   
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3.1 Overall thesis objectives: 
 
1) To identify cases of long-term (≥ 6 months) antipsychotic polypharmacy 
prescribing in South London and Maudsley electronic health records 
(EHR).  
 
2) To identify factors that predict long-term antipsychotic polypharmacy 
prescribing for SMI patients in secondary mental health care.  
 
3) To investigate whether outcomes including hospital readmission and 
mortality are associated with long-term antipsychotic polypharmacy 
prescribing in secondary mental health care.  
 
 
3.2 Study-specific rationale and aims: 
 
3.2.1 Chapter 5: Developing and evaluating a novel process of 
extracting antipsychotic polypharmacy data from electronic 
health records. 
 
Few existing studies have been able to distinguish between regular long-term 
antipsychotic polypharmacy prescribing and polypharmacy resulting from 
cross-titration or PRN medication administration (see Chapter 2 Table 2.1). 
Furthermore, existing evidence is mainly derived from studies using 
prescription databases (Boaz et al. 2013; Ganguly et al. 2004; Ortiz et al. 
2016; Katona et al. 2014), which have only limited contextual information. In 
contrast, EHRs contain large volumes of detailed information in free text and 
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structured fields, providing an important resource for conducting analyses 
using large samples, and investigating a multitude of patient characteristics 
and adjusting for a broad range of potential confounders. 
Aim: To develop, test and implement a novel algorithm for detecting 
long-term antipsychotic polypharmacy prescribing in secondary mental 
health care, through the use of electronic health records. 
 
3.2.2 Chapter 6: Predictors of long-term antipsychotic polypharmacy 
prescribing in secondary mental health care. 
   
Existing research examining predictors of long-term antipsychotic 
polypharmacy has been hampered by limited generalizability due to 
examining small and selective samples (Centorrino et al. 2005; Centorrino et 
al. 2004), limited number of predictors (see Chapter 2), and limited ability to 
distinguish temporally between the occurrence of polypharmacy prescribing 
and that of exposures, which has made it difficult to determine if the latter are 
predictors or consequences of polypharmacy (Suokas et al. 2012; Santone et 
al. 2011; Ortiz et al. 2016).  
Aim: To investigate socio-demographic, socioeconomic, clinical, and 
service-use predictors of long-term antipsychotic polypharmacy 
initiation in a population with serious mental illnesses, in secondary 
mental health care.  
 
3.2.3 Chapter 7: Antipsychotic polypharmacy prescribing and risk of 
hospital readmission in secondary mental health care.  
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Antipsychotic polypharmacy prescribing has not been found to be associated 
with more clinical improvement at the point of inpatient discharge, in 
comparison to monotherapy (Centorrino et al. 2005; Centorrino et al. 2004; 
Biancosino et al. 2005). However, despite the lack of evidence to support its 
effectiveness, the prescribing of antipsychotic polypharmacy has persisted 
across clinical services and over time (Gallego et al. 2012; Correll & Gallego 
2012; Paton et al. 2008).  At present, the evidence on the effectiveness of this 
regimen, once patients return to the community, is sparse and mixed, with 
studies reporting an association with both reduced and increased risk for 
hospital readmission (see Chapter 2 Table 2.3). However, research has 
indicated a modest benefit for clozapine co-prescribing in relation to outcomes 
such as readmission (Freudenreich & Goff 2002; Taylor et al. 2011). 
Aim: To investigate whether receiving an antipsychotic polypharmacy 
prescription at the point of inpatient discharge is associated with future 
hospital readmissions into secondary mental health care. In addition, I 
investigated whether receiving clozapine as part of the polypharmacy 
regimen had an effect on this risk. 
 
3.2.4 Chapter 8: Long-term antipsychotic polypharmacy prescribing in 
secondary mental health care and the risk of mortality.  
 
To date, it has been widely believed that antipsychotic polypharmacy 
increases the risk for detrimental health outcomes such as mortality 
(Waddington et al. 1998; Joukama et al. 2006; Kiviniemi et al. 2013). 
However, on closer inspection, research investigating the effect of long-term 
antipsychotic polypharmacy has been extremely sparse (see Chapter 2 Table 
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2.3). Findings have been primarily derived from small studies, examining 
antipsychotic polypharmacy of unspecified duration, and  therefore are likely 
to have included long-term polypharmacy as well as PRN medication and 
antipsychotic cross-titration. Furthermore, the effects of factors such as 
antipsychotic dose have been inconsistently investigated (see Chapter 2 
section 2.5.2), thus findings are subject to potential residual confounding. 
Consequently, it is difficult to known whether the observed associations are in 
fact due to antipsychotic polypharmacy prescribing.  
Aim: To determine whether long-term prescribing of antipsychotic 
polypharmacy has an effect on the risk of death in patients with serious 
mental illness receiving treatment in South London and Maudsley 
mental health services. Furthermore, I set out to investigate whether this 
risk varied depending on the cause of death and other factors such as 
antipsychotic dose.  
  
 86 




The contents of this chapter have contributed to the following: 
 
Publications in peer-reviewed journals 
Perera, G., Broadbent, M., Callard, F., Chang, C.-K., Downs, J., Dutta, R., 
Fernanades, A., Hayes, RD., Henderson, M., Jackson, R., Jewell, A., Kadra, 
G., Little, R., Pritchard, M., Shetty, H., Tulloch, A. & Stewart, R. (2016). 
Cohort profile of the South London and Maudsley NHS Foundation Trust 
Biomedical Research Centre (SLAM BRC) Case Register: current status and 
recent enhancement of an Electronic Mental Health Record-derived data 





Data used in the analyses described in Chapters 5,6,7,8 were derived from 
the Clinical Record Interactive Search (CRIS) data resource, developed within 
the NIHR Mental Health Biomedical Research Centre and Dementia Unit 
(BRC/U), which allows researchers to search and retrieve de-identified clinical 
data sourced from the SLAM EHRs. CRIS is a dynamic database, which 
updates against source files every 24 hours.  At the time of writing, it contains 
more than 280,000 cases.  
 
In this chapter I describe the study settings, the operational model of the CRIS 
interactive search tool, and the main exposure of interest. In addition, I 
provide a brief overview of the main statistical analyses that will be used in 
further individual chapters.  
 
4.2 Setting  
SLAM is one of the largest providers of secondary health care in the UK, 
serving a geographic catchment of 1.23 million residents across four London 
boroughs (Lambeth, Southwark, Lewisham and Croydon) (Stewart et al 
2009), which is representative of the population seen by the National Health 
Services in South East London. In addition, the Trust also provides care for 
some regional/national patients in specialist services. Overall, there are seven 
specialty groupings: Addictions; Behavioural and Developmental Psychiatry; 
Child and Adolescent Mental Health Services; Mental Health of Older Adults 
and Dementia; Mood, Anxiety and Personality; Psychological Medicine; 
Psychosis.  
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4.3 Data source  
 
4.3.1 Electronic Health Records  
 
EHRs have been kept by SLAM across all services since 2006, using the 
Patient Journey System (see below). SLAM EHRs contain a large volume of 
diverse data, thus making it possible to examine a multitude of factors and 
simultaneously control for a range of potential confounders in analyses. 
Furthermore, the above also makes it possible to examine outcomes that 
occur less frequently, such as death. In addition, the data are longitudinal, 
allowing for factors to be measured at multiple points, so that temporal 
relationships between measured factors can be determined. Moreover, 
findings are reflective of real-world clinical practice.  
 
4.3.2 The Patient Journey System  
 
The Patient Journey System (PJS) was developed between October 2005 
and October 2006 to integrate paper and EHRs across all services in SLAM, 
thus facilitating the recording and sharing of clinical information within and 
across multidisciplinary teams. PJS contains a comprehensive record of 
patient’s demographics, contact information, referrals, transfers, detailed 
clinical assessments, care plans, medication, clinical activity and reviews. 
Information is organized in structured fields (such as dates and drop down 
menus) and unstructured free text (including written assessments, progress 
notes and correspondence)(Stewart et al. 2009). 
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4.3.3 Clinical Record Interactive Search (CRIS) 
 
In 2008 the CRIS system was developed, which allows researchers to search 
and retrieve de-identified SLAM EHR data. CRIS currently accesses over 
280,000 cases. Patients are able to opt out from CRIS; however to date only 
three people have done so. Ethical approval as an anonymised database for 
secondary analysis was originally granted in 2008, and renewed for a further 
5 years in 2013 (Oxford C Research Ethics Committee, reference 
08/H0606/71+5). Figure 4.1 illustrates the CRIS security and operational 
model. The figure has been adapted from Fernandes et al. (Fernandes et al. 





Figure 4.1 CRIS security and operational m
odel.   
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The CRIS security model was developed and is managed by an Oversight 
Committee, which is chaired by a mental health service user; a SLAM BRC 
Stakeholder; a SLAM Research Ethics Committee representative; a SLAM 
Caldicott Guardian representative; a Child and Adolescent Mental Health 
representative; a CRIS Academic Lead; and a CRIS Project Manager. The 
Committee was formed to uphold and monitor CRIS security. In addition, the 
Committee is responsible for considering and approving potential CRIS 
project applications. In order for an applicant to be able to work with CRIS 
they require the following: a SLAM audit committee approval; a senior 
university or NHS affiliated supervisor attached to and taking responsibility for 
the project and the applicant; a formal affiliation (either honorary or 
substantive) with the hospital or the university (this ensures that the applicant 
is bound by NHS duty of confidentiality); to complete a Project Approval Form 
(where they are asked to describe the purpose of the proposed project and 
the nature of the data required for analysis) and obtain an approval from the 
Oversight Committee (Fernandes et al. 2013). All applications are considered 
carefully in relation to their scientific robustness and patient confidentiality (for 
example, research projects examining small patient samples with rare 
conditions, may pose risk regarding patient anonymity, therefore may not be 
approved)(Fernandes et al. 2013). If an approval is granted, the researcher is 
able to access CRIS within the SLAM firewall. All projects are audited weekly 
to ensure they adhere to the project approval.  
 
CRIS de-identifies PJS records by identifying, marking and masking patient 
identifiers with ZZZZZZ (and carer identifiers with QQQQQQ), thus facilitating 
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the use of clinical data for research purposes. Figure 4.2 illustrates how this 
appears in Front-End CRIS (see section 4.4.1). This figure has previously 
been published by Stewart et al. (Stewart et al. 2009). Due to confidentiality, I 
could not use a snapshot from my work. The bespoke de-identification 
algorithm was developed by the team and its performance evaluated using 
500 patient notes (Fernandes et al. 2013).  The algorithm achieved 98.8% 
precision (the proportion of personal identifiers that were correctly de-
identified, out of all those that were de-identified by the algorithm) and 97.6% 
recall (the number of personal identifiers the algorithm de-identified out of all 
the personal identifiers in the text). In addition the performance of the 
algorithm was also compared to a Machine learning Identification Scrubber 
Toolkit (MIST) (Aberdeen et al. 2010). In total 70 patient notes were 
investigated and the performance test indicated a superior precision and 
recall using the CRIS algorithm: precision 100% (CRIS) versus 95.6% (MIST) 
and recall 88.5% versus 78.1%, respectively. Although breaches in data are 
possible and did occur, they were very rare. In the above evaluation study, 1 
patient note out of 500 that were examined, was a potential breach (which 
was defined as having three or more instances of potential personal 
identifiers). The authors (Fernandes et al. 2013) concluded that even in such 
instances the information and identity of the patient cannot be established by 
the researcher. In addition, the researcher, who is also bound by the duty of 
confidentiality, would need to be actively trying to identify the patient in order 
to breach confidentiality. Furthermore, in order to minimize patient 
identification, some personal information has been truncated. For example 
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only the first half of postcodes and only the month and year of birth are 
included in CRIS (Stewart et al. 2009).  
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CRIS provides longitudinal information, which updates against source files 
every 24 hours (Perera et al. 2016). This allows researchers to examine 
dynamic cohorts, which not only have extensive historical data, but in addition 
could have new clinical information coming in. Data are available from both 
structured and unstructured fields from PJS. Structured data refers to 
information that is recorded as dates and in drop-down menu fields. It 
represents single entities such as ethnicity, marital status and employment. In 
addition, researchers can access routinely collected data resources such as 
the Health of the Nation Outcome Scale (HoNOS). Although none of the fields 
used in this thesis (see Table 4.2 below) require compulsory completion by 
clinicians, socio-demographic information tends to have a better completion 
rate than information such as clinical rating scales (e.g. HoNOS). This is 
further discussed below in section 4.8. However, it is important to highlight 
that there has been a variation on information completeness over the years, 
especially when considering clinical scales, with a trend towards higher 
completion rate in more recent years. However, in many cases clinical scales 
may be completed only once and not repeated in the observation period 
under investigation. Unstructured data refers to information available in free 
text fields such as clinical notes, correspondence and inpatients events.  
Although completion rate of free text is discretionary to staff, in the NHS 
clinicians are required to record every contact (e.g. telephone calls; face-to-
face meetings, paper and email correspondence) that they have with patients. 
However, the timely manner in which this is achieved can vary across 
clinicians and services.  
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4.4 Data extraction from CRIS  
 
4.4.1 Front-End CRIS 
 
Front-End CRIS allows researchers to view a de-identified version of PJS and 
search against any combination of structured (e.g. dates; diagnosis) and 
unstructured (e.g. progress notes, correspondence) fields. The system returns 
relevant  'hits' (i.e. records) based on entered search terms (see Figure 4.2). 
Results are collated in a spread sheet format and can be exported as CSV 
files for further analysis (Perera et al. 2016). In the context of my project, 
Front-End CRIS was used to manually validate information on antipsychotic 
polypharmacy cases and dose as described in Chapter 5 section 5.3.5 and 
Chapter 8 section 8.3.5, respectively.  
 
4.4.2 Structured Query Language (SQL) 
 
SQL is programming language designed to manage data from multiple 
sources. This approach allows researchers to combine information available 
from structured and unstructured fields in CRIS by writing queries and 
retrieving data for a specific cohort. Results are displayed as tables for 
researchers to allow manual coding of data. One of the advantages of this 
method is that it also allows researchers to devise further filters after 
examining the data. For example, in this project, to improve the identification 
of antipsychotic polypharmacy, following a manual examination of the data, I 
further applied filtering criteria to the data extraction to improve the precision 
and recall of the output data (as will be described in Chapter 5, section 5.3.5).  
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4.4.3 Natural Language Processing (NLP) 
 
In CRIS, specific NLP algorithms are available, which extract and code 
pharmacotherapy data from free-text fields, taking into account the linguistic 
context in which keywords appear. As opposed to simple keyword search, the 
application is able to distinguish between instances of antipsychotic 
prescription, which apply to the patient in question, as opposed to medication 
that has been prescribed for a family member, for example.  
 
The validity of the NLP applications has previously been evaluated in relation 
to diagnosis, smoking and antipsychotic medication. The smoking application 
(Wu et al. 2013; Perera et al. 2016) was developed by extracting information 
from unstructured fields on whether patients were either currently smoking, 
have smoked in the past, or have never smoked [smoking of substances other 
than tobacco (e.g., marijuana/cannabis and cocaine) were excluded]. The 
application was developed through an iterative process where a manual ‘gold 
standard’ annotation of documents consisting of unstructured fields were 
compared to the results generated by the application.  The final application 
was tested on clinical notes of 100 patients, yielding a precision of 0.93 and 
0.58 recall. To test the diagnosis application, any available text strings 
associated with a diagnosis statement were identified from free text. This 
information was designed to supplement information already available through 
the existing structured (International Classification of Diseases (ICD)-10) 
fields. The performance of the application was evaluated in a random sample 
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of 75 documents for ‘vascular dementia’, indicating 0.99 precision and 0.98 
recall (Sultana et al. 2014). The antipsychotic medication application was 
developed using a gazetteer of generic and commercial names for all 
medications in UK use. The application was first tested on clozapine use, 
investigating both current use of clozapine (precision 0.96; recall 0.92) and 
both past and present (ever) use (precision 0.99; recall 0.98). The evaluation 
for precision was based on comparing the performance of the application 
against a manual search of 279 documents. Recall was evaluated on a 
random set of 200 documents containing the word clozapine (Hayes et al. 
2014). In Chapter 5, I describe the validity of the application on antipsychotic 
polypharmacy.  
 
General Architecture for Text Engineering (GATE) software (Cunningham et 
al. 2013; Cunningham 2002) is a suite of tools that allows NLP applications to 
be built. It allows for a variety of text processing tools and document formats 
to be used, with individual tools being chained together into processing 
‘pipelines’, and documents processed in series through these pipelines 
(Perera et al. 2016). The GATE application used in this study was designed to 
extract antipsychotic prescription information data from free text, such as drug 
name, information on dose, frequency, the status of the prescription (start, 
stop, continuing) and the date and the relative nature of the prescription 
(current, in the past, or planned for the future). The full technical workings of 
the GATE application are beyond the scope of this project; however, they are 
available in this article (Cunningham 2002). GATE use for data extraction on 
antipsychotic polypharmacy is described in Chapter 5 section 5.3.3.  
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4.4.4 CRIS linkage with other databases  
 
CRIS has been linked to other national databases, such as Primary Care, 
Hospital Episode Statistics, Department of Education National Pupil 
Database, Cancer, and Mortality (from the Office of National Statistics). In this 
thesis I have focused on data linkage with Office of National Statistics (ONS) 
mortality data, which includes information available on patients’ death 
certificates, such as cause of death. Although, CRIS contains basic mortality 
information such as date of death, available through standard linkage with 
SLAM NHS numbers, it does not contain information such as causes of death 
(Perera et al. 2016).  To achieve this linkage, anonymised BRC IDs are linked 
to the ONS death register using the Clinical Data Linkage Service (see Figure 
4.1). More specifically, the Clinical Data Linkage Service sends identifiers 
(CRIS ID, first name, last name, date of birth, gender, postcode and NHS 
number) to the Health and Social Care Information Centre, who in turn 
request the mortality data from the ONS, and then return the mortality data to 
the Clinical Data Linkage Service via a secure file transfer protocol. In addition 
to securely linking and extracting data, the Clinical Data Linkage Service is 
also responsible for storing the data in accordance with the SLAM ICT 
Security Policy on a server within the SLAM firewall (Perera et al. 2016). 
 
4.5 Personal contribution to data extraction  
I am the first researcher to examine antipsychotic polypharmacy using the 
CRIS database. I was jointly responsible (with my supervisors) for designing 
the studies. Data extraction was completed in collaboration with the clinical 
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informaticians in the CRIS team; however, I provided detailed instructions on 
the selection parameters, specifying individual variables, coding and time 
frames. Furthermore, I developed a novel algorithm and devised a number of 
data extraction filters to derive information about polypharmacy (see Chapter 
5). This involved searching for empirical research and manual examination/ 
validation of clinical records through Front-End CRIS (see Chapter 5 section 
5.3.5 and Chapter 8 section 8.3.5 for a detailed description of the validation 
process).  In addition, I conducted all the data analyses, wrote manuscripts (in 
collaboration with my supervisors and co-authors), submitted and published 
my research in peer-reviewed journals.  
 
4.6 Studies selection criteria  
For each of the analyses described in Chapters 5,6,7 and 8, I identified all 
patients who had received a SMI diagnosis, were aged 16 years or over and 
were active in SLAM clinical services during the observation period. Study 
specific observation periods are defined within each chapter. Active in SLAM 
service was defined as having an open team episode in PJS, in other words, 
there was an on-going contact between the patient and a team within the 
service (for each project this has been specified in the respective chapter).  
SMI was defined as having received a schizophrenia (ICD-10 code: F20.x), 
schizoaffective disorder (F25.x) or bipolar disorder (F31.x) diagnosis in the 
study observation window. The SMI term is used to group diagnoses of 
psychotic disorders such as schizophrenia, schizoaffective disorder and 
bipolar affective disorder. Clinical symptoms are believed to lie on a 
continuum between these diagnoses and it is not uncommon that a diagnosis 
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is changed over the course of the patient’s illness (Esterberg & Compton, 
2009). A decision to include all three of the above diagnoses was made based 
on discussions with clinicians within the BRC and previous published 
literature. More specifically, previous research from SLAM (Grech & Taylor, 
2012) has indicated that a proportion of patients prescribed long-term 
antipsychotic polypharmacy have a bipolar affective disorder diagnosis. In 
addition there are several other UK and international studies examining 
physical and mortality outcomes in relation to antipsychotic polypharmacy, 
who have similarly indicated that this antipsychotic regimen is common 
amongst patients diagnosed with bipolar disorder (Osborn et al. 2014; 
Laursen et al. 2014; Morrato et al. 2007). Diagnostic data were derived from 
diagnostic structured fields within CRIS and supplemented by information 
available from free text, as discussed in this chapter.  
 
4.7 Main exposure variables  
Antipsychotic polypharmacy was the main exposure for all studies (Chapter 7 
and 8) apart from the study in Chapter 6, which aimed to identify predictors of 
long-term antipsychotic polypharmacy. Long-term antipsychotic polypharmacy 
was defined as the concomitant prescription of two or more antipsychotics for 
six or more months (see also Chapter 5 section 5.3.4). Previous research has 
examined antipsychotic polypharmacy of varying duration (Broekema et al. 
2007; Clark et al. 2002; Faries et al. 2005; Ganguly et al. 2004; Ito et al. 2005; 
Jaffe & Levine 2003; Janssen et al. 2005). Based on evidence presented in 
Chapter 1 and 2, I concluded that research that has investigate antipsychotic 
polypharmacy with a duration of 70 days or less cannot definitively exclude 
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switching (Barbui et al. 2006; Ganguly et al. 2004; Kreyenbuhl et al. 2007; 
Morrato et al. 2007), which can take up to 10 weeks to complete (Correll et al. 
2011; Lochmann van Bennekom et al. 2013). Therefore, following 
consultations with psychiatrists and pharmacists working in SLAM and the 
BRC, I decided that antipsychotic polypharmacy of six or more months was 
most likely to minimise the possibility of misclassifying brief periods of 
antipsychotic co-prescribing, such as switching and PRN medications, as 
regular long-term polypharmacy; although this approach cannot absolutely 
exclude cross-titration that has taken unusually long (see Chapter 1 section 
1.7). Antipsychotic monotherapy was defined as a patient receiving a 
prescription for a single antipsychotic medication listed in the BNF (British 
National Formulary 2015), see Table 4.1. Antipsychotic agents were further 
categorised as either FGA or SGA, to enable me to explore profiles of 
antipsychotic administration. Medication data were extracted from the SLAM 
pharmacy-dispensing database, and from structured and free-text fields in 
CRIS. SLAM pharmacy-dispensing database mostly reflects medications 
dispensed on the inpatient wards. However, at present some medications 
such as clozapine are better recorded than others. This information is 
available in CRIS as a structured field.  Chapter 5 describes in detail the data-
extraction process. Briefly, structured fields record specific antipsychotics that 
have been prescribed. Although these fields are expected to be regularly 
completed, upon manual examination, I established that the majority of 
medication information is provided in the free-text fields. Therefore, structured 
information on antipsychotic medications was supplemented by information 
derived from free text, using the NLP application, described above in section 
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4.4.3. Overall precision and recall of extracting antipsychotic medication data 
is discussed in detail in Chapter 5 section 5.3.5 and Chapter 8 section 8.3.5. 
However, below I outline how the validation of antipsychotic medications and 





Table 4.1 Antipsychotic medications.  
 






Clozapine (Clozaril®, Denzapine®, Zaponex®) 
Flupentixol (Fluanxol®, Depixol®) 
Fluphenazine (Modecate®) 
Haloperidol (Dozic®, Haldol®, Serenace®) 
Levomepromazine (Nozinan®) 
Olanzapine (Zyprexa®, ZypAdhera®) 






Quetiapine (Seroquel®, Seroquel XL®) 
Risperidone (Risperdal®, Risperdal Consta®) 










4.7.1 Validation process  
 
The validation of the antipsychotic polypharmacy algorithm that was 
developed as part of this thesis is described in detail in Chapter 5 section 
5.3.5. In this section, I outline the general framework that was used to re-
validate the algorithm, for the study discussed in Chapter 8, and also used to 
validate antipsychotic dose (Chapter 8). To establish precision (positive 
predictive value), I selected a number (specific information on the number of 
patients selected to validate antipsychotic medication and dose is described in 
Chapter 8 section 8.3.5) of random cases identified as taking antipsychotic 
polypharmacy in my cohort. This was achieved using a random number 
generator (www.random.org). Using Front-End CRIS (see section 4.4.1 of this 
chapter) I manually coded the patients’ clinical notes to establish whether the 
number of antipsychotics concomitantly prescribed and/or dose were correct 
in my data extraction. The index date of the antipsychotic regimen (see 
Chapter 8 section 8.3.4) was used as the start point for the search of clinical 
records, to ascertain whether the patient had been in fact prescribed the 
regimen for at least six months. Sources of information that I examined in 
Front-End CRIS were structured fields related to medication and pharmacy 
dispensation; in addition I examined two sources of free-text information 
(Ward progress notes and Correspondence). This manual examination 
established the ‘true’ occurrence of the antipsychotic regimen. The manually 
derived information was then compared to the information I had in my dataset, 
to establish precision. Match for antipsychotic polypharmacy was defined as 
the patient ‘currently’ (at the time of the document) receiving two or more 
antipsychotics in the documents available through Front-End CRIS. Common 
 106 
mismatches included antipsychotics that have been prescribed in the past and 
antipsychotics that were cross-titrated. The same principle was applied to 
validating antipsychotic monotherapy.  
 
To establish the total antipsychotic dose that was prescribed, I needed the 
following information: dose value (e.g. 15), dose unit (e.g. mg) and dose 
frequency (e.g. once a day). I generated a number of different rules based on 
specific assumptions, in order to be able to calculate the total prescribed 
dose, in cases where there was some missing information (the performance 
of all these assumptions was also validated prior to their application in the 
final validation). At the data extraction point, if a dose value was missing, 
within six weeks of the index date of the antipsychotic, then antipsychotic 
dose could not be calculated. At the post-processing stage, when total dose 
was calculated, if a dose unit was missing, then antipsychotic dose could not 
be calculated; if the dose frequency was missing, I assumed the medication 
was to be taken ‘once a day’. To establish antipsychotic dose precision, I 
used the same principle of checking the total dose from my dataset against 
documents in Front-End CRIS (using the index date as the reference point). 
Matches were defined as having the same dose value, unit and frequency (if 
available) in the extracted dataset as in the source record in Front-End CRIS. 
Common mismatches for dose included clinical suggestions to change 
antipsychotic dose that were not actually implemented; and detecting past 
antipsychotic doses.  
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To estimate recall (sensitivity), I selected a random subset of individuals from 
my dataset, irrespective of their antipsychotic regimen (no medication, 
antipsychotic monotherapy or polypharmacy) and manually coded their 
clinical notes for the periods that they were active in SLAM services (between 
1st January 2007 and 31st December 2014), using Front-End CRIS, to 
determine whether they were identified correctly, with respect to antipsychotic 
medication use.  
 
4.8 Covariates   
Table 4.2 describes socio-demographic, socioeconomic, clinical and service 
use covariates used in the different chapters of this thesis. Below I outline the 
source of these covariates from PJS and how well they have been populated. 
However for specific project timings please refer to individual chapter sections 
(see Chapter 6 section 6.3.3; Chapter 7 section 7.3.3; Chapter 8 section 
8.3.7). Although clinical staff are advised to complete as much patient 
information as possible, none of the factors discussed below are compulsory 
fields within PJS. Furthermore, over the years categories and groupings may 
have changed, such as for example, ethnicity has been expanded, including a 
larger choice of options. Other information such as clinical checklists (e.g. 
HoNOS see below) have been better completed in recent years, as compared 
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Age was derived from patient’s date of birth, which is a structured field in PJS 
and was calculated at the time the patient entered the cohort (e.g. in Chapter 
7, this was at patient’s index discharge date). Information on date of birth was 
available for 99.7 per cent of the sample. In each project, a likelihood ratio test 
was used to determine whether it was appropriate to use age as either a 
continuous or a categorical variable in the analysis (for a likelihood ratio test 
definition please see page 116).  
 
Gender  
Gender was derived from a structured field in PJS and classified as either 
male or female. Gender information was available for all patients included in 
the projects.  
 
Ethnicity  
Ethnicity was derived from a structured field in PJS. There were seventeen 
ethnic groups in the source data field (African; any other Asian background; 
any other black background; ant other ethnic group; any other mixed 
background; any other white background; Bangladeshi; British; Caribbean; 
Chinese; Indian; Irish; none; not stated; Pakistani; white and Asian; white and 
black African), which were collapsed into smaller categories due to small cell 
sizes.  Please refer to Table 4.2 for more information on how this variable was 
categorised in each project. Information on ethnicity was available for 98.65% 
of patients in the cohort.    
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Relationship status  
Relationship status was derived from structured fields and has a total of eight 
categories, which were re-categorised as follows:  “in a relationship” 
(cohabitating, married or civil partnership) and “not in a relationship” (single, 
divorced, separated, widowed, unknown).  The completion of this field (i.e. 
excluding those unknown) was 93.48 per cent.  
 
Employment status  
Employment status was derived from a structured field and completed for 
40.49 per cent of the sample (excluding those unknown). It contained sixteen 
categories, which were re-categorised as follows: “paid employment” 
(employed; other employment status; paid employment; part-time 
employment; self-employed) and “not in paid employment” (full-time student; 
full-time student school age; not known; not applicable; not disclosed; not 
known; other; registered disabled; retired; unemployed; volunteer).  
 
Social deprivation 
To estimate socioeconomic deprivation, the area-level index of multiple 
deprivation was used. It was derived by linking the patients’ postcode to UK 
Census data for 2007. This was performed on Lower Super Output Areas 
(LSOA), which cover on average 1,500 residents per area unit (DCLG 2011).  
This index is based on seven domains of deprivation: employment, income, 
education, health, barriers to housing and services, crime, living environment, 
which are weighted and combined into an overall score of multiple deprivation 
(DCLG 2011). Homelessness was considered as an additional category in this 
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variable (Noble et al. 2008) for patients with no fixed abode. Patient postcode 
information was available for 98.50 per cent of the cohort. 
 
Comorbid mental health diagnoses  
Comorbid mental health diagnoses were derived from structured fields from 
the source data and supplemented by information derived from free text.  
Information was derived for depression (ICD-10 Code: F32, F33); substance 
use (ICD-10 Code: F10-16); and personality disorder (ICD-10 Code: F60; 
F61). Each comorbid diagnosis was coded as a binary variable, where ‘1’ was 
allocated to patients who have received that particular diagnosis. All other 
patients were coded as ‘0’.   
 
Health of the Nation Outcome Scale (HoNOS) 
Clinical symptom presence/severity was estimated from the Health of the 
Nation Outcome Scale (HoNOS). HoNOS is a clinical outcome instrument in 
wide routine use, composed of 12 items designed to measure behaviour, 
impairment, symptoms, and social functioning (Wing et al. 1998). Items are 
scored on a scale of 0 (no problem) to 4 (severe to very severe problem). Due 
to small cell sizes, subscale scores were collapsed into three categories: 0 
“not a problem”; 1 “minor problem requiring no action”; 2–4 ‘‘significant 
problem’’ (Hayes et al. 2012). The internal consistency of HoNOS has been 
estimated as moderately high (Cronbach’s α=0.59-0.76) (Patterson et al. 
2013); inter-rater reliability range 0.03 to 0.65 (mean 0.395) (Patterson et al. 
2013; Delaffon et al. 2012); and test –retest reliability ranges between 0.33 
and 0.80 (mean 0.57)(Patterson et al. 2013; Delaffon et al. 2012). At least one 
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HoNOS was completed for 84.46 per cent of the cohort; however its use was 
sometimes restricted by the timing of the completion of the scale. For example 
in Chapter 7, a HoNOS had to be completed after the index discharge date.  
 
Inpatient admissions 
The number of days spent as an inpatient was extracted from structured fields 
in PJS. In each project, a likelihood ratio test was used to determine whether 
to use this variable as a continuous or categorical in the analysis. 
 
Outpatient contact  
Previous outpatient contact was determined through the days each person 
had received face-to-face contact as recorded in structured fields in PJS. 
Multiple events on a single day were counted as one day of clinical contact, 
whilst clinical contact with outpatient services during an inpatient admission 
was not counted. In each project, a likelihood ratio test was used to determine 
whether to use this variable as a continuous or categorical in the analysis. 
 
Time known to SLAM 
This variable is described in Chapter 8 section 8.3.7. I identified the lengths of 
time, in days, each patient was known to SLAM services at the index date, by 
examining all structured and free-text records available since 1st January 
2007 up until the point the patient qualified for the antipsychotic polypharmacy 
or monotherapy group. A likelihood ratio test was used to determine whether 
to use this variable as a continuous or categorical in the analysis. 
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Community treatment orders  
I identified all patients who had received a community treatment order (CTO) 
prior to the start of follow-up [CTOs refer to a conditional discharge from 
inpatient admission, commonly implemented for a period of six months to 
improve adherence to medication and promote regular contact with services 
(DoH 2007)]. Information on CTOs was extracted from structured fields and 
coded as a binary variable, where 1 indicated the presence of a previous 
CTO. 
 
Prior antipsychotic medication use  
Information on antipsychotic medications was extracted from structured 
medication fields and supplemented by information in free–text fields, and 
SLAM pharmacy records, see section 4.4 above.  
 
Antipsychotic dose 
Information on antipsychotic dose value, unit and frequency was extracted 
from structured and free-text fields (using NLP), for both monotherapy and 
polypharmacy, where such information was available. Antipsychotic 
polypharmacy cases where dose was not available for all antipsychotics that 
were part of the polypharmacy were not included. I validated prescribed dose 
manually by examining 43 randomly selected patients from the cohort. 
Precision (Positive predictive value) was observed to be 0.81. For details on 
the validation process see section 4.7.1 above. Chapter 8 section 8.3.5 also 




The smoking NLP application described in section 4.4.3 was used to extract 
information on whether the patients have ever smoked. Patients were 
classified in two groups, those who have never smoked (coded as 0) and 
those who have in the past or are currently (at present/ at the time of the 
document) smoking (coded as 1). 
 
4.9 Statistical analysis  
STATA 13 was used to conduct all statistical analyses, apart from the studies 
described in Chapter 5 and 6, where STATA 12 was used. I built multivariable 
logistic regression models to investigate the associations between potential 
predictors and long-term antipsychotic polypharmacy (Chapter 6). Odds ratios 
(OR) and 95 per cent confidence intervals (CI) were reported for crude and 
fully adjusted associations. Multivariable Cox proportion hazard models were 
built to investigate: the risk for hospital readmission into secondary mental 
health care of patients discharged on antipsychotic polypharmacy (Chapter 7); 
and to examine the association between antipsychotic polypharmacy and the 
risk of all-cause mortality (Chapter 8). ‘Cox proportion hazard model is a type 
of survival analysis where covariates are used to predict the hazard function. 
The model can accommodate multiple covariates that also act multiplicatively 
on the hazard function. The baseline hazard function is not specified however 
it must be positive. In this thesis, time for the Cox analysis began at the point 
a patient had been on a given antipsychotic regimen (the exposure) for six or 
more months. This approach assumes that the exposure carries forward and 
does not take into account that a patient may go off and back on different 
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treatment regimens. An alternative approach could have been time dependent 
exposure, which takes into account that a patient can have multiple 
antipsychotic episodes (e.g. antipsychotic monotherapy, polypharmacy and 
no antipsychotics) over a period of time. Unfortunately the data derived from 
CRIS did not have sufficient details (such as start and stop dates of 
medication) in order to be able to detect discrete pharmacological episodes. 
Therefore, I deemed Cox regression analysis as the most suitable approach. 
 
Kaplan-Meier curves with a log-rank test were used to compare those 
prescribed antipsychotic monotherapy to polypharmacy in both analyses 
described in Chapter 7 and 8. In addition, prior to conducting the Cox 
proportional hazard models, the proportional hazard assumption was checked 
using a formal test of assumptions, which evaluates whether the hazard ratios 
estimated by the Cox change with time. This was done by splitting time into 
tertiles. A new variable (which was the interaction term between the time 
tertiles and the two medication categories) was then created. This variable 
was added to the Cox model, and using a likelihood ratio test, was compared 
against the unadjusted Cox model, to test if it offers a better fit. Furthermore, I 
used likelihood ratio tests to determine if it was appropriate to include 
covariates in the models as continuous variables comparing two Cox models, 
one with the continuous covariate and one where the continuous variable was 
spilt in categories (i.e. quartiles), where they were used as levels of a factor. If 
there was no significant difference between the two models, I used the 
variable as continuous. To examine the risk for cause-specific mortality and 
antipsychotic polypharmacy prescribing, I used competing risk regression 
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analysis (Chapter 8). In Chapter 7 and 8, I also used standard propensity 
score methods to reduce the effect of confounding by indication. Propensity 
scores were used in two ways: 1) a propensity score was built through a 
regression model which included all covariates in the specific project (refer to 
Chapter 7 section 7.3.4; and Chapter 8 section 8.3.8). I then included the 
propensity score in place of these covariates in the Cox model; 2) I 
constructed a fully adjusted Cox model, where I only included patients who 
were at risk of being prescribed monotherapy and polypharmacy based on 
their propensity score. This was decided by summarising the distribution of 
the propensity scores for both medication groups (antipsychotic monotherapy 
and polypharmacy) and selecting the area of overlap, as the propensity 
scores indicative of being at risk for both antipsychotic monotherapy or 
polypharmacy prescribing. Details regarding the specific ‘at risk’ scores have 
been added in the relevant sections in each respective project chapter (see 
page 194 and 235).  Details for the specific projects analyses are available 




CHAPTER 5:  DEVELOPING AND EVALUATING A NOVEL 
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5.1 Abstract  
Background: Antipsychotic prescription information is commonly derived 
from structured fields in clinical health records. However, utilising diverse and 
comprehensive sources of information is especially important when 
investigating less frequent patterns of medication prescribing such as 
antipsychotic polypharmacy. This study describes and evaluates a novel 
method of extracting antipsychotic polypharmacy data from both structured 
and free-text fields in electronic health records (EHRs), and its use for 
research purposes. 
Methods: Using anonymised EHRs, I identified a cohort of SMI patients who 
were treated in SLAM NHS Foundation Trust mental health care services 
between 1 January and 30 June 2012. Information about antipsychotic co-
prescribing was extracted using a combination of natural language processing 
and a bespoke algorithm. The validity of the data derived through this process 
was assessed against a manually coded gold standard to establish precision 
and recall. Lastly, I estimated the prevalence and patterns of antipsychotic 
polypharmacy. 
Results: Individual instances of antipsychotic prescribing were detected with 
high precision (0.94 to 0.97) and moderate recall (0.57-0.77). I detected 
baseline antipsychotic polypharmacy (2 or more antipsychotics prescribed in 
any 6-week window) with 0.92 precision and 0.74 recall and long-term 
antipsychotic polypharmacy (antipsychotic co-prescribing for 6 months) with 
0.94 precision and 0.60 recall. Of the 7,201 SMI patients receiving active care 
during the observation period, 338 (4.7%; 95% CI 4.2-5.2) were identified as 
receiving long-term antipsychotic polypharmacy. Two second-generation 
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antipsychotics (64.8%); and first-second generation antipsychotic 
combinations were most commonly co-prescribed (32.5%). 
Conclusions: These results suggest that this is a potentially practical tool for 
identifying polypharmacy from mental health EHRs on a large scale. 
Furthermore, extracted data can be used to allow researchers to characterize 
patterns of polypharmacy over time including different drug combinations, 
trends in polypharmacy prescribing, predictors of polypharmacy prescribing 




5.2 Background  
 
5.2.1 Existing research using electronic health records (EHRs) 
 
Clinical health records have been previously used to examine antipsychotic 
medication prescribing (Munk-Jørgensen et al. 2014; Amaddeo 2014); 
however, the potential value of EHRs remains underexplored. In the context 
of mental health care, EHRs contain large volumes of detailed information in 
free text and structured fields, providing an important resource for conducting 
analyses using large samples and investigating a multitude of patient 
characteristics and outcomes simultaneously (Stewart 2014). 
 
Studies investigating prescription databases (Ganguly et al. 2004; Taylor et al. 
2003; Leckman-Westin et al. 2014) have been successful in deriving 
medication data for large populations and over long periods of time by 
predominately extracting data from structured fields (such as drop down 
menus, or dedicated response boxes) (Leckman-Westin et al. 2014).  
However, such studies have been restricted by the limited nature of the 
derived information (Taylor et al. 2000). Data on drug prescription, as well as 
related contextual information, is frequently embedded in free-text fields in 
mental health EHRs and this may be the only source of such information in 
the absence of e-prescribing or a Primary Care Linkage. Traditionally, 
extracting free-text information has necessitated manual coding (where a 
researcher reads free text and codes it by hand according to a defined set of 
coding rules) (Su et al. 2014), which is time and labour intensive and therefore 
not always feasible on a large scale. This can result in investigating a smaller 
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than ideal sample (Centorrino et al. 2008; Brown et al. 2000; Suzuki et al. 
2008; Centorrino et al. 2004). EHR text has been analysed automatically 
using techniques such as NLP for a variety of purposes (Meystre et al. 2008). 
However, although this has involved the identification of drugs (Uzuner et al. 
2010), as far as I am aware, there have been no attempts to develop and 
validate techniques for characterising meta-data such as polypharmacy. 
 
5.2.2 Antipsychotic polypharmacy  
 
Automated extraction of information on medication prescribing is potentially 
valuable for investigating specific but important clinical prescribing patterns 
such as the practice of prescribing more than one antipsychotic drug 
simultaneously, known as antipsychotic polypharmacy, which may be 
challenging to identify through manual searches.  The prevalence of 
antipsychotic polypharmacy in routine clinical practice has been estimated to 
vary between 10-30% (Gallego et al. 2012) in people with serious mental 
illness (SMI), despite little empirical evidence to support benefits associated 
with its use (Lochmann van Bennekom et al. 2013), and associations with 
adverse health outcomes, such as increased physical health problems (e.g. 
weight gain, diabetes, metabolic syndrome, dyslipidaemia) and death (Chang 
et al. 2010; Reynolds & Kirk 2010; Brown 1997). Therefore, we need to gain a 
better understanding of the clinical characteristics that predict antipsychotic 
polypharmacy prescribing and determine associated health outcomes. One 
way to achieve this is through research using “real-life” data available in 
EHRs.   Antipsychotic polypharmacy is thus an important exposure and 
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potential confounder to be considered in studies investigating the impact of 
antipsychotic drugs in clinical settings and yet, as stated, is difficult to 
characterise on a large scale. 
 
5.2.3 Aims  
 
The aim of this chapter is to present and evaluate a novel process of 
extracting antipsychotic polypharmacy data from a large EHR data resource, 
utilising information available from both structured and free-text fields. In 
addition, I used the processed data to estimate the prevalence of 
antipsychotic polypharmacy, as well as patterns in co-prescribing, for a six-











This investigation used electronic mental health records from SLAM 
secondary health care (see Chapter 4 section 4.2, for a detailed description of 




All adult service users with SMI diagnosis of schizophrenia (ICD-10: F20), 
schizoaffective disorder (F25) or bipolar disorder (F31) who received care 
from SLAM between January and June 2012 were considered.  
 
5.3.3 Deriving antipsychotic polypharmacy data from EHRs 
 
All antipsychotic drugs listed in the BNF 65 (British National Formulary 2015) 
were considered. The BNF is a reference book containing information on 
pharmacology and prescribing of many medicines (including 29 
antipsychotics) available on the British National Health Service (NHS).  
Structured fields for recording medications data are present in the source 
EHR interrogated by CRIS, and were used in this analysis, but these are 
infrequently completed. Information was also extracted from SLAM pharmacy 
records, although this only covers particular drugs that are subject to 
monitoring by the pharmacy, such as clozapine. Most antipsychotic 
prescription information was extracted from free-text fields, including those 
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recording clinician-patient encounters, and correspondence between health 
care professionals. 
 
I extracted antipsychotic medication data from the free text with a NLP 
information extraction application developed using GATE software 
(Cunningham et al. 2013; Cunningham 2002), a suite of tools that facilitates 
the use and development of NLP applications and features. NLP is able to 
identify and exclude negation statements and speculations about future 
prescribing and instances in the text where the drug is mentioned as being 
taken by a person other than the patient. In addition to this, the application 
allows the user to extract grammatical features, which I used to create specific 
filters to maximize precision and recall of antipsychotic prescribing. Two filters 
were initially applied: all instances of medication prescription that were not 
prescribed at the ‘present time’ (this refers to medication prescribed up until 
today, or from today with regard to the date the document was written) and 
that did not include a dose value were excluded at the point of data extraction. 
Therefore, any mentions of the drug without such supporting prescription 
information were not extracted, as these were deemed too imprecise. 
 
5.3.4 Antipsychotic polypharmacy algorithm 
 
Antipsychotic polypharmacy was ascertained using an algorithm comprising 
two steps, as illustrated by Figure 5.1. In step one, case records were 
examined to determine whether two or more antipsychotics were prescribed 
within a six-week period between January and June 2012. Co-prescribing at 
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this stage (t0) was defined as baseline polypharmacy. In other words, t0 was 
the date on which an additional antipsychotic was detected in the clinical 
records that was prescribed within 6 weeks of the first antipsychotic. At stage 
two, data on all patients with antipsychotic polypharmacy at baseline were re-
examined six months after t0. A manual inspection of the data revealed that I 
was initially omitting outpatients who had less frequent clinical appointments 
and longer periods of time with no entry in the clinical record. Consequently, I 
specified that the follow-up search should begin at the point of first clinical 
event occurring six months or more after t0, which I designated as t1. 
Antipsychotic information was extracted from the clinical records, for the first 
ten weeks following t1, to determine whether the same set of antipsychotics 
were prescribed; if so, this was classified as ‘long-term’ polypharmacy. In 
order to qualify for polypharmacy at t1, at least two of the antipsychotics from 










During further development of the algorithm, I established that NLP-derived 
time and dose features were not sufficient to identify cases of antipsychotic 
polypharmacy, as they were not able to completely exclude historic 
medication information in clinical summaries, resulting in false positive 
instances (this refers to cases that are not true polypharmacy, but are 
detected as such by the application). Therefore, two additional filters were 
devised, applying the following exclusions: i) antipsychotic drugs with only a 
single annotation (by annotation I mean the identification and marking of 
spans of text that represent the prescribing of an antipsychotic) for the entire 
study period; and ii) antipsychotic drugs with multiple annotations but where 
all annotations were restricted to a single document for the entire study 
period. I reasoned that it was unlikely that a patient prescribed particular 
medication would have it mentioned in their notes only once over this period 
or only on a single day (e.g. a single document) over this period. 
 
To evaluate the performance of the data extraction process (NLP application 
and antipsychotic polypharmacy algorithm), I measured two indicators of 
validity: precision and recall. Precision (equivalent to positive predictive value 
in psychometrics) represents the proportion of patients identified as 
polypharmacy considered to be ‘true positive’, out of all cases identified as 
such by the algorithm. Recall (equivalent to sensitivity) represents the 






Prior to testing the performance of the antipsychotic polypharmacy algorithm, I 
examined the NLP application of extracting information for specific 
antipsychotic agents prescribed at individual points in time (i.e. instances 
rather than episodes). I examined and manually coded free-text records over 
a 6-month period (January to June 2012) for a subset of 120 randomly 
selected patients, who had a mention of two or more antipsychotics at any 
point between January and June 2012. I chose to examine six frequently 
prescribed antipsychotics (Leucht et al. 2013) under the assumption that 
these medications would have a larger number of annotations for 
examination. Precision and recall for the extraction of clozapine prescriptions 
using this NLP algorithm is not included here as this has been described 
previously (Hayes et al. 2014). The instances of antipsychotic prescribing 
varied from 328 to 1150 instances, per antipsychotic agent. I ran the NLP 
application over this set of unseen documents (that had not been used in the 
development of the NLP application) and compared the results to the manual 
coding of the same dataset. 
 
As illustrated by Figure 5.2, the final antipsychotic polypharmacy algorithm 
was derived following an iterative validation process. From those that were 
initially identified as being on polypharmacy by the application, I selected a 
random subset of 40 patients and manually coded their clinical records for 
antipsychotic polypharmacy, in order to ascertain its ‘true’ occurrence (also 
referred to as the ‘gold standard’). The gold standard for antipsychotic 
polypharmacy at t0 included instances where: both antipsychotics are 
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mentioned as present; evidence of one antipsychotic added to an existing 
antipsychotic; two different antipsychotics are mentioned in the clinical notes 
within six weeks of each other. At this stage I did not attempt to distinguish 
between long-term and short form of polypharmacy such as PRN or cross-
titration. Short forms of antipsychotic polypharmacy were filtered out at t1, as 
these cases were unlikely to have continued for six or more months. The gold 
standard for antipsychotic polypharmacy at t1 included instances where: there 
is evidence that two or more antipsychotics are prescribed at least six months 
from the mention at t0. The extracted data were then compared against the 
gold standard to ascertain the validity of antipsychotic polypharmacy and to 
examine discrepancies. Instructions within the algorithm were then added or 
edited accordingly until a satisfactory performance was obtained. Good and 
poor performance was decided informally. Performance of 0.80 or above was 
considered as a good. To confirm generalizability, the ‘final’ algorithm was 
tested on a new subset of 30 randomly selected patients. To estimate recall, 
from all patients active in the observation period, I selected a random subset 




Output data derived from NLP and 
bespoke antipsychotic 
polypharmacy algorithm  
A ‘gold standard’ is established for 
a random set of 40 patients   
Derived output data is compared 
against the gold standard, 
ascertaining precision and recall   
Good performance  
Poor performance  
Examine discrepancies;  
Edit algorithm/ filters;  
Re-extract the data  








Having assessed the precision and recall of the NLP application and 
antipsychotic polypharmacy algorithm, using the antipsychotic polypharmacy 
algorithm I estimated the prevalence of baseline and long-term (≥ 6 months) 
antipsychotic polypharmacy. Prevalence estimates and 95% confidence 
intervals were reported for baseline and long-term polypharmacy, as well as 









5.4.1 Validation  
 
As summarised in Table 5.1, the NLP application was able to identify 
individual instances of the selected antipsychotic agents with high precision, 
although recall levels were more modest. For the antipsychotic polypharmacy 
algorithm, the precision obtained from the final validation set of 30 patients 
was 0.92 for baseline and 0.94 for long-term antipsychotic polypharmacy. 
Recall was measured at 0.74 and 0.60 for baseline and long- term 




Table 5.1 Precision and recall per individual antipsychotic agent. 
 
Antipsychotic agent  N* Precision (%) Recall (%) 
Amisulpride 619 97.4 61.0 
Flupentixol  328 94.1 77.0 
Haloperidol 747 94.0 57.0 
Olanzapine 1150 95.0 69.3 
Risperidone 737 95.0 64.1 
Zuclopenthixol 390 97.0 67.5 






5.4.2 Main results  
 
I determined that 7,201 adult patients with SMI diagnosis were active in SLAM 
services between January and June 2012. In total 830 (11.5%;95% CI: 10.8- 
12.3) patients were prescribed two or more antipsychotics in any six weeks 
between January and June 2012, and 338 (4.7%; 95% CI: 4.2-5.2) were 
prescribed the same set of antipsychotics for six or more months. Twenty 
patients prescribed antipsychotic polypharmacy at t0 died before t1. I was 
unable to determine reasons other than the above for not continuing 
antipsychotic polypharmacy between t0 and t1.  
 
Amongst patients prescribed long-term antipsychotic polypharmacy, co-
prescribing two or more SGAs was most common (n=219; 64.8%; 95% CI: 
59.7- 69.9), followed by FGA and SGA (n=110; 32.5%; 95% CI: 27.5- 37.6) 
combinations, and two or more FGAs (n=9; 2.7%; 95% CI: 0.9- 4.4). 
 
Table 5.2 summarises long-term co-administration patterns by individual 
agents. Similarly to co-administration by class, the combination of two (or 
more) FGAs was relatively rare. The most common antipsychotic used in 
combination was clozapine, combined with at least one other SGA. 
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Table 5.2 Prevalence of long-term antipsychotic polypharmacy 
combinations (n=338). 
 
Antipsychotic medication   
 
n 
Plus at least one 
other FGA* 
n (%) 





   
Chlorpromazine 8 1 (12.5) 7 (87.5) 
Flupentixol 26 6 (23.1) 20 (76.9) 
Fluphenazine 4 2 (50.0) 2 (50.0) 
Haloperidol 30 5 (16.7) 25 (83.3) 
Levomepromazine 1 - 1 (100.0) 
Pericyazine 1 1 (100.0) - 
Pimozide 2 - 2 (100.0) 
Pipothiazine 10  2 (20.0) 8 (80.0) 
Sulpiride 33 1 (3.0) 32 (97.0) 
Trifluoperazine 3 - 3 (100.0) 
Zuclopenthixol 25  - 25 (100.0) 
Second Generation 
Antipsychotics (SGA)* 
   
Amisulpride 118  18 (15.3) 100 (84.7) 
Aripiprazole 79 12 (15.2) 67 (84.8) 
Clozapine  168 27 (16.1) 141 (83.9) 
Olanzapine 95 44 (46.3) 51 (53.7) 
Paliperidone 40 8 (20.0) 32 (80.0) 
Quetiapine 21 11 (52.4) 10 (47.6) 
Risperidone 64 21 (32.8) 43 (67.2) 
* These are overlapping categories; antipsychotic combinations may include 









5.5 Discussion  
To my knowledge, this is the first report investigating the feasibility and yield 
for a process of extracting antipsychotic polypharmacy data from both 
structured and free-text fields in EHRs, using a combination of NLP and a 
bespoke algorithm. This process enabled me to identify instances where 
specific antipsychotic agents were prescribed, then classify baseline and long-
term antipsychotic polypharmacy profiles over time. 
 
The NLP application combined with the antipsychotic polypharmacy algorithm 
performed at a high precision, suggesting that individuals classified as being 
prescribed antipsychotic polypharmacy were very likely to be classified 
correctly. The moderate recall suggested that I was less able to detect all 
antipsychotic polypharmacy cases. In designing the antipsychotic 
polypharmacy algorithm, I noticed that some of the rules used to decrease the 
false positive cases of antipsychotic polypharmacy filtered out some of the 
‘true’ cases, requiring a trade-off decision. Although detecting all cases is 
desirable, especially when investigating relatively uncommon phenomenon 
such as polypharmacy, I chose to prioritise precision over recall due to the 
large number of non-cases in the sample, which might be expected to dilute 
the impact of any such misclassification in future analyses. Similarly, the NLP 
application was developed to favour precision over recall. In this study I 
considered date-specific recall when evaluating the NLP application for 
extracting individual medications; however, in longitudinal studies a single 
patient often has a number of documents containing the same prescription 
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information, therefore relatively low recall could be compensated for by 
combining results extracted from several documents. 
 
I estimated that just under five per cent of all adult patients with SMI were 
prescribed two or more antipsychotics for six or more months. Although this is 
comparable to some research investigating antipsychotic polypharmacy with 
longer duration (Morrato et al. 2007) found 6.4% antipsychotic polypharmacy 
prevalence in a Medicaid population), it is somewhat lower in comparison to 
other previous research (10-30%) (Gallego et al. 2012). The lower prevalence 
could be attributable to a more conservative approach that was adopted in 
detecting antipsychotic polypharmacy, by examining long-term co-prescription 
with a minimum duration of six months. Some previous studies that have 
examined concomitant prescribing for 28 days (Jaffe & Levine 2003), 6 weeks 
(Broekema et al. 2007; Taylor et al. 2002) and 60 days (Ganguly et al. 2004; 
Suokas et al. 2012) may have included instances of ‘as required’ medication 
and switching. It is also possible that some polypharmacy cases were omitted 
because I prioritized precision over recall in developing the NLP application 
and algorithm. It is further possible that the low prevalence of antipsychotic 
polypharmacy that I have detected reflects a recent drive within UK health 
services to decrease antipsychotic polypharmacy prescribing. For example, 
Mace and Taylor (Mace & Taylor 2015) demonstrated that antipsychotic 
polypharmacy in inpatient settings can be reduced through regular patient 
reviews and collaborative work between clinicians and pharmacists. Their 
quality improvement programme managed to successfully reduce the rate of 
polypharmacy from 57% to 16% in inpatient settings and intensive care units. 
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This was clearly a substantial decrease and suggests that even though some 
patients may be more likely to be prescribed polypharmacy, this is not 
necessarily a long-term treatment management strategy and can be 
successfully transitioned to monotherapy. 
 
On the other hand, the findings are consistent with previous research on 
antipsychotic co-administration, where two or more SGAs, and FGA-SGA 
combinations are found to be the most prevalent combinations in clinical 
settings (Gallego et al. 2012; Broekema et al. 2007; Taylor et al. 2002; 
Centorrino et al. 2005; Ganguly et al. 2005). 
 
Previous research has suggested that olanzapine and risperidone are most 
commonly combined in co-prescribing (Broekema et al. 2007; Bernardo et al. 
2012). Clozapine was the most commonly co-prescribed antipsychotic in our 
sample. Although the therapeutic benefits of clozapine co-prescribing has 
been previously called into question (Taylor et al. 2011), this antipsychotic 
remains one of few that has some empirical support when used in 
polypharmacy (Freudenreich & Goff 2002). Furthermore, most research to 
date has examined shorter periods of antipsychotic polypharmacy (i.e. 6 
weeks)(Broekema et al. 2007), whereas studies investigating long-term 
antipsychotic polypharmacy have reported a higher prevalence of clozapine 
as a component (Ganguly et al. 2004). Clinically, this may indicate that 
patients persistently prescribed antipsychotic polypharmacy over longer 
periods of time are different from those on other forms of antipsychotic 
polypharmacy (e.g. short bouts of co-prescribing); more specifically, it is likely 
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that this sub-group are more unwell and possibly treatment-refractory (Lerner 
et al. 2004). 
 
5.5.1 Strengths  
 
The process of extracting medication data from EHRs has a number of 
advantages. For example, in instances where structured fields are poorly 
populated or incomplete, using supplementary information available in free-
text fields provides more detailed and complete information of treatments. A 
particular advantage of NLP is its ability to take into account the linguistic 
context around terminology of interest. Therefore, I was able to identify and 
exclude negation statements, past rather than current prescribing, 
speculations about future prescribing and instances in the text where the drug 
is mentioned as being taken by a person other than the patient. Furthermore, 
the antipsychotic polypharmacy algorithm allowed me to distinguish between 
different modes of polypharmacy administration, such as shorter (which would 
potentially include ‘as required’ and switching occurrences) and longer forms 
of co-prescribing. 
 
Data from EHRs are a source of rich and diverse contextual information, 
much of which may be embedded in free-text fields. The process described 
here may be adapted to extract an array of factors, which may predict 
antipsychotic polypharmacy and/or confound associations between 
antipsychotic polypharmacy and mental or physical health outcomes. 
Routinely collected EHRs capture a range of populations, such as patients in 
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different clinical settings (e.g. inpatients/ outpatients) and with different socio-
demographic profiles who have been previously under-represented and/or 
under-investigated in research. Moreover, EHRs more closely approximate 
real-life clinical practice than formal research projects involving de novo data 
collection, permitting the identification of trends in medication prescribing that 
are not otherwise captured by clinical trials. This could be valuable information 
that can be fed back into prescribing guidelines. Finally, the historic nature of 
EHRs allows longitudinal research, where medication profiles can be 
examined in relation to multiple predictors and outcomes. 
 
5.5.2 Limitations  
 
The protocol for extracted antipsychotic polypharmacy data has a number of 
limitations, which should be borne in mind. As indicated by the recall for 
individual antipsychotics and long-term antipsychotic polypharmacy, the 
approach may under-estimate the true prevalence of antipsychotic 
polypharmacy. Furthermore, the output data depends on the quality and 
accuracy of clinical entries (Stewart et al. 2009), which may vary by clinicians 
and services. Finally, it is important to note that I examined antipsychotic 
polypharmacy over a relatively short period of time, and it is possible that the 
data reflects a specific pattern in medication prescribing during that period. 
 
5.5.3 Conclusions  
 
In conclusion, I was able to develop a novel process for extracting 
antipsychotic polypharmacy information from a secondary care EHR at high 
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levels of precision. The implications for effectively utilising clinical information 
for research purposes are manifold. De-identified clinical records are reflective 
of health care service provision for large and diverse populations, therefore 
enabling researchers to examine clinical characteristics that predict 
antipsychotic profiles and confound the relationship with negative health 
outcomes. Furthermore, EHRs allow researchers to prospectively examine 
multiple outcomes in relation to polypharmacy such as mortality and physical 
health consequences; therefore, advancing our understanding of the impact of 
antipsychotic profiles on patients. 
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CHAPTER 6:  PREDICTORS OF LONG-TERM ANTIPSYCHOTIC 
POLYPHARMACY PRESCRIBING IN SECONDARY 





The contents of this chapter have contributed to the following: 
 
 
Publication in peer-reviewed journal (full text available in Appendix B) 
Kadra, G., Stewart, R., Shetty, H., Downs, J., MacCabe, J. H., Taylor, D., & 
Hayes, R. D. (2016). Predictors of long-term (≥6 months) antipsychotic 
polypharmacy prescribing in secondary mental health care. Schizophrenia 







6.1 Abstract    
Background: The predictors of long-term antipsychotic polypharmacy 
initiation are poorly understood. Existing research has been hampered by 
residual confounding, failure to exclude cross-titration, and difficulties in 
separating the timing of predictors and antipsychotic polypharmacy 
administration.   
Methods: Using data from the SLAM case register, I identified all adult 
patients with SMI who were receiving care between 1st July 2011 and 30th 
June 2012. Exposures measured between 1st July and 31st December 2011 
included socio-demographic, socioeconomic, clinical and service use 
characteristics. I then determined if long-term antipsychotic polypharmacy (six 
or more months) had been initiated between 1st January and 30th June 2012. 
Multivariable logistic regression models, adjusted for socio-demographic and 
socioeconomic factors, were built to investigate the associations between the 
above factors and the initiation of long-term antipsychotic polypharmacy.  
Results: I identified 6857 adults with SMI receiving SLAM care, of whom 115 
(1.7%) were newly prescribed long-term antipsychotic polypharmacy. In the 
adjusted models, predictors of long-term antipsychotic polypharmacy initiation 
included: symptoms (severity of hallucinations and/or delusions), previous 
treatments (clozapine and long-acting injectable antipsychotic agents), service 
use (more contact with outpatient services, community treatment order 
receipt), social factors (higher area-level deprivation, homelessness) and 
socio-demographic status (younger age, not in a relationship). 
Conclusion: The findings highlight that certain patient groups are at an 
increased risk for long-term antipsychotic polypharmacy initiation. Identifying 
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these groups earlier in their treatment could encourage clinicians to employ a 
broader range of interventions in addition to pharmacotherapy to reduce the 




6.2 Background   
Antipsychotic polypharmacy (the concomitant administration of two or more 
antipsychotics) remains common practice in treatment of serious mental 
illnesses. Its prevalence is estimated to vary between 10-30% (Freudenreich 
& Goff 2002; Gallego et al. 2012), despite current guidelines recommending 
against antipsychotic polypharmacy use, except during clozapine 
augmentation (APA 2010; Lochmann van Bennekom et al. 2013; NICE & 
NCCMH 2013), and evidence of associations with increased mortality 
(Ganguly et al. 2004; Joukama et al. 2006; Waddington et al. 1998) and 
physical health problems (including metabolic and cardiovascular disorders) 
(Ganguly et al. 2004; Raedler 2010). Examining factors that may predict 
antipsychotic polypharmacy prescribing is key to understanding its continued 
use.   
 
To date, male gender (Ganguly et al. 2004; Morrato et al. 2007; Suokas et al. 
2012; Santone et al. 2011), and younger age (Kreyenbuhl et al. 2007; Morrato 
et al. 2007; Suokas et al. 2012) have been found to be associated with 
antipsychotic polypharmacy, but there has been a lack of information on 
socioeconomic factors such as social deprivation. Antipsychotic polypharmacy 
has been found to be associated with more frequent previous hospital 
admissions (Ganguly et al. 2004; Kreyenbuhl et al. 2007; Ortiz et al. 2016), 
longer duration of previous admissions (Suokas et al. 2012), higher number of 
previous outpatient contacts (Ganguly et al. 2004; Kreyenbuhl et al. 2007) and 
previous antipsychotic medication use (Barbui et al. 2006; Suokas et al. 
2012). Findings regarding the role of clinical symptoms in antipsychotic 
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polypharmacy prescribing have been inconsistent (Barbui et al. 2006; 
Biancosino et al. 2005; Gallego et al. 2012; Moilanen et al. 2016).  
 
Previous research has examined antipsychotic polypharmacy of varying 
duration (Broekema et al. 2007; Clark et al. 2002; Faries et al. 2005; Ganguly 
et al. 2004; Ito et al. 2005; Jaffe & Levine 2003; Janssen et al. 2005) and has 
often included polypharmacy during cross-titration, which has hampered 
definitive conclusions on predictors. More recently research has begun to 
investigate antipsychotic polypharmacy with longer duration (>60 days) in an 
attempt to distinguish between cross-titration and long-term treatment (Barbui 
et al. 2006; Ganguly et al. 2004; Kreyenbuhl et al. 2007; Morrato et al. 2007). 
However, cross-titration is a process that can take up to 10 weeks to complete 
(Correll et al. 2011; Lochmann van Bennekom et al. 2013); therefore studies 
examining antipsychotic polypharmacy with a duration of 70 days or less 
cannot definitively exclude switching. Aside from heterogeneity in 
antipsychotic polypharmacy definition, investigations to date have risked 
residual confounding due to limited covariates in models (Centorrino et al. 
2004; Faries et al. 2005). Furthermore, limitations in being able to distinguish 
temporally between the occurrence of antipsychotic polypharmacy prescribing 
and associated factors make it difficult to determine if the latter are predictors 
or consequences (Kreyenbuhl et al. 2007). Other limitations include small 
homogeneous inpatient samples (Centorrino et al. 2004; Centorrino et al. 
2005), restricting generalizability. 
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Using data derived from a large de-identified electronic health records case 
register with near-universal coverage of a defined population, I investigated 
socio-demographic, socioeconomic, clinical, and service-use predictors of 
long-term antipsychotic polypharmacy initiation in SMI.  
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6.3 Methods  
 
6.3.1 Study design, data source and study sample  
 
This was a retrospective cohort study within a comprehensive register of 
patients treated with SMI in the SLAM NHS Foundation Trust (see Chapter 4 
section 4.2 for a detailed description of SLAM electronic health records and 
CRIS).  
 
Using CRIS, I ascertained all adult patients with a diagnosis of schizophrenia 
(ICD-10 code: F20.x), schizoaffective disorder (F25.x) or bipolar disorder 
(F31.x) and who were in contact with SLAM clinical services between 1st July 
2011 and 30th June 2012 (Figure 6.1). All potential predictors were measured 
between 1st July and 31st December 2011. Antipsychotic polypharmacy 
initiation was determined for the period between 1st January and 30th June 
2012, also referred to as the follow-up period. In other words, I began to 
search clinical records for antipsychotic polypharmacy on 1st January 2012. 
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N=7,215 active between 1/1/12-30/06/12 
 
• 344 dropped as they were not active 
between 1/07/11 and 31/12/11). 
n=6,871 
• 14 dropped as death occurred prior to 
the start of the follow-up period (1/1/12-
30/06/12). 
n=6,857 final sample 
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6.3.2 Outcome measures  
 
The primary outcome was long-term antipsychotic polypharmacy initiation, 
defined as the concomitant prescription of two or more antipsychotic agents 
for at least six months, with the aim of minimising the likelihood of cross-
titration being classified as polypharmacy. All service users who commenced 
antipsychotic polypharmacy at some point from 1st January to 30th June 2012, 
but who had not received antipsychotic polypharmacy in the 6 months prior to 
this were considered to have been ‘initiated’ on long-term antipsychotic 
polypharmacy. A detailed account of the method used for antipsychotic 
polypharmacy ascertaining in CRIS and the validation of this technique have 
been described in Chapter 5 section 5.3.4.  
 
6.3.3 Explanatory variables   
 
For a detailed description of these variables please refer to Chapter 4 section 
4.8. Age was calculated on the 1st January 2012 and categorised by quartiles. 
The remaining socio-demographic and socioeconomic factors were derived 
from the last entry recorded prior to 1st January 2012. Seventeen ethnic group 
categories were collapsed into “White”, “Black Caribbean”, “Black African” and 
“Other”, due to small numbers in some cells. Relationship status was defined 
as “in a current relationship” (cohabitating, married or civil partnership) and 
“not in a relationship” (single, divorced, separated, widowed, unknown). 
Employment status was recorded as being in “paid employment” (part-time, 
full-time, self-employed) and “not in paid employment” (unemployed, 
registered disabled, retired, student, looking after children, volunteer, in 
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training, not known, other). I used an area-level index of multiple deprivation 
to estimate socioeconomic status and categorised in tertiles based on the four 
catchment boroughs.  
 
Clinical symptom presence/severity was estimated from the most recent 
HoNOS completed prior to 1st January 2012. HoNOS is a clinical outcome 
instrument in wide routine use, composed of 12 items designed to measure 
behaviour, impairment, symptoms, and social functioning (Wing et al. 1998). 
Items are scored on a scale of 0 (no problem) to 4 (severe to very severe 
problem). Due to small cell sizes, subscale scores were collapsed into three 
categories: 0 “not a problem”; 1 “minor problem requiring no action”; 2–4 
‘‘significant problem’’. Items that provided overlapping information to other 
variables used in this analyses were removed; therefore I did not include item 
9 (assessing relationship problems), item 11 (assessing living conditions) and 
item 12 (assessing occupational problems). Item 8 (assessing other mental 
health problems) was also excluded, as the following comorbid diagnoses 
were ascertained using information available from free text and structured 
fields: i) depression [having received a diagnosis of depression (ICD-10: F32, 
F33) and/or scoring ‘mild’ to ‘significant’ on HoNOS item 7 problems with 
depressed mood]; ii) substance use [having received a diagnosis of 
substance use disorder (ICD-10: F10-16) and/or scoring ‘mild’ to ‘significant’ 
on HoNOS item 3 problems with drinking or drug-taking]; and iii) personality 




I considered six measures of service use: i) previous outpatient contact was 
determined through the proportion of days each person had received face-to-
face contact as an outpatient between 1st July and 31st December 2011 
(multiple events on a single day were counted as one day of clinical contact, 
whilst clinical contact with outpatient services during an inpatient admission 
was not counted); ii) the number of days spent as an in-patient between 1st 
July and 31st December 2011 were determined separately; iii) I identified the 
number of previous antipsychotics used in the six months prior to follow-up; 
iv) I identified all patients who had received a community treatment order 
(CTO) [CTOs refer to a conditional discharge from involuntary inpatient 
admission, commonly implemented for a period of six months to improve 
adherence to medication and promote regular contact with services (DoH 
2007)] prior to the start of follow-up (since 2007); dichotomous variables were 
generated to indicate whether, since 2007, patients v) had ever used 
clozapine or vi) ever used a long-acting injectable (LAI) antipsychotic agent.   
 
6.3.4 Statistical Analysis  
 
STATA 12 was used to conduct all statistical analyses. I estimated 
antipsychotic polypharmacy prevalence and incidence of newly initiated long-
term antipsychotic polypharmacy in a six-month window.  Further analyses 
focussed on predictors of long-term polypharmacy initiation. Multivariable 
models included potential confounders such as age, gender, ethnicity, 
relationship status, employment, and deprivation status. Clinical and service 
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use factors were not included as covariates due to possible over-adjustment 
for potential causal pathway factors.  
 
Several sensitivity analyses were carried out. Firstly, I tested whether the 
timing of the HoNOS assessment had an effect on the association between 
clinical items and antipsychotic polypharmacy initiation, by restricting the 
analyses to HoNOS scores obtained within the last year prior to the start of 
follow-up. I further tested whether being a local resident (as opposed to 
patients referred from the wider national catchment area) had an effect on the 
association between antipsychotic polypharmacy and all exposure variables. 
Patients residing outside the local catchment area can be referred to SLAM 
services for specialist treatment, due to particularly severe or treatment-





I identified 7201 adults with a SMI diagnosis who were receiving SLAM care 
between January and June 2012. I excluded 344 patients as they were not 
receiving care in SLAM services in the six months prior to 1st January 2012, 
resulting in a total sample size of 6857 patients. I found that 331 (4.8%) 
patients were receiving antipsychotic polypharmacy for six or more months 
between 1st January and 30th June 2012 (this sample is also referred to as 
overall antipsychotic polypharmacy) and 115 (1.7%) were newly initiated on 
long-term antipsychotic polypharmacy. Table 6.1 summarises the 
characteristics for the total cohort and by overall and newly prescribed 
antipsychotic polypharmacy.  
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Table 6.1 Cohort characteristics.  
Variables  Total cohort  







initiation*          
N (%) 
Total sample 6857 331 (4.8) 115 (1.7) 
Socio-demographic and 
socioeconomic factors  
   
Age     
16-35 1,737 (25.3) 117(35.3) 45 (39.1) 
36-45 1,789 (26.1) 105 (31.7) 31 (27.0) 
46-55 1,678 (24.5) 77 (23.3) 22 (19.1) 
56+ 1,653 (24.1) 32 (9.7) 17 (14.8) 
  Gender    
Female 2,821 (41.1) 111 (33.5) 40 (34.8) 
Male 4,036 (58.9) 220 (66.5) 75 (65.2) 
Ethnicity group    
White  3,124 (45.6) 125 (37.8) 41 (35.7) 
Black Caribbean 992 (14.5) 54 (16.3) 16 (13.9) 
Black African 1,851 (26.9) 106 (32.0) 43 (37.4) 
Other  890 (13.0) 46 (13.9) 15 (13.0) 
Relationship status     
Not in a relationship 6,052 (88.3) 311 (94.0) 111 (96.5) 
In relationship  805 (11.7) 20 (6.0) 4 (3.5) 
Employment status    
Not in paid employment  6,521 (95.1) 326 (98.5) 113 (98.3) 
In paid employment  336 (4.9) 5 (1.5) 2 (1.7) 
Deprivation level in area of 
residence  
   
Low level  2,087 (32.7) 95 (30.2) 25 (22.5) 
Medium level  2,111 (33.1) 113 (35.9) 40 (36.1) 
High level  2,107 (33.0) 97 (30.8) 42 (37.8) 
Homelessness 74 (1.2) 10 (3.1) 4 (3.6) 
Clinical factors     
Comorbid diagnosis    
Depression 3,437 (50.1) 165 (49.9) 50 (43.5) 
Personality disorder 895 (13.1) 63 (19.0) 20 (17.4) 
Substance use 1,956 (28.5) 103 (31.1) 38 (33.0) 
Overactive and aggressive 
behaviour 
   
Not a problem 4,127 (64.9) 198 (62.3) 64 (59.3) 
Minor problem 1,333 (21.0) 66 (20.8) 26 (24.0) 
Significant problem  898 (14.1) 54 (16.9) 18 (16.7) 
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* Antipsychotic polypharmacy lasting for six or more months  
  
Non-accidental self-injury 
Not a problem 5,850 (92.1) 292 (91.8) 100 (92.6) 
Minor problem 326 (5.1) 20 (6.3) 5 (4.6) 
Significant problem  179 (2.8) 6 (1.9) 3 (2.8) 
Cognitive problems     
Not a problem 3,799 (59.9) 181 (57.3) 64 (59.8) 
Minor problem 1,578 (24.9) 83 (26.3) 23 (21.5) 
Significant problem  966 (15.2) 52 (16.4) 20 (18.7) 
Physical illness or disability    
Not a problem 3,502 (55.2) 175 (55.0) 57 (52.8) 
Minor problem 1,254 (19.8) 73 (23.0) 23 (21.3) 
Significant problem  1,591 (25.0) 70 (22.0) 28 (25.9) 
Hallucinations and delusions     
Not a problem 2,688 (42.3) 97 (30.5) 34 (31.5) 
Minor problem 1,314 (20.7) 74 (23.3) 25 (23.1) 
Significant problem  2,348 (37.0) 147 (46.2) 49 (45.4) 
Problems with activities of 
daily living  
   
Not a problem 2,842 (44.8) 121 (38.2) 44 (41.1) 
Minor problem 1,572(24.8) 86 (27.1) 28 (26.2) 
Significant problem  1,934 (30.4) 110 (34.7) 35 (32.7) 
Service use     
Days of inpatients stay in 
previous six months mean 
±SD (range)  
11.8 ±36.3       
(0-184) 
35.8 ±60.0      
(0-184) 
18.8 ±44.2          
(0-184) 
Days of outpatient contact in 
previous six months-  mean 
±SD (range) 
9.4±13.9      
(0-174) 
12.5±15.1       
(0-153) 
12.2±20.1     
(0-153) 
Previous CTOs    
No 6,483 (94.6) 394 (88.8) 98 (85.2) 
Yes 374 (5.4) 37 (11.2) 17 (14.8) 
Number of antipsychotics 
used in the previous six 
months  mean ±SD (range) 
1.0±1.0 (0-8) 2.2±1.2 (0-7) 1.2±1.0 (0-6) 
Previous clozapine use     
No 5,643 (82.3) 151 (45.6) 80 (69.6) 
Yes 1,214 (17.7) 180 (54.4) 35 (30.4) 
Previous LAI use    
No 4,405 (64.2) 167 (50.5) 52 (45.2) 
Yes 2,452 (35.8) 164 (49.5) 63 (54.8) 
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Table 6.2 describes the prevalence of FGAs and SGAs that were prescribed 
as part of antipsychotic polypharmacy. Two or more SGAs were most 
commonly co-prescribed. Of the newly initiated sample, 24.3% were receiving 
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Table 6.3 summarises results from the unadjusted and adjusted logistic 
regression models, which examine the potential socio-demographic and 
socioeconomic predictors of newly prescribed antipsychotic polypharmacy. In 
the fully adjusted model, individuals in early adulthood (aged 16-35) were 
more likely to be initiated on antipsychotic polypharmacy than older adults 
(aged 56+) (OR=2.1, 95% CI: 1.1-3.7, p=0.016), whereas being in a 
relationship was associated with a reduced risk for antipsychotic 
polypharmacy initiation (OR=0.3, 95% CI: 0.1-0.9, p=0.043). Experiencing a 
high level of deprivation and more specifically being homeless was also 
associated with an increased risk for being newly initiated on long-term 
antipsychotic polypharmacy (OR=3.3, 95% CI: 1.1- 9.9, p=0031). 
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Table 6.3 Logistic regression analysis of socio-demographic and 
socioeconomic predictors of antipsychotic polypharmacy initiation. 
* Models adjusted for all socio-demographic and socioeconomic factors  
  
 Crude OR    
(95% CI) 




Age     
16-35 2.6 (1.6- 4.5) 2.1 (1.1- 3.7) p=0.016 
36-45 1.7 (0.9- 3.0) 1.4 (0.8- 2.6) p=0.291 
46-55 1.3 (0.7- 2.4) 1.1 (0.6- 2.1) p=0.749 
56+ Reference Reference  
Gender    
Female Reference Reference  
Male 1.3 (0.9- 1.9) 1.1 (0.7- 1.7) p=0.621 
Ethnicity group    
White  Reference Reference  
Black Caribbean 1.2 (0.7- 2.2) 1.1 (0.6- 2.1) p=0.691 
Black African  1.8 (1.2- 2.8) 1.4 (0.9- 2.3) p=0.129 
Other  1.3 (0.7- 2.3) 1.3 (0.7- 2.4) p=0.403 
Relationship status     
Not in a relationship Reference Reference  
In relationship  0.3 (0.1- 0.7) 0.3 (0.1- 0.9) p=0.043 
Employment status    
Not in paid 
employment  
Reference Reference  
In paid employment  0.3 (0.1- 1.4) 0.4 (0.1- 1.6) p=0.181 
Deprivation level     
Low level  Reference Reference  
Medium level  1.6 (0.9- 2.6) 1.4 (0.9- 2.4) p=0.164 
High level  1.7 (1.0- 2.8) 1.5 (0.9- 2.5) p=0.116 
Homelessness 4.7 (1.6- 13.9) 3.3 (1.1- 9.9) p=0.031 
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As described in Table 6.4, overall clinical symptoms, as measured by HoNOS 
administered closest to the start of follow-up, were not predictive of 
antipsychotic polypharmacy initiation, with the exception of significant 
problems with hallucinations and/or delusions (OR=1.6, 95% CI:1.0-2.5, 
p=0.048).  In a sensitivity analysis, where the investigation was restricted to 
HoNOS scores obtained within the last year prior to the observation period, 
this association was not substantially changed in strength, although fell 
outside statistical significance (OR=1.5, 95% CI: 0.9-2.4, p=0.146).  
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Table 6.4 Logistic regression analysis of clinical predictors of 
antipsychotic polypharmacy initiation.  
 
* Models adjusted for all socio-demographic and socioeconomic factors 
Predictors Crude OR 
(95%CI) 




Comorbid diagnosis     
Depression    
No Reference Reference  
Yes 0.8 (0.5- 1.1) 0.8 (0.6- 1.2) p=0.286 
Personality disorder    
No Reference Reference  
Yes 1.4 (0.9- 2.3) 1.2 (0.7- 2.0) p=0.464 
Substance use    
No Reference Reference  
Yes 1.2 (0.8- 1.8) 1.0 (0.6- 1.5) p=0.873 
Overactive and 
aggressive behaviour  
   
Not a problem Reference Reference  
Minor problem 1.3 (0.8- 2.0) 1.3 (0.8- 2.0) p=0.331 
Significant problem  1.3 (0.8- 2.2) 1.3 (0.8- 2.2) p=0.339 
Non-accidental self-
injury  
   
Not a problem Reference Reference  
Minor problem 0.9 (0.4- 2.2) 0.9 (0.4- 2.2) p=0.804 
Significant problem  1.0 (0.3- 3.1) 0.9 (0.3- 3.0) p=0.922 
Cognitive problems     
Not a problem Reference Reference  
Minor problem 0.9 (0.5- 1.4) 0.9 (0.6- 1.5) p=0.818 
Significant problem  1.2 (0.7- 2.0) 1.4 (0.8- 2.3) p=0.222 
Physical illness or 
disability  
   
Not a problem Reference Reference  
Minor problem 1.1 (0.7- 1.8) 1.4 (0.9- 2.4) p=0.159 
Significant problem  1.1 (0.7- 1.7) 1.6 (0.9- 2.6) p=0.064 
Hallucinations and 
delusions  
   
Not a problem Reference Reference  
Minor problem 1.5 (0.9- 2.5) 1.5 (0.9- 2.5) p=0.141 
Significant problem  1.7 (1.1- 2.6) 1.6 (1.0- 2.5) p=0.048 
Problems with 
activities of daily living  
   
Not a problem Reference Reference  
Minor problem 1.2 (0.7- 1.9) 1.2 (0.7- 1.9) p=0.506 
Significant problem  1.2 (0.8- 1.8) 1.2 (0.8- 1.9) p=0.414 
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Table 6.5 summarises associations between newly prescribed antipsychotic 
polypharmacy and service use. I found that the risk of antipsychotic 
polypharmacy initiation increased with every additional day of outpatient 
contact (OR=1.0099, 95% CI: 1.0002-1.0197, p=0.045) received in the 
previous six months, even after adjusting for possible confounders. Similarly, 
having previously received a CTO (OR=2.6, 95% CI: 1.5-4.5, p<0.001), 
previous use of clozapine (OR=1.8, 95% CI: 1.2-2.7, p=0.006), and previous 
LAI use (OR=2.2, 95% CI: 1.5-3.2, p<0.001) were all associated with 
increased risk of being newly prescribed long-term antipsychotic 
polypharmacy in the fully adjusted models.   
 
In total, 419 (6.7%) patients in the sample had been referred for SLAM 
services from other boroughs rather than being catchment area residents. A 
sensitivity analysis indicated that after restricting the analyses to patients 
residing in the SLAM catchment area, the magnitude and direction of ORs 
were similar for all associations; however some were no longer significant 
including being in a relationship (p=0.056), having problems with 
hallucinations and/or delusions (p=0.123) and outpatient contact in the 
previous 6 months (p=0.058). Also, after excluding patients from outside the 
catchment there were no longer any homeless people prescribed long-term 





Table 6.5 Logistic regression analysis of service use predictors of antipsychotic polypharm
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6.5 Discussion  
The results indicate that age, socioeconomic circumstances, psychotic 
symptoms, prior outpatient contact, CTOs, prior clozapine and/or LAI use are 
significant, independent predictors of newly prescribed long-term 
antipsychotic polypharmacy.  
 
The findings are in keeping with existing research (Mace & Taylor 2015) 
indicating that SLAM has a considerably lower prevalence of antipsychotic 
polypharmacy in comparison to a UK national sample and other US studies 
(Freudenreich & Goff 2002; Gallego et al. 2012). Considering service use 
measures, the results both confirm previous research and generate novel 
findings. For example, the results support previous research which has 
indicated that prior service use, such as more frequent outpatient contact 
(Ganguly et al. 2004; Kreyenbuhl et al. 2007), previous use of LAI, and 
clozapine (Ganguly et al. 2004), are associated with an increased risk for 
longer term antipsychotic polypharmacy (e.g. >60 days). Importantly, the 
findings further indicate that only a third of the patients initiated on 
antipsychotic polypharmacy had previously been trialled on clozapine. This 
has been previously suggested (Howes et al. 2012; Nielsen et al. 2012), and 
highlights that prescribing guidelines (i.e. that antipsychotic polypharmacy 
should only be considered after trials of two individual agents followed by 
clozapine) are not consistently applied in ‘real world’ practice. Contrary to 
some previous reports, I found no evidence to suggest that antipsychotic 
polypharmacy initiation is predicted by the number of days spent as an 
inpatient or number of antipsychotics used (Barbui et al. 2006; Ganguly et al. 
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2004; Morrato et al. 2007) in the previous six months. An important issue to 
bear in mind is that I specifically investigated antipsychotic polypharmacy 
initiation, while previous research has rarely been able to account for pre-
existing antipsychotic polypharmacy use and thus has not been able to 
distinguish factors associated with its initiation from those associated with its 
continuation. Furthermore, it is important to consider service use predictors in 
the context of the service where they are examined. For example, in the UK, 
there has been a nationwide drive to reduce the number and duration of 
inpatient admissions. Therefore, it is possible that factors, which would have 
previously warranted an inpatient admission, are now possibly driving 
antipsychotic polypharmacy prescribing due to limited beds. Future studies 
may benefit from testing further whether antipsychotic polypharmacy is 
initiated in the community in order to prevent hospital admission. The results 
further suggest that factors such as prior history of CTOs (a proposed proxy 
for non-adherence) are associated with an increased risk for long-term 
antipsychotic polypharmacy, something that has not been previously 
investigated (Biancosino et al. 2005; Patel et al. 2011).  
 
Experiencing significant hallucinations and/or delusions, as rated on the 
respective HoNOS sub-scale, emerged as the sole symptomatic predictor of 
long-term antipsychotic polypharmacy initiation. Previous research has 
detected no association between general psychopathology and long-term 
antipsychotic polypharmacy (Barbui et al. 2006); however, most studies of 
smaller inpatient samples (Biancosino et al. 2005; Centorrino et al. 2004; 
Centorrino et al. 2005) have indicated an association between antipsychotic 
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polypharmacy and positive symptoms. Lastly, despite some previous 
evidence indicating that comorbid diagnoses such as personality disorder 
(Ganguly et al. 2004) and depression (Kreyenbuhl et al. 2007) are associated 
with reduced likelihood of antipsychotic polypharmacy prescribing, I detected 
no such associations with antipsychotic polypharmacy initiation.  
 
Of the demographic factors that I examined, I found a positive association 
between antipsychotic polypharmacy and younger age (Kreyenbuhl et al. 
2007; Morrato et al. 2007; Suokas et al. 2012). There are several potential 
explanations. For example, it is possible that younger patients are seen as 
better able to tolerate side effects associated with antipsychotic polypharmacy 
(Alexopoulos et al. 2004; Shin et al. 2013) or that higher perceived risk (e.g. of 
violence) influences prescribing behaviour. Ethnic background and gender, in 
contrast to other studies (Ganguly et al. 2004; Kreyenbuhl et al. 2007; Suokas 
et al. 2012), were not significantly associated with antipsychotic 
polypharmacy.  I found a potentially protective effect of being in a relationship 
(Kreyenbuhl et al. 2007; Santone et al. 2011), which could suggest that being 
able to sustain an intimate relationship may be seen as a marker for better 
functioning and less impairment. Deprivation level emerged as the sole 
socioeconomic factor that predicted initiating long-term antipsychotic 
polypharmacy. In contrast with previous research where the principal focus 
has been on employment status (Barbui et al. 2006; Biancosino et al. 2005; 
Santone et al. 2011), the study suggests that deprivation is potentially a more 
meaningful measure of socioeconomic status. It is possible that 
homelessness acts as a proxy for illness severity (Gaebel & Zielasek 2015); 
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however, this association is novel, and the role of socioeconomic features in 
general warrants further investigation. 
 
This study had several strengths. Measuring predictors prior to antipsychotic 
polypharmacy initiation allowed us to separate the exposures and outcome, 
thereby reducing the influence of reverse causality. I also examined 
antipsychotic polypharmacy of at least six months duration, which is likely to 
have excluded cross-titration, although it is possible that some instances may 
have begun with this (e.g. where a cross-titration was commenced but not 
completed due to worsening symptoms, resulting in the observed 
antipsychotic polypharmacy). I explored multiple factors simultaneously as 
predictors and confounders, and used data from a large sample including both 
inpatients and outpatients. Finally, in common with most NHS Mental Health 
Trusts in the UK, SLAM is close to being a monopoly mental health care 
provider for its geographic catchment; therefore the sample is likely to be 
representative of patients seen by secondary care (Stewart et al. 2009).   
 
There were several potential limitations. Despite adjusting for multiple 
confounders, it is possible that some residual confounding may have 
occurred. I was unable to measure factors such as duration of illness or 
stages of treatment as patients entered the observation period. In addition, I 
was unable to measure clinician-related factors such as prescriber experience 
of initiating antipsychotic polypharmacy and knowledge of side effects and 
adverse outcomes (Correll & Gallego 2012; Correll et al. 2011; Gee et al. 
2014). In contrast to previous research where standardised symptomatic 
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assessments have been used (e.g. PANSS, BPRS), symptom assessment in 
this study was limited to individual HoNOS items, measured at one point in 
time. This scale has received some previous criticism with regards to its 
measurement of symptoms (Bebbington et al. 1999; Stein 1999), and I was 
only able to analyse a composite measure of psychotic symptoms. It is 
possible that true associations may have been concealed, and further 
research is required into the role of observed and recorded symptomatology 
in clinical decision-making. Finally, I was unable to establish reasons for not 
trialling patients on clozapine. It is possible that some patients may refuse 
clozapine initiation; therefore, what may seem as inappropriate initiation of 
antipsychotic polypharmacy may be the result of the latter being the only 
treatment option available.  
 
I believe that the findings have several important clinical implications. Long-
term antipsychotic polypharmacy prescribing is unlikely to be predicted by a 
single factor; rather, it is precipitated by a complex interplay between patient 
and wider environmental contexts, where clinical symptoms as well as service 
use such as previous treatment and contact with services may influence 
decision-making. Furthermore, the study highlights that there are certain 
patient groups, such as patients whose symptoms are resistant to treatment, 
that are at an increased risk for antipsychotic polypharmacy initiation. 
Although a proportion of patients prescribed antipsychotic polypharmacy do 
receive pharmacotherapy that is in line with current treatment guidelines (e.g. 
LAI and clozapine trials that precede antipsychotic polypharmacy initiation), a 
subgroup is offered antipsychotic polypharmacy sooner than recommended. 
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Future research would benefit from focusing further on patients that are 
inappropriately initiated on antipsychotic polypharmacy, as a long-term 
treatment plan. Identifying these groups could encourage clinicians to employ 
a broader range of interventions, including earlier trials of clozapine and/or 
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Background: Despite the lack of empirical evidence to support its superiority 
over monotherapy, clinicians continue to prescribe antipsychotic 
polypharmacy. However, little is known about the risk of readmission of 
patients discharged from hospital on antipsychotic polypharmacy.  
Methods: Using data from the SLAM case register, service users with SMI 
who were discharged between 1st January 2007 and 31th December 2014, 
were followed up for six months, to estimate their risk of hospital readmission. 
Patients were classified as either receiving monotherapy or polypharmacy at 
index discharge. Multivariable Cox regression models were constructed, 
adjusting for socio-demographic, socioeconomic, clinical and service use 
factors to examine the risk for readmission in relation to antipsychotic 
polypharmacy prescribing.  
Results: I identified 5,523 adults with SMI who had been admitted at least 
once to SLAM, of whom 1,355 (24.5%) were readmitted into secondary 
mental health care within six months of the index discharge. Being discharged 
on antipsychotic polypharmacy was associated with a significantly increased 
risk of readmission, in comparison to patients discharged on monotherapy 
(HR=1.4, 95% CI: 1.2- 1.7, p<0.001). This association was maintained in the 
fully adjusted model and following several sensitivity analyses.  
Conclusion: The results suggest that patients discharged on antipsychotic 
polypharmacy are more likely to be readmitted into hospital within six months 
in comparison to those discharged on monotherapy. This needs to be 
considered in treatment decisions and the reasons for the association 
clarified.  
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7.2 Background  
An additional regular antipsychotic is frequently added to treatment [as 
opposed to pro re nata (PRN)] in inpatient settings to manage residual clinical 
symptoms following monotherapy (Centorrino et al. 2008; Taylor et al. 2002; 
Grech & Taylor 2012; Lelliott et al. 2002; Barnes & Paton 2011a). However, 
antipsychotic polypharmacy has not been found to be associated with more 
clinical improvement from the time of admission, to the point of discharge, in 
comparison to monotherapy (Centorrino et al. 2005; Centorrino et al. 2004; 
Biancosino et al. 2005), and little is currently known about the effectiveness of 
antipsychotic polypharmacy, once patients return to the community.  
 
Hospital readmission rates are high amongst individuals with SMI (Weiden & 
Olfson 1995; Schennach et al. 2012), with the risk for rehospitalisation 
peaking in the first months after discharge (Bodén et al. 2011). Factors that 
have been associated with an increased risk for readmission are shorter 
hospital stays (Boaz et al. 2013); medication non-adherence (Weiden et al. 
2004; Haddad et al. 2014) and comorbid substance use (Boaz et al. 2013).  
 
Research examining predictors of antipsychotic polypharmacy has indicated 
that patients with higher inpatient and outpatient contact (Kadra et al. 2016; 
Ortiz et al. 2016; Centorrino et al. 2004; Faries et al. 2005; Ganguly et al. 
2004; Kreyenbuhl et al. 2007; Morrato et al. 2007; Connolly & Taylor 2014a) 
and greater illness severity (Kadra et al. 2016; Correll & Gallego 2012) are at 
particular risk of receiving antipsychotic polypharmacy prescription. 
Furthermore, research has indicated that antipsychotic polypharmacy 
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treatment has been characterised by being less likely to prevent hospital 
admission and significantly worse clinical symptoms and functioning 
(Moilanen et al. 2016; Kreyenbuhl et al. 2007). However, research to date 
examining the clinical stability of patients discharged on antipsychotic 
polypharmacy has been sparse and findings are inconclusive (Correll et al. 
2009). Evidence has been mainly derived from health insurance records, with 
findings indicating that the choice between antipsychotic polypharmacy or 
monotherapy has no effect on the risk for readmission (Boaz et al. 2013); and 
that antipsychotic polypharmacy is associated with lower hospital readmission 
in comparison to monotherapy (Katona et al. 2014). There has been sparse 
evidence to suggest that clozapine is associated with reduced 
rehospitalisation (Valevski et al. 2012; Nielsen et al. 2012; Gee et al. 2016), 
and clozapine augmentation is currently the only antipsychotic polypharmacy 
regimen that has some empirical support (Freudenreich & Goff 2002; Howes 
et al. 2012; Taylor et al. 2011), hence its acceptance as a third-line treatment 
for SMI (NCCMH 2010). However, it is unclear whether people receiving 
clozapine polypharmacy or non-clozapine polypharmacy differ in risk of 
readmission.  
 
7.2.1 Aims and hypotheses  
 
The aim of this study was to determine if there was an association between 
being discharged on antipsychotic polypharmacy and risk of readmission, in a 
large cohort using de-identified electronic health records. Furthermore, I set 
out to investigate if the inclusion of clozapine in antipsychotic polypharmacy 
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had an impact on this risk. I hypothesised that those discharged on 
antipsychotic polypharmacy would be at increased risk of hospital 
readmission compared to antipsychotic monotherapy. I further hypothesised 
that clozapine polypharmacy prescription will make no difference to the risk of 




I carried out a cohort study using de-identified data from SLAM EHRs, 
collected retrospectively for the time period between 1st January 2007 and 
31st December 2014. For further information on SLAM and CRIS please refer 
to Chapter 4 section 4.2.   
 
7.3.1 Selection criteria and primary outcome  
 
I identified all adults who had received a SMI diagnosis such as schizophrenia 
(ICD-10 code: F20.x), schizoaffective disorder (F25.x) or bipolar disorder 
(F31.x) between 1st January 2007 and 31st December 2014. I further identified 
all patients with at least one inpatient admission during the observation period 
(1st January 2007 and 31st December 2014) and who were residents in the 
boroughs of SLAM. Patients resident outside the local catchment area can be 
referred to SLAM services for specialist treatment, due to particularly severe 
or treatment-resistant symptoms. However, these patients return to their 
borough of residence following discharge, and therefore follow-up for 
readmission is not possible for this group. Therefore, this group was excluded. 
For patients with multiple admissions, I selected admissions that were 
followed by a discharge on clozapine either as a single antipsychotic or part of 
polypharmacy, otherwise the first recorded admission was used. This was 
based on previous evidence suggesting that clozapine is often under-
prescribed in relation to other antipsychotics and to polypharmacy (Lochmann 
van Bennekom et al. 2013), so I sought to identify as many cases as possible 
to increase statistical power sufficient to carry out an analysis for this group. I 
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followed up all patients from the point of their index inpatient discharge for a 
six-month period to establish whether or not they were readmitted into 
secondary mental health care. Previous research indicates that the risk for 
readmission is highest in the 30 days after inpatient discharge (Boaz et al. 
2013) and I reasoned that a six-month window would thus capture most 
readmissions. Readmissions data were derived from structured fields in CRIS. 
Follow-up stopped at the first hospital readmission, date of death, or 31st 
December 2014, whichever occurred first. Date of death within the 
observation window was traced for the entire cohort through routine 
nationwide mortality tracing linked to the electronic health record and carried 
out on a monthly basis (Chang et al. 2010; Perera et al. 2016). 
 
7.3.2 Data Extraction  
 
I extracted clinical information in the EHR through CRIS from structured and 
unstructured fields (see Chapter 4 section 4.4). For antipsychotic prescribing I 
also used information available from SLAM pharmacy records. I examined all 
antipsychotic drugs listed in the BNF (see Table 4.1 in Chapter 4). 
Antipsychotic medication data in free text was also extracted using a NLP 
information extraction application developed using GATE software 
(Cunningham et al. 2013; Cunningham 2002)(for further information on NLP 
and GATE see Chapter 4 section 4.4.3), a suite of tools that facilitates the use 
and development of NLP applications and features, and which has been used 
to derive a large volume of meta-data in CRIS for previous and current 
research (Perera et al. 2016). NLP applications take into account the linguistic 
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context when extracting data from free text, therefore offering a more 
sophisticated approach to extracting information than basic key word 
searches.  
 
7.3.3 Exposures of interest and other covariates 
 
I examined individual EHRs to ascertain whether patients were discharged on 
a single antipsychotic (i.e. monotherapy) or two or more antipsychotics (i.e. 
antipsychotic polypharmacy). Antipsychotic regimen was determined by a 
patient being prescribed the same antipsychotic/s during their inpatient stay 
and in the six weeks following their discharge. Six weeks was chosen as 
patients are often given medication to take home for a maximum of four 
weeks, therefore medication prescription and repeat prescriptions are most 
often mentioned in the clinical notes within that time. In addition, I extracted a 
number of socio-demographic, socioeconomic, clinical and service use 
features.   
 
Data extraction for age, gender, ethnicity, relationship status, and social 
deprivation are described in detail in Chapter 4 section 4.8. Age was 
calculated at index discharge and a likelihood ratio test indicated that it was 
appropriate to use age as a continuous variable in the analysis [x2(2)=1.42, 
p=0.49]. Clinical symptoms were evaluated through HoNOS (see Chapter 4 
section 4.8), prioritising those completed on or before the index discharge 
date. In cases where a HoNOS at or prior to discharge was not available, I 
took the closest score available after the discharge date. I further ascertained 
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whether or not the patient had received a mental illness diagnosis due to 
alcohol (ICD 10: F10) or opioid use (ICD 10: F11) prior to the index discharge 
(for further details see Chapter 4 section 4.8). I extracted two measures of 
prior service use: 1) the number of days spent as an inpatient in the six 
months prior to the index discharge date; the variable was used as 
categorical, following a likelihood ratio test [x2(1)=11.97, p=0.001]; and 2) the 
proportion of face-to-face contact received as an outpatient in the six months 
prior to the index discharge; the variable was used as categorical following a 
likelihood ratio test [x2(1)=4.77, p=0.029].  
 
7.3.4 Statistical Analysis  
 
STATA 13 was used to conduct all statistical analyses. Sample characteristics 
were summarised by percentage of readmission for the total cohort and by 
antipsychotic group. Kaplan–Meier curves with a log-rank test were used to 
compare those who were prescribed antipsychotic polypharmacy and 
monotherapy in relation to readmission. Following checks of proportional 
hazards assumptions (p=0.82), Cox regression procedures were used to 
examine the associations between antipsychotic polypharmacy and risk of 
readmission.  
 
Age, gender, ethnicity, relationship status, deprivation status, clinical 
symptoms (HoNOS), comorbid diagnoses and service use in the six months 
prior to the index discharge date were included as covariates in the 
multivariable analysis. I further conducted several sensitivity analyses to test 
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whether any possible associations between antipsychotic polypharmacy and 
hospital readmissions were maintained after removing factors that may have 
had an effect: 1) I excluded patients with prior history of CTOs and long-acting 
injectable (LAIs) antipsychotics use. The above are potential markers of non-
adherence and therefore important to account for when considering 
medication use. 2) I restricted the analysis to all patients with a diagnosis of 
schizophrenia (F20) in order to test if the association was maintained for this 
group. 3) I excluded patients from the borough of Lewisham as they did not 
have SLAM pharmacy data (however they did have medication data from 
structured and free-text fields in PJS). 4) I excluded patients with HoNOS 
scores obtained after the index discharge. 5) I restricted the analysis to 
patients who had not been prescribed clozapine. 6) Lastly, to reduce the 
effect of confounding by indication, I used standard propensity score methods, 
where the propensity score was the probability of being placed on 
polypharmacy at index discharge where all the potential confounders 
described in Table 7.1 were included in the model. The propensity scores 
were then used as a covariate in place of all of the aforementioned 
confounders (e.g. socio-demographic, socioeconomic, clinical and service 
use) in the Cox model. Propensity score was further used to identify patients 
who were at risk of being prescribed monotherapy and polypharmacy at 
discharge. I then constructed a fully adjusted Cox model and restricted the 
analysis to patients with this restricted range of propensity scores. Finally, I 
carried out a fully adjusted Cox model, where patients on clozapine 
antipsychotic polypharmacy and non-clozapine polypharmacy were compared 
to patients on clozapine monotherapy on their risk of hospital readmission. In 
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this latter analysis, clozapine monotherapy was considered to be, clinically, 
the most meaningful reference group. Clozapine prescribing often involves a 
period of clinical discussion, physical and blood checks. Therefore, patients 
who are initiated on clozapine could be somewhat different to patients that 
have not been initiated on clozapine. Therefore, restricting this latter analysis 




Figure 7.1 describes the selection process for the final sample. In total 14,389 
patients were dropped as a result of either not being prescribed antipsychotics 
and/or not having an inpatient admission. I compared the distribution of 
gender across patients who entered the monotherapy, polypharmacy cohort 
and everyone else and there was no significant difference in the distribution of 
gender across the three groups x2(2)= 2.85, p=0.241. In total 5,523 
individuals met the inclusion criteria for the study. Table 7.1 describes the 
characteristics of the total cohort.  Twenty five per cent (n=1,355) of the 
sample were readmitted within six months post-discharge. In total, 15.0% 
(n=826) of patients were discharged on antipsychotic polypharmacy and 85 
per cent (n=4,697) patients were discharged on monotherapy. Of these, 
30.9% (n=255) and 23.4% (n=1,100) were readmitted respectively.  
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(active SMI patients between 1/01/2007-31/12/2014) 
• 14,389 were dropped as not prescribed antipsychotics;  
and/or had no inpatient admission  
n=6,189 
• 72 dropped as the age at discharge was less than 16 years  
n=6,117 
• 3 dropped as death occured before the discharge date  
• 5 dropped as death was the same as the discharge date  
• 2 dropped as discharge date was the same as the end of 
window date  
• 584 dropped as they were referred from out of SLAM 
borough  
n=5,523 final sample  
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Table 7.1 Cohort characteristics.  
Variables  Total sample  
n (%) 
 
Total  5,523 
Monotherapy  4,697 (85.0) 
Antipsychotic polypharmacy 826  (15.0) 
Socio-demographic and 
socioeconomic factors  
 
Age  Mean (SD) 41.3 (14.5) 
  16- 34 2,052 (37.1) 
  35- 45 2,571 (46.6) 
55+ 900 (16.3) 
Gender  
Female 2,573 (46.6) 
Male 2,950 (53.4) 
Ethnicity group  
British   1,662 (30.1) 
Other White 453 (8.2) 
Asian 334 (6.0) 
Caribbean 730 (13.2) 
African   1,926 (34.9) 
Other  418 (7.6) 
Relationship status   
No relationship 4,806 (87.0) 
Relationship  717 (13.0) 
Deprivation level in area of 
residence   
 
Low level  1,834 (33.2) 
Medium level  1,844 (33.4) 
High level  1,845 (33.4) 
Clinical factors   
Diagnosis  
Schizophrenia (ICD-10: F20) 3,706 (67.1) 
Schizoaffective disorder (ICD-10: F25) 490 (8.9) 
Bipolar affective disorder (ICD-10:F31) 1,327 (24.0) 
Overactive and aggressive 
behaviour 
 
Not a problem 3,081 (56.3) 
Minor problem 1,222 (22.3) 




Not a problem 2,769 (50.7) 
Minor problem 1,574 (28.8) 
Significant problem  1,119 (20.5) 
Non-accidental self-injury  
Not a problem 4,829 (88.3) 
Minor problem 312 (5.7) 
Significant problem  326 (6.0) 
Physical illness or disability  
Not a problem 3,715 (68.1) 
Minor problem 824 (15.1) 
Significant problem  917 (16.8) 
Hallucinations and delusions   
Not a problem 1,824 (33.4) 
Minor problem 1,208 (22.1) 
Significant problem  2,423 (44.5) 
Problems with activities of daily 
living  
 
Not a problem 2,791 (51.5) 
Minor problem 1,376 (25.4) 
Significant problem  1,256 (23.1) 
Problems with Living Conditions   
Not a problem 3,069 (57.9) 
Minor problem 1,126 (21.2) 
Significant problem  1,106 (20.9) 
Problems with Occupation  
Not a problem 2,179 (41.1) 
Minor problem 1,542 (29.1) 
Significant problem  1,580 (29.8) 
Problems with Relationships  
Not a problem 2,199 (40.6) 
Minor problem 1,590 (29.4) 
Significant problem  1,628 (30.0) 
Prior alcohol use (ICD-10:F10)  
No 5,053 (91.5) 
Yes 470 (8.5) 
Prior opioid use (ICD-10:F11)  
No  5,442 (98.5) 
Yes 81 (1.5) 
Service use   
Days of inpatients stay in previous 
six months (tertiles) 
 
0-24 days 1,777 (32.2) 
25-65 days 1,904 (34.5) 
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  66-185 days 1,842 (33.3) 
Days of outpatient contact in 
previous six months (tertiles)  
 
1-2 days 1,112 (27.2) 
3-8 days 1,502 (36.7) 
9-117 days 1,479 (36.1) 
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Characteristics of patients discharged on either monotherapy or 
polypharmacy are compared in Table 7.2. The two groups were very similar in 
their socio-demographic and socioeconomic characteristics. However, there 
was a higher proportion of white patients in the monotherapy group, whereas 
the polypharmacy group had a higher proportion of patients from black African 
and black Caribbean ethnic backgrounds. In addition, patients on 
monotherapy were more likely to have been diagnosed with bipolar affective 
disorder (ICD 10: F31), whereas patients prescribed polypharmacy were more 
likely to receive a schizophrenia diagnosis. Furthermore, patients discharged 
on antipsychotic polypharmacy were more likely to have significant problems 
with hallucinations and/or delusions, and had more contact with services in 
the previous six months, both inpatient and outpatient.  
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Table 7.2 Sample characteristics by antipsychotic regimen prescribed at 
index discharge. 








Socio-demographic and socioeconomic factors   
Age     
Mean (SD)  41.3 (14.7)  41.4 (13.1)  t(5521)=0.05, 
p=0.95 
Gender    
Female 2,185 (46.5) 388 (47.0) X2(1)=0.81,  
Male 2,512 (53.5) 438 (53.0) p=0.58 
Ethnicity group    
White  1,447 (30.8) 215 (26.0) X2(5)=14.05,  
Other White 383 (8.2) 70 (8.5) p=0.02 
Asian 285 (6.1) 49 (5.9)  
Caribbean 596 (12.7) 134 (16.2)  
African   1,623 (34.6) 303 (36.7)  
Other  363 (7.7) 55 (6.7)  
Relationship status     
No relationship 4,083 (86.9) 723 (87.5) X2(1)=0.23,  
Relationship  614 (13.1) 103 (12.5) p=0.64 
Deprivation level in area of 
residence   
   
Low level  1,548 (33.0) 286 (34.6) X2(2)=1.29,  
Medium level  1,581 (33.7) 263 (31.8) p=0.53 
High level  1,568 (33.4) 277 (34.0)  
 
Clinical factors  
   
Diagnosis    
Schizophrenia (ICD-10: F20) 3,103 (66.1) 603 (73.0) X2(2)=57.59,  
Schizoaffective disorder 
(ICD-10: F25) 
386 (8.2) 104 (12.6) p<0.001 
Bipolar affective disorder 
(ICD-10:F31) 
1,208 (25.7) 119 (14.4)  
  Overactive and aggressive behaviour  
Not a problem 2,625 (56.4) 456 (55.8) X2(2)=0.20,  
Minor problem 1,039 (22.3) 183 (22.4) p=0.90 
Significant problem  987 (21.2) 179 (21.9)  
Depressed Mood    
Not a problem 2,335 (50.3) 434 (53.2) X2(2)=3.52, 
Minor problem 1,341 (29.0) 233 (28.6) p=0.17 
Significant problem  970 (20.9) 149 (18.3)  
Non-accidental self-injury    
Not a problem 4,105 (88.3) 724 (88.5) X2(2)=4.05, 
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Minor problem 257 (5.5) 55 (6.7) p=0.13 
Significant problem  287 (6.2) 39 (4.8)  
Physical illness or 
disability 
   
Not a problem 3,177 (68.5) 538 (65.9) X2(2)=2.27,  
Minor problem 689 (14.9) 135 (16.5) p=0.32 
Significant problem  774 (16.7) 143 (17.5)  
Hallucinations and 
delusions  
   
Not a problem 1,609 (34.7) 215 (26.3) X2(2)=23.52, 
Minor problem 1,023 (22.1) 185 (22.7) p<0.001 
Significant problem  2,008 (43.3) 415 (51.0)  
Problems with activities of 
daily living  
   
Not a problem 2,405 (52.1) 386 (47.7) X2(2)=5.64,  
Minor problem 1,150 (24.9) 226 (27.9) p=0.06 
Significant problem  1,059 (23.0) 197 (24.4)  
Problems with Living 
Conditions  
   
Not a problem 2,559 (57.6) 470 (59.7) X2(2)=2.15,  
Minor problem 974 (21.6) 152 (19.3) p=0.34 
Significant problem  941 (20.8) 165 (21.0)  
Problems with Occupation    
Not a problem 1,865 (41.3) 314 (39.8) X2(2)=0.95,  
Minor problem 1,302 (28.9) 240 (30.4) p=0.62 
Significant problem  1,344 (29.8) 236 (29.9)  
Problems with 
Relationships 
   
Not a problem 1,883 (40.9) 316 (39.1) X2(2)=1.04,  
Minor problem 1,343 (29.1) 247 (30.5) p=0.59 
Significant problem  1,382 (30.0) 246 (30.4)  
Prior alcohol use (ICD-
10:F10) 
   
No 4,300 (91.5) 753 (91.2) X2(1)=0.13,  
Yes 397 (8.5) 73 (8.8) p=0.71 
Prior opioid use (ICD-
10:F11) 
   
No  4,624 (98.4) 818 (99.0) X2(1)=1.67, 
Yes 73 (1.6) 8 (1.0) p=0.19 
 
Service use  
   
Days of inpatients stay in previous six months (tertiles)  
0-24 days 1,573 (34.5) 204 (24.7) X2(2)=50.42, 




66-185 days 1,481 (31.5) 361 (43.7)  
Days of outpatient contact in previous six months (tertiles)   
1-2 days 979 (28.1) 133 (22.0) X2(2)=19.12, 
3-8 days 1,294 (37.1) 208 (34.4) p<0.001 
9-117 days 1,215 (34.8) 264 (43.6)  
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Figure 7.2. presents the Kaplan–Meier curves comparing readmission over 
time for patients discharged on either antipsychotic monotherapy or 
polypharmacy. Those prescribed monotherapy displayed significantly less 
readmission (p < 0.001) over time.  
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Figure 7.2 Kaplan-Meier survival curves displaying the readmission 
status of people with serious mental illnesses comparing those 





Table 7.3 summarises the Cox proportional hazards models of the 
associations between being discharged on antipsychotic polypharmacy and 
being readmitted into secondary mental health care. Antipsychotic 
polypharmacy was associated with a significantly increased risk for hospital 
readmission (adjusted HR=1.4, 95% CI: 1.2- 1.7, p<0.001), an association, 
which was sustained after adjusting for a number of socio-demographic, 
socioeconomic, clinical and service use factors. In addition, this association 
changed little after I further adjusted for propensity scores, in place of the 
above factors. I further conducted a number of sensitivity analyses, as 
described by Table 7.4, and restricted the analysis to patients who were at 
risk of being prescribed either monotherapy or polypharmacy (based on 
propensity scores). Patients with a propensity score ranging from 0.043 to 
0.400 were considered to be at risk for both antipsychotic monotherapy and 
polypharmacy prescribing.  
  
 195 
Table 7.3 Multivariable Cox regression analysis of the association 
between antipsychotic polypharmacy prescribing and hospital 
readmission in individuals with serious mental illnesses. (Monotherapy 













N = 5,523  
Number of readmissions = 1,355 
Total person-time at risk (days) = 2,238 








 HR (95% CI) p value  
Unadjusted  Model 1.4 (1.2- 1.6) p< 0.001 
Model adjusted for socio-
demographic and 
socioeconomic factors  
1.4 (1.2- 1.6) p< 0.001 
Model adjusted for clinical 
symptoms  
1.4 (1.3- 1.7) p< 0.001 
Model adjusted for service use 
in previous 6 months  
1.3 (1.1- 1.6) p< 0.001 
Model adjusted for all of the 
above factors  
1.4 (1.2- 1.7) p< 0.001 
Model adjusted by using 
propensity score as a 
covariate 
1.4 (1.2- 1.7) p< 0.001 
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Table 7.4 Sensitivity analyses of the association between antipsychotic 
polypharmacy prescribing and hospital readmission in individuals with 
serious mental illness. (n=5,523 individuals; n=1,355 readmissions) 






















 HR (95% CI) p value  
Analysis excluding patients on 
CTOs and previously 
prescribed LAI  
1.3 (1.1- 1.6) p=0.006 
Analysis restricted to patients 
with ICD 10:F20 diagnosis  
1.5 (1.2- 1.8) p< 0.001 
Analysis restricted to patients 
with ICD 10:F31 diagnosis 
1.3 (0.9- 1.9) p=0.224 
Analysis excluding patients 
from the borough of Lewisham  
1.4 (1.2- 1.8) p< 0.001 
Analysis excluding patients 
who have obtained their 
HoNOS score after the index 
antipsychotic prescription 
1.4 (1.2- 1.7) p< 0.001 
Analysis restricted to patients  
who were at risk of being 
prescribed both monotherapy 
and polypharmacy (based on 
propensity scores) 
1.4 (1.2- 1.7) p< 0.001 
Analysis restricted to patients 
without clozapine  
1.4 (1.1-1.6) p=0.001 
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Clozapine polypharmacy constituted four per cent of the sample (n=200), 
whereas non-clozapine polypharmacy was 11.3 per cent (n=626). A fully 
adjusted Cox proportional hazards model indicated that clozapine 
antipsychotic polypharmacy was associated with significantly increased risk 
for readmission in comparison to clozapine monotherapy (HR=1.8, 95% CI: 
1.2-2.6, p=0.008) (Table 7.5). However, when I compared the risk for 
readmission between clozapine monotherapy and non-clozapine antipsychotic 
polypharmacy, I found no significant difference between the two regimens 
(HR=1.4, 95% CI: 0.9-1.9, p=0.063). As an additional analysis I also 
compared clozapine to non-clozapine polypharmacy. The results indicated no 
statistical difference between the two groups in relation to hospital 




ultivariable Cox regression analysis of the association between clozapine and non-clozapine antipsychotic 
polypharm
acy prescribing and hospital readm
ission in individuals with serious m
ental illness. (n=1,221; 
readm
issions=340)(clozapine m
onotherapy group has been used as a reference) 
          
a adjusted for all socio-dem
ographic, socioeconom













p value  
HR (95%
 CI) 




1.6 (1.2- 2.2) 
p= 0.004 
1.6 (1.2- 2.0) 
p<0.001 
M




ic factors  
1.6 (1.2- 2.3) 
p=0.003 
1.7 (1.3- 2.2) 
p<0.001 
M




1.7 (1.2- 2.4) 
p=0.003 
1.5 (1.1- 1.9) 
p=0.004 
M
odel adjusted for service 
use in previous 6 m
onths  
1.6 (1.1- 2.4) 
p=0.012 




odel   
1.8 (1.2- 2.6) 
p= 0.008 
1.4 (0.9- 1.9) 
p=0.063 
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7.5 Discussion  
This study examined the association between being discharged on 
antipsychotic polypharmacy from inpatient settings and subsequent mental 
health care readmissions in a retrospective analysis of a large cohort of 
patients, taking into account a wide range of other covariates. In summary, I 
found that patients discharged on antipsychotic polypharmacy were at an 
increased risk of re-hospitalisation. This association remained statistically 
significant and relatively unaltered in strength after multiple adjustments, 
sensitivity analyses and the use of propensity score methods to address 
confounding by indication. The results further indicated that patients 
discharged on clozapine polypharmacy had a greater risk for readmission 
when compared to patients on clozapine monotherapy.  
 
Previous research on antipsychotic polypharmacy as a predictor of 
readmission has been sparse and inconclusive. My findings were consistent 
with evidence from clinical records studies (Moilanen et al. 2016; Kreyenbuhl 
et al. 2007; Kreyenbuhl et al. 2007), indicating that patients prescribed 
antipsychotic polypharmacy were more likely to be admitted to secondary 
mental health care inpatient settings.  For example, Kreyenbuhl and 
colleagues (Kreyenbuhl et al. 2007) found that patients who had an additional 
antipsychotic prescribed, as opposed to being switched to a different 
antipsychotic, were three times more likely to be hospitalised. However, my 
findings were not in agreement with previous research investigating medical 
insurance records and rehospitalisation amongst patients prescribed long-
term antipsychotic polypharmacy (Boaz et al. 2013; Katona et al. 2014). For 
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example, Boaz and colleagues (Boaz et al. 2013) found that polypharmacy at 
discharge was not associated with future hospital readmissions; rather 
readmission was associated with patients being insufficiently stable at the 
point of initial discharge. Greater clinical severity in patients prescribed 
antipsychotic polypharmacy is one possible mechanism proposed to explain 
the higher level of readmission, and is consistent with the associations I found 
for antipsychotic polypharmacy at discharge with schizophrenia diagnosis, 
positive symptoms, and higher service contact (Kadra et al. 2016; Correll & 
Gallego 2012; Centorrino et al. 2004; Faries et al. 2005; Ganguly et al. 2004; 
Kreyenbuhl et al. 2007; Morrato et al. 2007). However, the association with 
readmission persisted and was largely unaltered after adjusting for these 
factors. Adjusting for other factors known to affect levels of readmission such 
as possible medication non-adherence (Weiden et al. 2004; Haddad et al. 
2014) as indicated by previous CTOs and LAI prescription, and substance use 
(Boaz et al. 2013), also made little difference to the results. Furthermore, the 
association between polypharmacy and readmission was sustained after 
restricting the analysis to patients who potentially might have been prescribed 
antipsychotic monotherapy or polypharmacy based on their propensity scores. 
This would suggest that patients discharged on antipsychotic polypharmacy 
are at a particular risk of readmission even after controlling for their personal 
and symptom characteristics by adjusting for these in the models. I found no 
evidence to suggest that antipsychotic polypharmacy (whether this was 
clozapine or non-clozapine) was associated with a lower risk for readmission, 
as indicated by Katona and colleagues (Katona et al. 2014). An important 
caveat to consider is that both of the aforementioned studies have considered 
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medical insurance population. Therefore, it is likely that differences in results 
are partly due to differences in the populations that were examined. For 
example, in the US patients that can pay for health care can be inherently 
different to patients that cannot afford private health care. Furthermore, 
despite general consensus across countries with regard to treatment 
guidelines (APA 2010; NICE & NCCMH 2013), it is possible that clinical 
practices does differ, and the aforementioned evidence reflects true 
prescribing differences across countries.  
 
Contrary to my hypothesis that clozapine polypharmacy would have no effect 
on the risk for readmission, the results indicated that this risk was significantly 
higher for this group as compared to clozapine monotherapy. The same 
pattern was not observed for patients on non-clozapine polypharmacy. 
Existing research, mainly based on randomised controlled trials and open 
label trials, examining clozapine polypharmacy has indicated little to no 
benefit of this regimen (Freudenreich & Goff 2002; Taylor et al. 2011; Galling 
et al. 2017). However, there has been a general lack of previous research 
examining this treatment regimen in relation to readmission in large 
observational cohort studies that are representative of real-life clinical 
practice. The latter findings are important for another reason. The evidence 
suggests that within the groups of patients receiving antipsychotic 
polypharmacy, there could be a sub-population that is at a particularly high 
risk for readmission. This could be due to a number of different factors (such 
as severity of clinical symptoms), which need further investigation. 
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7.5.1 Strengths  
 
This study had several strengths. SLAM, in common with other UK secondary 
mental health services, is a near-monopoly provider for its geographic 
catchment (Stewart et al. 2009; Perera et al. 2016), increasing the potential 
generalizability of findings and maximising their reflection of real-world clinical 
practice (Stewart et al. 2009). In addition, the large cohort provided statistical 
power to detect the primary association of interest and to adjust for broad 
range of potential confounders. All exposures were measured on or before the 
index discharge, therefore enabling us to make temporal inference with 
regards to antipsychotic polypharmacy and readmission.  
 
7.5.2 Limitations  
 
There were several potential limitations in this study, which need to be borne 
in mind. Despite multiple adjustments, residual confounding cannot be 
excluded absolutely in an observational design. Specifically, I did not capture 
factors such as duration of prior hospital admissions (Bodén et al. 2011; Boaz 
et al. 2013). In addition, as I did not measure the length of the antipsychotic 
regimen prescription after discharge, beyond looking for medication 
prescription within the first six weeks post discharge to confirm the regimen, it 
is possible that risk of readmission varies by length of medication prescription 
(e.g. short term verses long-term medication prescribing). Further research 
would benefit from examining differences in risk of readmission by length of 
antipsychotic regimen prescription. Symptom assessment in this study was 
limited to individual HoNOS items, measured at one point in time. This scale 
 203 
has received some previous criticism with regards to its measurement of 
symptoms (Bebbington et al. 1999; Stein 1999), and I was only able to 
analyse a composite measure of clinical symptoms and daily functioning. 
Although I employed propensity score adjustment and restriction, confounding 
by indication cannot be completely ruled out.  
 
7.5.3 Implications  
 
The findings of this study have several important implications. The high level 
of inpatient readmission can be interpreted as an indicator that antipsychotic 
polypharmacy is not effective in managing mental health symptoms in the 
community. The results further indicated that patients on antipsychotic 
polypharmacy are generally more unwell, therefore the prescription of 
regimens that lack empirical support are likely to further increase patient 
burden already present in this population (Kreyenbuhl et al. 2007; Gallego et 
al. 2012; Waddington et al. 1998; Ganguly et al. 2004; Paton et al. 2008; 
Taylor et al. 2000). I found that patients receiving clozapine polypharmacy 
had a particularly elevated risk for readmission as compared to clozapine 
monotherapy. This is suggestive of potential difference in treatment needs 
across patients receiving antipsychotic polypharmacy, and further indicating 
this is not a homogeneous population. Therefore, future research would 
benefit from further examining this sub-group in relation to their clinical 
symptoms, treatment needs and course of antipsychotic medication 
prescribing (e.g. time from non-clozapine monotherapy to clozapine 
augmentation). Lastly, the findings provide further support for the need to 
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reduce antipsychotic polypharmacy prescribing. Antipsychotic polypharmacy 
prescribing has remained widespread not only across clinical services but 
also across countries and time (Gallego et al. 2012), with a trend that has 
been resistant to change (Paton et al. 2008) and  with a high cost to service. 
More specifically, antipsychotic polypharmacy has been associated with a 
higher bed occupancy and length of inpatient stay, in addition to extra cost 
associated with multiple medication prescribing (Baandrup et al. 2012; Gilmer 
et al. 2007; Valuck et al. 2007). Evidence from a recent quality improvement 
programme has indicated that polypharmacy can be reduced successfully 
(Mace & Taylor 2015). Therefore, there is a clear need for similar 
programmes to be implemented on a wider national level.  
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CHAPTER 8:  LONG-TERM ANTIPSYCHOTIC POLYPHARMACY 
PRESCRIBING IN SECONDARY MENTAL HEALTH CARE 




The content of this chapter has contributed to the following:  
Giouliana Kadra, Robert Stewart, Hitesh Shetty, James H. MacCabe, Chin-
Kuo Chang, David Taylor and Richard D. Hayes. (Submitted). Long-term 
antipsychotic polypharmacy prescribing in secondary mental health care and 






8.1 Abstract  
Background: This study has addressed a recent call for research to examine 
the risk of mortality for patients prescribed regular long-term antipsychotic 
polypharmacy. Existing evidence has been hampered by several 
methodological problems, such as problems with the measurement of 
antipsychotic polypharmacy and residual confounding. 
Methods: Using data from the South London and Maudsley (SLAM) 
anonymised case register (CRIS), I identified all adult patients with serious 
mental illness (SMI) who had been prescribed a single antipsychotic or 
polypharmacy, for six or more months between 2007 and 2014. Data on all-
cause and cause-specific mortality were extracted using existing linkages 
between CRIS and death certification (Office of National Statistics). 
Multivariable Cox regression models were constructed, adjusting for socio-
demographic, socioeconomic, clinical factors and smoking, to examine the 
association between antipsychotic polypharmacy prescribing and the risk for 
death. 
Results: I ascertained 10,945 adults with SMI who had been prescribed long-
term antipsychotic monotherapy (76.9%) or polypharmacy (23.1%). In total, 
920 deaths occurred in the observation period. Patients on long-term 
antipsychotic polypharmacy had a small, elevated relative risk of mortality, 
which was significant in some, but not all models. The adjusted hazard ratios 
for death from natural and unnatural causes associated with antipsychotic 
polypharmacy were 1.2 (95% CI: 0.9-1.4, p=0.111) and 1.1 (95% CI: 0.7-1.9, 
p=0.619) respectively.  The strength of the associations between 
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antipsychotic polypharmacy and mortality outcomes were similar after 
adjusting for antipsychotic dose or other potential confounders.  
Conclusion: I found insufficient evidence to indicate that long-term 
antipsychotic polypharmacy is associated with a significantly elevated risk of 




Patients with SMI have been estimated to die approximately 15 to 20 years 
earlier than the general population (Chang et al. 2011; Brown et al. 2000; 
Auquier et al. 2006). Although suicide, accidents, violence and poor lifestyle 
choices such as smoking (Goff et al 2005; Auquier et al. 2006; Osborn et al. 
2014) partially explain some of this mortality gap, the underlying factors 
remain unclear.  
 
8.2.1 Antipsychotic medications  
 
The prescribing of antipsychotic medications to individuals with SMI has been 
questioned as a possible contributing factor to premature death in this 
population.   Although research has been sparse, there is some evidence to 
suggest that FGAs are associated with a higher mortality rate from natural 
causes and suicide (Kiviniemi et al. 2013; Joukama et al. 2006). Research 
examining SGAs has been more ambiguous. For further details see Chapter 1 
section 1.2. 
 
8.2.2 Antipsychotic polypharmacy  
 
Antipsychotic medications, and more specifically the widespread prescribing 
of medication regimens not recommended by existing guidelines (NICE & 
NCCMH 2013; APA 2010), such as antipsychotic polypharmacy, are believed 
to significantly contribute to this increased mortality (Waddington et al. 1998; 
Joukama et al. 2006) observed in patients with SMI. Furthermore, this risk has 
been reported to increase if the dose prescribed is high, especially when 
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exceeding national recommendations (e.g. BNF)(Barbui et al. 2016; Connolly 
& Taylor 2016; Moilanen et al. 2016; Torniainen et al. 2015; Ray et al. 2009; 
Osborn et al. 2014). This literature has been reviewed and discussed in detail 
in Chapter 2. Briefly, there have been considerable differences in findings 
between studies examining long-term and unspecified antipsychotic 
polypharmacy duration (Waddington et al. 1998; Joukama et al. 2006; 
Baandrup et al. 2010; Katona et al. 2014). Therefore, it is possible that 
discrepancies have been due to methodological differences in measuring 
antipsychotic polypharmacy. Furthermore, studies that have detected an 
increased risk for death have examined smaller and/or specific groups in the 
population such as inpatients, possibly limiting the generalizability of their 
findings (Waddington et al. 1998; Joukama et al. 2006). Conversely, some 
studies that have found no effect of polypharmacy on death, have examined a 
limited number of potential confounders (Tiihonen et al. 2012), such as 
antipsychotic dose, therefore risking residual confounding. There is some 
evidence indicating that patients prescribed antipsychotic polypharmacy are 
more likely to be prescribed a higher combined dose of antipsychotics in 
comparison with patients on antipsychotic monotherapy (Roh et al. 2013). The 
receipt of high antipsychotic dose has in turn been associated with increased 
risk for death and more specifically mortality from cardiovascular and stroke 
causes (Osborn et al. 2014). In fact, some research has argued that the risk 
of death in SMI patients is associated with antipsychotic dose rather than 
antipsychotic regimen (Torniainen et al. 2014), where patients exposed to no 
antipsychotics and to high antipsychotic doses are at a particularly increased 
risk of dying. 
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Consequently the effect of antipsychotic polypharmacy on serious outcomes 
such as death remains unclear. Several recent papers have called for further 
research in this field (Grech & Taylor 2012; Kreyenbuhl et al. 2006), given that 
polypharmacy prescribing remains persistently common in clinical practice, 
despite guidelines explicitly advocating against its use. Furthermore, 
programmes that have aimed to reduce its prevalence have had limited 
success (Paton et al. 2008). Therefore, findings in this field could have 
important treatment implications at individual and service levels.   
 
8.2.3 Aims and hypotheses  
 
The aim of this study was to determine if there was an association between 
long-term use of antipsychotic polypharmacy and risk of death, in a large 
cohort using de-identified EHRs. Furthermore, I set out to investigate whether 
this risk varies depending on the cause of death and other factors such as 
antipsychotic dose. I hypothesised that patients receiving long-term 
antipsychotic polypharmacy would be at increased risk of all-cause mortality, 
in comparison to patients on long-term monotherapy. I further expected that 
the risk for death will be greater for natural causes of death and for patients 
on a higher dose of combined antipsychotics. In addition, I investigated 
whether patients on higher doses are at increased risk of death and the extent 
to which this accounted for any associations with antipsychotic polypharmacy.   
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8.3 Methods  
 
8.3.1 Study design and data source 
 
This was a retrospective cohort study, which examined anonymised data from 
SLAM EHRs between 1st January 2007 and 31st December 2014. For further 
detail on CRIS and SLAM please refer to Chapter 4 section 4.2. 
 
8.3.2 Study sample 
 
Using CRIS, I ascertained all adult patients with a diagnosis of schizophrenia 
(ICD-10 code: F20.x), schizoaffective disorder (F25.x) or bipolar disorder 
(F31.x) and who were in contact with SLAM clinical services during the 
observation period between 1st January 2007 and 31st December 2014 (for 
further details see Chapter 4 section 4.6). In this study, I used a looser 
definition of ‘active’, where a first contact could be a telephone call. This was 
done in order to identify the very first time a patient became known to 
services.  In the previous chapters ‘active’ was identified as the first attended 




Mortality data extraction is described in detail in Chapter 4 section 4.4.4. 
Exact date of death was extracted to determine all-cause mortality in the 
observation period. I further determined the primary cause of death for each 
patient (cause-specific mortality). Causes of death were categorised into two 
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groups. Unnatural death included the following ICD10 diagnostic codes 
recorded on the death certificate: S00-T98 (injury, poisoning and certain other 
consequences of external causes); V01-Y98 (external causes of morbidity 
and mortality); and U509 (death from injury or poisoning, or event awaiting 
determination). All other codes were classified as natural causes of death.  
Cause-specific mortality data were extracted using a CRIS linkage with death 
records held by the Office of National Statistics (ONS), a process whereby 
anonymised BRC IDs are linked to the death register (Perera et al. 2016)(for 
further details please refer to Chapter 4 section 4.4.4).  
 
8.3.4 Exposures of interest  
 
Antipsychotic medication data were extracted from the SLAM pharmacy-
dispensing database, and from structured and free-text fields in CRIS (see 
Chapter 4 section 4.4 for description). All antipsychotic medications listed in 
the BNF65 were considered (see Chapter 4, Table 4.1). A long-term 
antipsychotic polypharmacy episode was defined as the first record of 
concurrent prescription of two or more antipsychotics for six or more months, 
in the observation window (also referred to as the index polypharmacy date). 
A detailed description of how antipsychotic polypharmacy was derived is 
provided in Chapter 5 section 5.3.4. The first recorded episode of 
antipsychotic polypharmacy was selected in order to minimise previous 
antipsychotic polypharmacy episodes having an effect on the outcome of 
interest. The 1st January 2007 was selected as the point at which I began 
searching for a polypharmacy episode, due to having more complete EHRs 
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from this point onwards. If an antipsychotic polypharmacy episode was not 
recorded, I looked for the first episode of antipsychotic monotherapy in the 
observation period: where a patient was prescribed a single antipsychotic for 
six or more months (also referred to as the index monotherapy date). I 
considered several other possible reference groups (discussed in detail in the 
section 8.4.4 of this chapter); however, selecting the first episode of 
monotherapy maximised the time available for follow-up, thus limiting the 
possibility for potential biases in relation to follow-up.  
 
For each patient, the follow-up time commenced at the point they were 
receiving antipsychotic polypharmacy or monotherapy for six or more months 
(index date). Follow-up continued until a death was recorded or the end of the 




The validation process is described in more detail in Chapter 4 section 4.7.1. I 
validated the performance of the algorithm described in Chapter 5, to ensure it 
was working well for this specific cohort. I conducted a manual examination of 
clinical notes for 35 patients who were identified as receiving long-term 
antipsychotic polypharmacy. I detected a positive predictive value (PPV) (i.e. 
precision) of 0.8. I further examined 17 cases identified as long-term 
monotherapy and detected a PPV of 0.9. Sensitivity (recall) was calculated as 
0.8 after examining a random set of 20 cases including both antipsychotic 
monotherapy and polypharmacy.  
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8.3.6 Antipsychotic dose 
 
Information on antipsychotic dose value, unit and frequency was extracted 
from free text, using NLP and structured fields, for both monotherapy and 
polypharmacy, where such information was available. Antipsychotic 
polypharmacy cases, where dose was not available for all antipsychotics that 
were part of the polypharmacy, were not included in the analysis. I manually 
validated prescribed daily dose by examining 43 randomly selected patients 
from the cohort. Positive predictive value (i.e. precision) was observed to be 
0.8. 
 
I used two different methods to calculate dose equivalents. Percentage out of 
maximum BNF recommended dose is currently recommended by the Royal 
College of Psychiatrists (Royal College of Psychiatrists 2014) as one of the 
preferred approaches to identify high-dose prescribing. However, this 
approach does not take into account the fact that efficacy for some 
antipsychotics takes place at lower doses (Connolly & Taylor 2014b), 
therefore creating a clustering towards lower values when converting overall 
dose into a percentage. I therefore used olanzapine equivalence (Gardner et 
al. 2010) as an alternative approach, which has been favoured by recent 
publications in antipsychotic polypharmacy (Patel et al. 2013; Gisev et al. 




Percentage BNF dose (%BNF) 
This was calculated by converting the dose of each drug into a percentage of 
the BNF (%BNF) maximum recommended dose for that drug. For 
polypharmacy, the percentages for individual antipsychotics were added 
together into a summed value. A cumulative dose of more than 100% was 
considered a high dose (Royal College of Psychiatrists 2014). 
 
Information regarding the maximum recommended doses for individual 
antipsychotics was derived from the BNF 65 (British National Formulary 
2015). Seven antipsychotics have an oral and depot form. Therefore, I 
created several rules to calculate the dose for these specific medications, in 
order to distinguish between the two forms of the same antipsychotic. In the 
first instance, where an initiation dose for depot was available, I used it to 
specify that any instance where the patient was prescribed a dose equal or 
above this value would be considered as depot, whereas doses lower than 
the depot initiation dose would be considered as oral. In cases where the 
depot initiation dose and the maximum oral dose were very close in value, I 
used the usual maintenance dose for depot to distinguish from oral 
prescriptions. This is described in Table 8.1. The maximum dose for oral and 
depot, respectively, were used to calculate the final percentage BNF dose. A 
likelihood ratio test indicated that it was appropriate to use this as a 
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Olanzapine equivalence dose  
An alternative method to comparing dose across antipsychotics is to convert 
each into an olanzapine equivalent dose. To achieve this I used the Gardner 
et al. (Gardner et al. 2010) consensus method, which has been applied in 
several previous studies (Gisev et al. 2014; Patel et al. 2013). Polypharmacy 
doses were calculated by adding up the equivalence doses of all 
antipsychotics that were part of the polypharmacy regimen. A total dose 
above 20 milligrams (mg) was classified a high dose, based on previous 
research in this field (Gardner et al. 2010; Gisev et al. 2014; Patel et al. 2013). 
A likelihood ratio test indicated that it was most appropriate to use this 
variable as categorical (p=0.002), where 1-10mg was identified as a low dose, 
11-20mg as medium dose and 21mg or above as high dose. Due to no 
previous published information on olanzapine equivalence for asenapine, I 
was unable to generate an olanzapine equivalence conversion, resulting in 
dropping a total of five cases for this specific analysis.    
 
8.3.7 Covariates  
 
Age, gender, ethnicity, and relationship status were derived from structured 
fields, closest to the index date. A likelihood ratio test indicated that it was 
appropriate to use age as a continuous variable in the analysis (p=1.000). 
Ethnicity, relationship status, employment and deprivation level data 
extraction and classification are detailed in Chapter 4, section 4.8.  
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Clinical factors included the patient receiving a comorbid diagnoses of 
depression (ICD-10: F32, F33); personality disorder (ICD-10: F10-16); 
substance use (ICD-10: F60; F61), prior to or at the point follow-up began. I 
ascertained this using information available from free text and structured 
fields. In addition, I identified the lengths of time, in days, each patient was 
known to SLAM services at the index date, by examining all structured and 
free-text records available since 1st January 2007 up until the point the patient 
qualified for antipsychotic polypharmacy or monotherapy group. A likelihood 
ratio test indicated that it was appropriate to use this variable as a continuous 
in the analysis (p=0.597). The extraction and coding of these variables is 
described in Chapter 4 section 4.8.  
 
Given the increased risk of death amongst smokers (Goff et al. 2005; 
Dickerson et al. 2013), patients were classified in two groups, those who have 
never smoked and those who have in the past or are currently smoking 
(further details on classification are described Chapter 4 section 4.4.3).  
 
8.3.8 Statistical analysis 
  
STATA 13 was used to conduct all statistical analyses. Sample characteristics 
were summarised for the total cohort, as well as for all those who were in the 
long-term antipsychotic polypharmacy and monotherapy group. Cox 
proportional hazard models were used to determine whether any of the socio-
demographic, socioeconomic or clinical factors were significantly associated 
with all-cause mortality. I further used chi-square tests to investigate whether 
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the monotherapy and polypharmacy group differed in relation to their sample 
characteristics. Kaplan–Meier curves with a log-rank test were used to 
compare those who were prescribed antipsychotic polypharmacy and 
monotherapy in relation to all-cause mortality. Following checks of 
proportional hazards assumptions [x2(2)=2.12, p=0.346], Cox regression 
procedures were used to examine the associations between antipsychotic 
regimen and risk of death. 
 
Multivariable models included potential confounders such as age, gender, 
ethnicity, relationship status, deprivation status, comorbid diagnoses 
(depression; personality disorder, and substance use), time known to SLAM 
and smoking. Two additional fully adjusted models including percentage BNF 
and olanzapine equivalence dose, respectively, were also run. To reduce the 
effect of confounding by indication, I used a standard propensity score 
methods, where the propensity score was the probability of being placed on 
polypharmacy at index discharge based on all variables described above 
(aside from dose). Dose was not included in calculating the propensity score 
due to not having available dose information for all patients in the cohort. The 
propensity scores were then used as a covariate in place of all of the 
aforementioned confounders in the Cox model. In addition, the following 
sensitivity analysis were planned to test whether any associations between 
polypharmacy and all-cause mortality were maintained after removing 
particular subgroups: 1) I restricted the analysis to patients who had not been 
prescribed clozapine, following evidence that clozapine could reduce the risk 
of death (Hayes et al. 2014);  2) I restricted the analysis to all patients who 
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had a FGA as part of their treatment regimen. FGAs have previously been 
associated with an increased risk of death (Kiviniemi et al. 2013; Joukama et 
al. 2006); 3) I excluded all patients who came from outside the four catchment 
boroughs. Patients resident outside the local catchment area can be referred 
to SLAM services for specialist treatment, due to particularly severe or 
treatment-resistant symptoms. Therefore, this group could be inherently 
different to local patients; 4) Lastly, standard propensity score methods were 
used to restrict the analysis only to patients who were at risk of both 
monotherapy and polypharmacy prescribing, based on their propensity 
scores. More specifically, this was achieved by removing patients from the 
analysis who, based on their propensity score, could have only been 
prescribed antipsychotic monotherapy or polypharmacy. In addition, separate 
Cox models were built to test the association between all-cause mortality and 
prescribed dose. However, Cox regression does not allow for the occurrence 
of two competing risks (i.e. different causes of death). Therefore, to examine 
the risk for cause-specific mortality, I used competing risk regression 
analyses, which allows for more than one competing risk in the cohort. 
Competing risk regression focuses on the cumulative incidence function, 
which indicates the probability of the event happening before a given time. 
Chi-square test was used to compare the sample characteristics between 




8.4 Results  
I identified 21,398 patients with SMI active in SLAM services during the eight-
year follow up. Out of those 10,945 individuals met the inclusion criteria for 
the study. Figure 8.1, illustrates the sample selection process for this study. I 
compared the individuals from the final cohort (n=10,945) to those who were 
not prescribed a long-term antipsychotic regimen (i.e. everyone else) 
(n=9,422) in relation to their gender and age. Patient prescribed a long-term 
antipsychotic regimen were older [long-term antipsychotic regimen (Mean= 
41.2, SD=15.1) and everyone else (M= 40.6, SD= 16.4), ttest (df=20367)= -
2.995, p=0.0027] and more likely to be male [56.2% as compared to 51.6% in 
the everyone else sample, x2(df=1)=44.39, p<0.001]. The mean time of follow 
up was 1636 days (standard deviation= 839), which is approximately four and 









active SMI patients between 01/01/2007-
31/12/2014  
n=20,407 
•  986 observations dropped  as they were 
younger than 16 years of age 
•  5 dropped as age was 100 years old 
n=20,367 
• 10 observations dropped as death 
occured prior to antipsychotic index date   
• 30 observations dropped as death 
occured prior to monotherapy index date 
n=10,945 final sample  
• 9422 dropped as they did not have long-
term antipsychotic polypharmacy or 
monotherapy 
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Table 8.2 describes the characteristics of the total cohort, together with an 
age and gender adjusted Cox regression analysis of the associations between 
death and sample characteristics. In total, 920 (8.4%) patients died within the 
observation window. Age, gender, comorbid substance use and having ever 
smoked were all associated with an increased risk for all-cause mortality, 
whereas being in a relationship at the time the follow-up began or being of 




Table 8.2 Cox regression analysis of the association between sample 
characteristics and mortality.  
 
N = 10,945  
Number of deaths = 920 
Total person-time at risk (years) =49,026 
Rate per 100 person-years = 1.88 (1.76- 2.00) 
Variables  Total Cohort  
n(%) 
HR (95% CI)* 
Socio-demographic and 
socioeconomic factors  
  
Age    
Mean (SD)  57.4 (17.0)  1.1 (1.06-1.07) 
Gender   
Female 427 (46.4) Reference  
Male 493 (53.6) 1.4 (1.2-1.6) 
Ethnicity group   
British 468 (50.9) Reference 
Other White 91 (9.9) 0.8 (0.6- 1.0) 
Asian 54 (5.9) 0.8 (0.6- 1.0) 
Caribbean 140 (15.2) 0.7 (0.6- 0.9) 
Black African  129 (14.0) 0.8 (0.7- 0.9) 
Other 38 (4.1) 0.8 (0.6- 1.2) 
Relationship status    
No relationship 808 (87.8) Reference 
Relationship  112 (12.2) 0.8 (0.6- 0.9) 
Employment    
Not in paid   employment  910 (98.9) Reference 
Paid employment  10 (1.1) 0.6 (0.3- 1.1) 
Deprivation level in area of  
residence   
  
Low level  328 (35.7) Reference 
Medium level  299 (32.8) 1.0 (0.9- 1.2) 
High level  283 (30.9) 0.9 (0.8- 1.1) 
Homelessness 5 (0.6) 0.6 (0.2- 1.4) 
 
Clinical factors  
  
Diagnosis   
  Schizophrenia (ICD-10: F20) 690 (75.0) Reference 
Schizoaffective disorder (ICD-10: 
F25) 
60 (6.5) 0.9 (0.7- 1.2) 
Bipolar affective disorder (ICD-10: 
F31) 
170 (18.5) 0.9 (0.8- 1.1) 
Comorbid Depression   
No 816 (88.7) Reference 
Yes 104 (11.3) 0.9 (0.7- 1.2) 
 225 
Comorbid Personality Disorder   
No 858 (93.3) Reference 
Yes 62 (6.7) 1.2 (0.9- 1.6) 
Comorbid Substance Use   
No  835 (90.8) Reference 
Yes 85 (9.2) 1.7 (1.3- 2.1) 
  Time known to SLAM   
Mean (SD)  1667.15 (996.7) 1.0 (0.9999- 1.0000) 
%BNF   
Mean (SD) 53.95 (49.7) 1.0 (0.9991- 1.0017) 
Olanzapine equivalence dose    
1-10mg 373 (45.5) Reference 
11-20mg 211 (25.7) 0.9 (0.8- 1.2) 
21+mg 236 (28.8) 1.1 (0.9- 1.3) 
  Smoking   
Never smoked 301 (32.7) Reference 
Have smoked ever  619 (67.3) 1.5 (1.3- 1.8) 
* All HR have been age and gender adjusted
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8.4.1 Antipsychotic regimen and all-cause mortality  
 
Table 8.3 summarises the sample characteristics by antipsychotic 
monotherapy and polypharmacy group. In total, 8,421 (76.9%) sample cases 
were prescribed long-term monotherapy, of whom 758 (9%) died in the follow-
up. A further 2,524 sample cases (23%) were prescribed long-term 
antipsychotic polypharmacy, of whom 162 (6.4%) died. Patients prescribed 
monotherapy differed significantly from those prescribed polypharmacy across 
all socio-demographic, socioeconomic, clinical and smoking characteristics 
apart from comorbid substance use, where a comparable proportion of 
patients received a comorbid substance use diagnoses. Patients prescribed 
antipsychotic polypharmacy were on average younger, more likely to be of 
black African or Caribbean ethnicity, less likely to be in a relationship or 
employed and had a higher level of deprivation. Furthermore, antipsychotic 
polypharmacy patients were more likely to be diagnosed with schizophrenia, 
whereas patients on monotherapy had a higher prevalence of bipolar affective 
disorder diagnosis. However, patients on monotherapy were more likely to 
have a comorbid depression diagnosis, whereas patients on polypharmacy 
had a higher prevalence of personality disorders. Polypharmacy prescribed 
patients were known to mental health service for longer, were more likely to 
receive a high antipsychotic dose (as measured by both %BNF and 





Table 8.3 Sample characteristics of patients prescribed monotherapy 
and antipsychotic polypharmacy. (n=10,945)  
Antipsychotic Monotherapy  
Total person-time at risk (years) =39,474 
Rate per 100 person-years = 1.92 (1.79- 2.06) 
 
Antipsychotic Polypharmacy  
Total person-time at risk (years) =9,551 
Rate per 100 person-years = 1.70 (1.45- 1.98) 








Total  8,421 (76.9) 2,524(23.1)  





   
Age                                               
Mean (SD)  
42.2 (15.4) 38.1 (13.5) t(10943)=12.13, 
p<0.001 
Gender    
Female 3,737 (44.4) 1,054 (41.8) X2(1)=5.40, 
p=0.02 
Male 4,684 (55.6) 1,470 (58.2)  
Ethnicity group    
British 3,160 (37.6) 838 (33.2) X2(5)=49.76,  
Other White 791 (9.4) 184 (7.3) p<0.001 
Asian 566 (6.7) 159 (6.3)  
Caribbean 1,072 (12.7) 354 (14.0)  
Black African  2,198 (26.1) 813 (32.2)  
Other 634 (7.5) 176 (7.0)  
Employment     
Not in paid    
employment  
8,132 (96.6) 2,461 (97.5) X2(1)=5.46, 
p=0.02  
Paid employment  289 (3.4) 63 (2.5)  
Relationship 
status  
   
No relationship 7,198 (85.5) 2,303 (91.2) X2(1)=56.39, 
p<0.001 
Relationship  1,223 (14.5) 221 (8.8)  
Deprivation level 
in area of 
residence   
   
Low level  2,726 (32.6) 805 (32.2) X2(3)=10.54,  
Medium level  2,758 (33.0) 808 (32.3) p=0.01 
High level  2,742 (32.8) 821 (32.9)  





Clinical factors  
   
Schizophrenia 
(ICD-10: F20) 









1,886 (22.4) 339 (13.4)  
Comorbid 
Depression 
   
No 7,235 (85.9) 2,223 (88.1) X2(1)=7.71,  





   
No 7,642 (90.8) 2,145 (85.0) X2(1)=68.22,  
Yes 779 (9.2) 379 (15.0) p<0.001 
Comorbid 
Substance Use 
   
No  7,581 (90.0) 2,252 (89.2) X2(1)=1.37,  
Yes 840 (10.0) 272 (10.8) p=242 
Time known to 
SLAM 
   
Mean (SD)  1603.5 
(1138.2) 
2223.9 (1468.9) t(10943)=-22.36, 
p<0.001 
%BNF    
Mean (SD) 45.8 (36.8) 101.8 (68.8) t(10020)=-50.84, 
p<0.001 
Olanzapine 
equivalence dose  
   
1-10mg 4,341 (55.7) 134 (6.0) X2(2)=3.1,  
11-20mg 2,427 (31.2) 557 (25.0) p<0.001 
21+mg 1,022 (13.1) 1,536 (69.0)  
  Smoking    
Never smoked 3,016 (35.8) 374 (14.8) X2(1)=400.46,  
Have smoked ever  5,405 (64.2) 2,150 (85.2) p<0.001 
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Antipsychotic dose information was available for 92% of the sample. 
Therefore the total cohort sample for the analysis including %BNF dose was 
n=10,022. Gardner et al. (Gardner et al. 2010), do not provide an olanzapine 
equivalent dose for asenapine, therefore five further cases were dropped 
resulting in n=10,017 for the analysis including olanzapine equivalence dose.   
 
Tables 8.4 and 8.5 summarise the prescribing patterns for specific 
antipsychotic groups (such as first and second generation antipsychotics) by 
antipsychotic regimen and %BNF dose (Table 8.4); and olanzapine 
equivalence dose (Table 8.5). Overall, following a chi-square test, there was a 
higher proportion of FGA prescribing for patients on a high-dose monotherapy 
regimen, as categorized by both %BNF and olanzapine equivalence.   
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Table 8.4 Distribution of antipsychotics by generation across low, m
edium
 and high %
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Table 8.5 Distribution of antipsychotic type by generation across low, m
edium
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Figure 8.2 represents the Kaplan–Meier curves comparing mortality over time 
for patients prescribed either long-term antipsychotic monotherapy or 
polypharmacy. There was no significant difference in mortality across the two 
groups over time (p= 0.1656).   
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Figure 8.2 Kaplan-Meier survival curves comparing mortality over time 





Table 8.6 summarises Cox proportional hazards models of the associations 
between being prescribed long-term antipsychotic polypharmacy and all-
cause mortality. Age and gender appeared to have a negative confounding 
effect, and adjusting for those in the multivariable model, increased the 
strength of the association of interest. Adjusting the model for smoking 
resulted in a decrease in the strength of the association, and the association 
was no longer statistically significant. The fully adjusted model indicated a 
slightly elevated risk, but this was not statistically significant. Furthermore, the 
association remained unchanged after I adjusted for propensity scores, in 
place of the above factors. A likelihood ratio test revealed no interaction 
between either dose [%BNF (p=0.083); olanzapine equivalence (p=0.1510)] 
and antipsychotic regimen for all-cause mortality. I included %BNF and 
olanzapine equivalence dose as covariates in two separate models. The 
%BNF dose adjustment revealed a modest significant association between 
polypharmacy prescribing and death; however this association was not 
significant in the model where olanzapine equivalence was included as a 
covariate. I further conducted several sensitivity analyses, described in Table 
8.7. Although restricting the analysis to patients not prescribed clozapine, or 
to patients prescribed FGAs, indicated no association between antipsychotic 
polypharmacy prescribing and risk of death, restricting the analysis to patients 
residing within the SLAM catchment, and to patients with a propensity score 
indicating they could have been prescribed both monotherapy and 
polypharmacy, indicated similar risk for all-cause mortality, which was just 
below statistical significance. Patients with a propensity score ranging from 
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0.023 to 0.631 were considered to be at risk for both antipsychotic 




Table 8.6 Multivariable Cox regression analysis of the association 
between antipsychotic polypharmacy prescribing and mortality in 
individuals with serious mental illness.  
 
a socio-demographic factors included age, gender, ethnicity, relationship 
status  
b socioeconomic factors included employment and deprivation level  
c clinical factors comprised comorbid depression, personality disorder and 
substance use; and time known to SLAM services.  
N = 10,945  
Number of deaths = 920 
Total person-time at risk (years) =49,026 
Rate per 100 person-years = 1.88 (1.76- 2.00) 
Association between antipsychotic 
polypharmacy and mortality  
Antipsychotic polypharmacy  v 
monotherapy  
Models HR (95% CI) p value  
Unadjusted  Model 0.9 (0.7- 1.1) p=0.166 
Model adjusted for age and gender  1.2 (1.0- 1.5) p=0.016 
Model adjusted for socio-
demographica and socioeconomicb 
factors  
1.2 (1.0- 1.5) p=0.020 
Model adjusted for age, gender and 
clinical factors c 
1.2 (1.0- 1.5) p=0.017 
Model adjusted for age, gender and 
smoking  
1.1 (0.9- 1.4)  p=0.111 
Fully adjusted model  1.2 (0.9- 1.4) p=0.079 
Fully adjusted model by using 
propensity score as a covariate  
1.2 (0.9- 1.4) p=0.084 
Fully adjusted model and %BNF dose 1.3 (1.0- 1.5) p=0.031 
Fully adjusted model and olanzapine 
equivalence dose  
1.2 (0.9- 1.5) p=0.088 
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Table 8.7 Sensitivity analyses of the association between antipsychotic 
polypharmacy prescribing and all-cause mortality in individuals with 
serious mental illness. 
 
a age, gender, ethnicity, relationship status, employment, deprivation level, 
comorbid depression, personality disorder and substance use, time known to 
SLAM services and smoking.  
 
  
N = 10,945  
Number of deaths = 920 
Total person-time at risk (years) =49,026 
Rate per 100 person-years = 1.88 (1.76- 2.00) 
Fullya adjusted models HR (95% CI) p value  
Analysis restricted to patients not 
prescribed clozapine    
1.1 (0.9- 1.4) p=0.266 
Analysis restricted to patients 
prescribed FGA     
1.1 (0.9- 1.4) p=0.444 
Analysis restricted to patients residing 
within SLAM   
1.2 (0.9- 1.4) p=0.076 
Analysis restricted to patients who 
were at risk of being prescribed both 
monotherapy and polypharmacy 
(based on propensity scores)  
1.2 (0.9- 1.4) p=0.085 
 
Analysis restricted to patients with 
schizophrenia (ICD-10: F20) 
 




Analysis restricted to patients with ICD 
10:F31 diagnosis 
 




8.4.2 Antipsychotic dose and all-cause mortality 
 
Table 8.8 and 8.9 summarise the cohort composition by %BNF dose and 
olanzapine equivalence dose, respectively. There were significant differences 
in characteristics across categories, for both %BNF and olanzapine 
equivalence dose. Overall, patients prescribed lower dose (for both %BNF 
and olanzapine equivalence dose) were more likely to be of British ethnicity, 
to be in a relationship, to be employed, to have a bipolar affective disorder 
diagnosis, and comorbid depression diagnosis. Patients prescribed a high 
antipsychotic dose were more likely to live in a more deprived area (based on 
deprivation index score), to have a schizophrenia diagnosis, comorbid 
personality disorder diagnosis, to have smoked and to have been known to 
SLAM services for longer. 
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Table 8.8 Sample characteristics by percentage out of the maximum 
BNF recommended dose for antipsychotic medications.  
N = 10,945  
Low dose  
Total person-time at risk (years) =21,299 
Rate per 100 person-years = 2.00 (1.81- 2.19) 
 
Medium dose 
Total person-time at risk (years) =18,376 
Rate per 100 person-years = 1.64 (1.46- 1.84) 
 
High dose  
Total person-time at risk (years) =4,677 
Rate per 100 person-years = 1.96 (1.60- 2.40) 
 
Dose Category                    
n(%) 














Total Death  426 (52.0) 302 (36.8) 92 (11.2) X2(2)=8.31, 
p=0.016 
Age      
Mean (SD)  42.9 (16.1)  39.5 (13.9)  39.9 (14.5)  F(2,10019)=58.
06, p<0.001 
Gender     
Male 2,395 (50.6) 2,511 (60.9) 701 (60.3) X2(2)=105.47, 
p<0.001 
Ethnicity group     
British 1,872 (39.5) 1,405 (34.1) 415 (35.7) X2(10)=63.82,  
Other White 438 (9.2) 384 (9.3) 74 (6.4) p<0.001 
Asian 335 (7.2) 261 (6.3) 82 (7.0)  
Caribbean 569 (12.0) 515 (12.5) 175 (15.0)  
Black African  1,165 (24.6) 1,230 (29.8) 342 (29.4)  
Other 357 (7.5) 328 (8.0) 75 (6.5)  
Relationship status    
Relationship  760 (16.1) 489 (11.9) 105 (9.0) X2(2)=55.68, 
p<0.001 
Employment      
Paid employment  184 (3.9) 109 (2.6) 27 (2.3) X2(2)=14.22, 
p<0.001 
Deprivation level in area of residence    
Low level  1,639 (34.8) 1,263 (30.9) 357 (31.1) X2(6)=30.24,  
Medium level  1,528 (32.5) 1,372 (33.6) 370 (32.2) p<0.001 
High level  1,472 (31.3) 1,364 (33.4) 388 (33.8)  
Homelessness 65 (1.4) 89 (2.2) 33 (2.9)  
Diagnosis     
   ICD-10: F20 3,241 (68.4) 3,008 (73.0) 903 (77.6) X2(4)=122.56,  
ICD-10: F25 320 (6.8) 356 (8.6) 119 (10.2) p<0.001 
ICD-10: F31 1,175 (24.8) 759 (18.4) 141 (12.1)  
Comorbid Depression    
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Yes 745 (15.7) 516 (12.5) 117 (10.1) X2(2)=34.32, 
p<0.001 
Comorbid Personality Disorder  
Yes 450 (9.5) 435 (10.6) 167 (14.4) X2(2)=23.47, 
p<0.001 
Comorbid Substance Use    
Yes 385 (8.1) 511 (12.4) 123 (10.6) X2(2)=44.13, 
p<0.001 
Time known to SLAM    









Smoking     
Have smoked 
ever  
2,880 (60.8) 3,040 (73.7) 967 (83.2) X2(2)=298.63, 
p<0.001 
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Table 8.9 Sample characteristics by olanzapine equivalence dose group. 
N = 10,945  
Low dose  
Total person-time at risk (years) =19,512 
Rate per 100 person-years = 1.91 (1.73- 2.11) 
 
Medium dose 
Total person-time at risk (years) =13,525 
Rate per 100 person-years = 1.56 (1.36- 1.79) 
 
High dose  
Total person-time at risk (years) =11,310 




















Total Death  373 (45.5) 211 (25.7) 236 (28.8) X2(2)=8.75, 
p=0.01 
Age      
Mean (SD)  41.67 (16.3)  39.82 (14.0)  41.85 (14.2)  F(2,10014)=1
6.96, p<0.001 
Gender     
Male 2,179 (48.7) 1,835 (61.5) 1,589 (62.1) X2(2)=172.33, 
p<0.001 
Ethnicity group     
British 1,721 (38.5) 1,039 (34.8) 931 (36.4) X2(10)=89.40,  
Other White 441 (9.9) 281 (9.4) 173 (6.8) p<0.001 
Asian 314 (7.0) 210 (7.0) 154 (6.0)  
Caribbean 495 (11.1) 341 (11.4) 423 (16.5)  
Black African  1,141 (25.4) 881 (29.6) 715 (27.9)  
Other 363 (8.1) 232 (7.8) 162 (6.4)  
Relationship status    
Relationship  765 (17.1) 359 (12.0) 229 (8.9) X2(2)=100.30, 
p<0.001 
Employment      
Paid employment  199 (4.5) 71 (2.4) 50 (1.9) X2(2)=41.82, 
p<0.001 
Deprivation level in area of residence    
Low level  1,524 (34.3) 930 (31.5) 804 (31.7) X2(6)=22.51,  
Medium level  1,462 (32.9) 1,003 (34.0) 805 (31.8) p=0.001 
High level  1,390 (31.2) 972 (32.9) 858 (33.9)  
Homelessness 73 (1.6) 46 (1.6) 68 (2.7)  
Diagnosis     
  ICD-10: F20 2,844 (63.5) 2,228 (74.7) 2,079 (81.3) X2(4)=408.41,  
ICD-10: F25 321 (7.2) 247 (8.3) 227 (8.9) p<0.001 









Comorbid Depression   
Yes 809 (18.1) 357 (11.9) 211 (8.3) X2(2)=144.03, 
p<0.001 
Comorbid Personality Disorder  
Yes 431 (9.6) 316 (10.6) 305 (11.9) X2(2)=9.13, 
p=0.01 
Comorbid Substance Use   
Yes 391 (8.7) 355 (11.9) 273 (10.7) X2(2)=20.49, 
p<0.001 
Time known to SLAM   
Mean (SD)  1511.3 
(1094.1) 





Smoking     
Have smoked 
ever  
2,671 (59.7) 2,177 (72.9) 2,036 (79.6) X2(2)=335.48, 
p<0.001 
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Table 8.10 summarises the crude and fully adjusted Cox regression analyses 
between antipsychotic dose and the risk for all-cause mortality. I found no 
evidence to indicate that dose had an effect on the risk of death for patients 
with SMI. The results were very similar for both percentage BNF and 
olanzapine equivalence dose.  
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Table 8.10 Multivariable Cox analysis of the association between all 
cause mortality and antipsychotic dose.  
 
a %BNF used as continuous variable  
b Factors included: age, gender, ethnicity, relationship status, employment,  
deprivation level, comorbid depression, personality disorder, substance use, 
time known to SLAM services and smoking.  
c low dose (1-10mg) was used as the reference group for the analysis.  
  
Dose calculated as %BNFa   
 
HR (95% CI) p-value  
Unadjusted Model 
 
1.0 (0.997- 1.000) p= 0.064 
Fullyb Adjusted Model  1.0 (0.999- 1.001) p= 0.996 
 
Dose calculated as olanzapine 
equivalencec   
  
11- 20mg   
Unadjusted Model 0.8 (0.7- 0.9) p= 0.018 
Fullyb Adjusted Model  0.9 (0.8- 1.1) p= 0.532 
21+ mg   
Unadjusted Model 1.1 (0.9- 1.3) p= 0.296 
Fullyb Adjusted Model  1.1 (0.9- 1.3) p= 0.377 
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8.4.3 Antipsychotic regimen and cause-specific mortality  
 
Cause of death was available for 892 (97%) of all deaths recorded for the 
monotherapy and polypharmacy groups. Table 8.11 summarises the 
prevalence of natural and unnatural causes of deaths across the two 
antipsychotic regimens.  
 
As illustrated by Table 8.12, patients who died from unnatural causes of death 
were younger, more likely to be of black African, Asian or Other ethnicity, in 
comparison to patients dying from natural causes of death. Furthermore, this 
group had significantly more comorbid personality disorder, substance use, 
and overall higher percentage BNF antipsychotic dose.    
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Table 8.11 Causes of death by antipsychotic monotherapy and 
polypharmacy medication group. (n=892 deaths)  
 
N = 10,945  
Natural Deaths= 783 
Total person-time at risk (years) =49,025 
Rate per 1000 person-years = 15.97 (14.89- 17.13) 
 
Unnatural deaths= 109 
Total person-time at risk (years) =49,025 
Rate per 1000 person-years = 2.22 (1.84- 2.68) 
 









Natural   652 131 
Infections  10 8 (1.1) 2 (1.3) 
Neoplasms  153 131 (17.8) 22 (14.3) 
Immune 7 5 (0.7) 2 (1.3) 
Endocrine  33 26 (3.5) 7 (4.5) 
Mental  68 52 (7.1) 16 (10.3) 
Nervous system 25 22 (2.9) 3 (1.9) 
Circulatory 211 175 (23.7) 36 (23.2) 
Respiratory  159 131 (17.8) 28 (18.1) 
Digestive  57 50 (6.8) 7 (4.5) 
Skin and Muscle 10 10 (1.4) 0 
Genitourinary  19 16 (2.2) 3 (1.9) 
Not elsewhere  31 26 (3.5) 5 (3.2) 
  
Unnatural  85 24 
External causes 109 85 (11.5) 24 (15.5) 
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Table 8.12 Sample characteristics by natural and unnatural causes of 
death. (n=892)  









socioeconomic factors  
   
Age     
Mean (SD) min-max 60.6 (15.3)  40.7 (16.1)  t(890)=12.65,
p<0.001 
Gender    
Female 381 (48.7) 40 (36.7) X2(1)=5.49,  
Male 402 (51.3) 69 (63.3) p=0.019 
Ethnicity group    
British 414 (52.9) 53 (48.6) X2(5)=17.42,  
Other White 84 (10.7) 5 (4.6) p=0.004 
Asian 41 (5.2) 9 (8.3)  
Caribbean 120 (15.3) 13 (11.9)  
Black African  97 (12.4) 18 (16.5)  
Other 27 (3.4) 11 (10.1)  
Relationship status     
No relationship 685 (87.5) 100 (91.7) X2(1)=1.64,  
Relationship  98 (12.5) 9 (8.3) p=0.200 
Employment     
Not in paid employment  776 (99.1) 108 (99.1) X2(1)=0.0006, 
Paid employment  7 (0.9) 1 (0.9) p=0.981 
Deprivation level in area 
of residence   
   
Low level  290 (37.2) 40 (36.7) X2(3)=4.58,  
Medium level  244 (31.3) 38 (34.9) p=0.206 
High level  242 (31.1) 29 (26.6)  
Homelessness 3 (0.3) 2 (1.8)  
 
Clinical factors  
   
Diagnosis    
  ICD-10: F20 588 (75.1) 75 (68.8) X2(2)=2.23,  
ICD-10: F25 50 (6.4) 10 (9.2) p=0.327 
ICD-10: F31 145 (18.5) 24 (22.0)  
Comorbid Depression    
No 696 (88.9) 95 (87.2) X2(1)=0.28,  
Yes 87 (11.1) 14 (12.8) p=0.593 
Comorbid Personality 
Disorder 
   
No 740 (94.5) 92 (84.4) X2(1)=15.57,  






   
No  721 (92.1) 90 (82.6) X2(1)=10.48,  
Yes 62 (7.9) 19 (17.4) p=0.001 
Time known to SLAM     
Mean (SD) 1686 (1016.8) 1598 (967.0) t(890)=0.86, 
p=0.720 
%BNF dose     




   
1-10mg 318 (45.7) 49 (48.0) X2(2)=0.60,  
11-20mg  182 (26.1) 23 (22.6) p=0.739 
21mg+ 196 (28.2) 30 (29.4)  
  Smoking    
Never smoked 266 (34.0) 33 (30.3) X2(1)=0.58,  
Have smoked ever  517 (66.0) 76 (69.7) p=0.444 
 249 
Table 8.13 summarises the competing risk regression analysis of the 
associations between being prescribed long-term antipsychotic polypharmacy 
and natural causes of death. Age and gender appeared to have a negative 
confounding effect, and adjusting for those in the multivariable model, resulted 
in an increase in the strength of the association with natural causes of death. 
However, adjusting for smoking reduced the strength of the association, 
below the statistical significance level. Similarly, the fully adjusted model 
indicated a modest effect of antipsychotic polypharmacy on natural causes of 
death, which did not reach statistical significance.  
 
A likelihood ratio test revealed a significant interaction between dose [for both 
%BNF (p=0.046) and olanzapine equivalence dose (p=0.029)] and 
antipsychotic polypharmacy for natural causes of death. A crude stratification 
of antipsychotic polypharmacy by dose indicated that antipsychotic 
polypharmacy of high dose (for both %BNF and olanzapine equivalence) were 
associated with a lower risk for natural causes of death. However, this 
association was not maintained in the fully adjusted models for both %BNF 
and olanzapine equivalence (Table 8.14). 
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Table 8.13 Competing risk regression analysis of the association 
between antipsychotic polypharmacy prescribing and natural causes of 
death in individuals with serious mental illnesses. (n=783 natural 
deaths; n=10,945 total sample) 
 
a socio-demographic factors included age, gender, ethnicity, relationship 
status  
b socioeconomic factors included employment and deprivation level   
c clinical factors included comorbid depression, personality disorder and 




Association between  
antipsychotic polypharmacy and 
natural causes of death  
Antipsychotic polypharmacy  v 
monotherapy  
Models HR (95% CI) p-value  
Unadjusted  Model 0.8 (0.7- 1.0) p= 0.062 
Model adjusted for age and gender  1.3 (1.0- 1.5) p= 0.016 
Model adjusted for socio-
demographica and socioeconomicb 
factors  
1.3 (1.0- 1.5) p= 0.020 
Model adjusted for age, gender and 
clinical factorsc  
1.3 (1.0- 1.5) p= 0.024 
Model adjusted for age, gender and 
smoking  
1.2 (0.9- 1.4) p= 0.102 
Fully adjusted model   1.2 (0.9- 1.4) p= 0.111 
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Table 8.14 Competing risk regression analysis of the association 
between antipsychotic polypharmacy prescribing and natural causes of 
death, stratified by %BNF dose and olanzapine equivalence dose.  
 
a age, gender, ethnicity, relationship status, employment, deprivation level, 
comorbid depression, personality disorder and substance use, time known to 











%BNF dose   1-49% 
HR (95% CI) 
50-100% 
HR (95% CI) 
101%+ 
HR (95% CI) 
Crude model  1.1 (0.8- 1.7) 0.9 (0.7- 1.3) 0.6 (0.4- 0.9) 
Fullya adjusted 
model 
1.5 (0.9- 2.4) 1.1 (0.8- 1.5) 1.4 (0.8- 2.3) 
Olanzapine 
equivalence 
dose   
 
1-10mg 
HR (95% CI) 
 
11-20mg 
HR (95% CI) 
 
21+mg 
HR (95% CI) 
Crude model  1.1 (0.5- 2.2) 1.1 (0.7- 1.7) 0.6 (0.4- 0.8) 
Fullya adjusted 
model 
1.9 (0.9-3.9) 1.4 (0.9- 2.1) 1.1 (0.8- 1.4) 
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Table 8.15 summarises the competing risk regression analysis for unnatural 
causes of death and long-term antipsychotic polypharmacy. I found no 
evidence to suggest that long-term antipsychotic polypharmacy prescribing 
was associated with a change in risk for unnatural causes of death. As 
indicated by a likelihood ratio test, there was no interaction between 
polypharmacy and dose with unnatural causes of death as the outcome 
[%BNF (p=0.1903); olanzapine equivalence dose (p=0.1556)]. I included 
%BNF and olanzapine equivalence dose, sequentially in the fully adjusted 
model to examine if dose had an effect on the overall association. Dose had 
little effect on the overall association.   
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Table 8.15 Competing risk regression analysis of the association 
between antipsychotic polypharmacy prescribing and unnatural causes 
of death in individuals with serious mental illness. (n=109 unnatural 
deaths; n=10,945 total sample)  
 
a socio-demographic factors included age, gender, ethnicity, relationship 
status  
b socioeconomic factors included employment and deprivation level  
c clinical factors included comorbid depression, personality disorder, 







Association between  
antipsychotic polypharmacy  and 
unnatural causes of death  
Antipsychotic polypharmacy  v 
Monotherapy  
Models HR (95% CI) p value  
Unadjusted Model 1.1 (0.7- 1.8) p= 0.601 
Model adjusted for age and gender  1.1 (0.7- 1.8) p= 0.669 
Model adjusted for socio-
demographica and socioeconomicb 
factors  
1.1 (0.7- 1.8) p= 0.677  
Model adjusted for age, gender and 
clinical factorsc  
1.1 (0.7- 1.8) p= 0.654 
Model adjusted for age, gender and 
smoking  
1.1 (0.7- 1.8) p= 0.698 
Fully adjusted model  1.1 (0.7- 1.9) p= 0.619 
Fully adjusted model and %BNF 0.9 (0.6- 1.7) p= 0.960 
Fully adjusted model and 
Olanzapine equivalence dose 
1.1 (0.6- 1.9) p= 0.821 
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8.4.4 Additional analysis  
 
In order to investigate whether patients with a first episode of monotherapy 
was the most appropriate reference group, I extracted information and 
conducted analyses using two additional reference groups, where first 
episode of long-term polypharmacy was compared to: 1) a long-term 
monotherapy episode that occurred at or after the midpoint of the observation 
window (2010) (Appendix C); 2) everyone else in the sample who did not 
qualify for the long-term antipsychotic polypharmacy group (Appendix D). The 
latter group included patients who were on long-term monotherapy and all 
other patients who were known to SLAM services for six or more months and 
that did not qualify for the polypharmacy group. Changing the reference group 
made little difference to the overall findings in the fully adjusted Cox 
regression models, suggesting that the use of the first episode of long-term 
monotherapy, as the primary reference group was reasonable. The last 
monotherapy episode was not considered as an alternative reference group 
as it is likely to have occurred too close to the end of the observation period, 
thus limiting follow-up time.  
In addition I also conducted an analysis comparing the risk of all-cause 
mortality between patients prescribed clozapine as a monotherapy as 
opposed to polypharmacy. In total 540 (51.63) patients were prescribed 
clozapine monotherapy and 506 (48.37) were prescribed clozapine 
polypharmacy. A fully adjusted Cox analysis indicated no statistically 
significant difference in the risk of death between the two groups: HR 1.3 
(95% CI: 0.9- 2.2), p=0.184. It is possible that there was not a sufficient power 
to detect an effect, in total there were 78 deaths between the two groups.    
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8.5 Discussion 
As far as I am aware, this is the first study to investigate the association 
between regular long-term antipsychotic polypharmacy use and all-cause and 
cause-specific mortality in a large and diverse cohort, adjusting for multiple 
confounders, in addition to investigating the effects of combined antipsychotic 
dose. I hypothesised that long-term antipsychotic polypharmacy would be 
associated with an increased risk for all-cause mortality and, specifically, of 
death from natural causes. The results indicated a weak association between 
long-term antipsychotic use with all-cause mortality and with natural causes of 
death, after adjusting for gender and age. Although these associations were 
not markedly confounded by other factors, the fully adjusted hazard ratios fell 
below statistical significance in most models. The association with unnatural 
causes of death was weaker still, and no evidence was found that factors 
such as antipsychotic dose had a direct effect on the risk of death in this 
sample with SMI or confounded the associations between antipsychotic 
polypharmacy and mortality.  
 
8.5.1 Antipsychotic polypharmacy and all-cause mortality  
 
In keeping with existing literature, I found that patients prescribed 
antipsychotic polypharmacy were younger, less likely to be employed, less 
likely to be in a relationship, had a higher proportion of schizophrenia 
diagnosis and were known to services for longer, in comparison to patients on 
monotherapy (Correll & Gallego 2012; Ganguly et al. 2004; Kreyenbuhl et al. 
2007; Morrato et al. 2007). However, aside from gender and age, the 
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aforementioned factors seemed to have only a small effect on the strength of 
the association between long-term antipsychotic polypharmacy and all-cause 
mortality.  
 
Overall, the literature to date examining antipsychotic polypharmacy and the 
risk of death in SMI has been mixed and inconclusive (see Chapter 2 section 
2.4.3). As I have previously described, there is some evidence from research 
including antipsychotic polypharmacy of unspecified duration, indicating that 
polypharmacy increases the risk for death (Waddington et al. 1998; Joukama 
et al. 2006). However, findings from larger epidemiological studies have been 
mixed, with evidence to indicate no association (Tiihonen et al. 2006; 
Baandrup et al. 2010) and possibly lower risk for mortality (Katona et al. 2014) 
in patients prescribed antipsychotic polypharmacy compared to those on 
monotherapy. My findings further indicate that the risk in the SMI cohort I 
examined is not clear-cut. There did appear to be a small effect of long-term 
antipsychotic polypharmacy on all-cause mortality and the strength of this 
association was similar in most models; however, the statistical significance of 
the association varied and was generally borderline (Table 8.6).   
 
Evidence regarding the role of specific antipsychotics in the risk for death has 
been mixed (Kiviniemi et al. 2013; Hayes et al. 2014; Montout et al. 2002; 
Tenback et al. 2012; Tiihonen et al. 2009). There is some evidence to suggest 
that FGAs are associated with increased risk for mortality, whereas clozapine 
is associated with a decreased risk for death (Kiviniemi et al. 2013; Hayes et 
al. 2014; Montout et al. 2002; Tenback et al. 2012). In this study, the 
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prescribing of FGAs or clozapine, as part of the antipsychotic regimen, made 
no difference to the overall risk (see Table 8.7).   
 
8.5.2 Antipsychotic polypharmacy and cause-specific mortality  
 
People with schizophrenia have an increased risk for premature death from 
natural causes such as cardiovascular diseases (Kiviniemi et al. 2013; Osborn 
et al. 2014; Laursen et al. 2014; Joukama et al. 2001) and unnatural causes 
such as suicide (Osby et al. 2000; Reininghaus et al. 2015) compared to the 
general population. However, research examining the effect of long-term 
antipsychotic polypharmacy prescribing on cause-specific mortality has been 
extremely sparse. I was able to identify only one study, which examined the 
risk for cause-specific mortality in patients prescribed long-term 
polypharmacy. In this, Baandurp and colleagues (Baandrup et al. 2010) 
reported that the risk for natural causes of death did not increase when 
patients were prescribed two or more antipsychotics, as compared to 
monotherapy. Although my findings did not indicate a statistically significant 
difference between patients prescribed antipsychotic polypharmacy and 
monotherapy in most of the fully adjusted models, the association of 
polypharmacy with increased risk for natural causes of death changed little, 
once adjusted for gender and age, which might be indicative of a modest 
effect. Associations between long-term antipsychotic polypharmacy and 
unnatural cause of death were weaker and also not statistically significant.  
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8.5.3 Antipsychotic dose and mortality   
 
In keeping with existing literature (Gisev et al. 2014; Grech & Taylor 2012; 
Roh et al. 2015), patients prescribed long-term antipsychotic polypharmacy 
were more likely to be prescribed a higher combined dose of antipsychotics in 
comparison to patients on long-term monotherapy; however adjusting for dose 
had very little effect on the association between antipsychotic polypharmacy 
and mortality. Also dose was not associated with mortality in the fully adjusted 
models. Previous research has indicated that high antipsychotic dose is 
associated with increased risk for all-cause mortality, and more specifically for 
cancer, cardiovascular and respiratory causes of death (Torniainen et al. 
2015; Ray et al. 2009; Osborn et al. 2014). There are several possible factors 
that could offer an explanation for these differences in results across studies. 
It is possible that different methods of calculating antipsychotic dose would 
yield different results. Methods such as %BNF dose and defined daily dose 
(DDD) are calculated by using the upper licensed dose range of 
antipsychotics (Patel et al. 2013).  This poses a problem for antipsychotics 
that reach their maximum efficacy at a lower dose range, such as risperidone, 
and which are thus rarely prescribed at maximum or above maximum 
recommended dose. Furthermore, over the years, there have been changes 
to the recommended maximum doses for some antipsychotics, which makes it 
difficult to compare findings from different studies across time. An alternative 
explanation for differences in findings across studies is the possibility of 
residual confounding. For example, although Torniainen et al. (Torniainen et 
al. 2015) used age and gender matched case and controls, their Cox model 
did not account for any other factors that may affect mortality such as 
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smoking, which is associated with significant risk for death (Goff et al. 2005; 
Brown et al. 2000).  
 
There is some previous research (Langan & Shajahan 2010) that has 
suggested that the increased mortality observed in patients with SMI, could be 
a consequence of antipsychotic dose, rather than the antipsychotic regimen 
that is prescribed. Furthermore, a more recent study (Torniainen et al. 2015) 
found that the patients who were either receiving no antipsychotic treatment 
or very high dose antipsychotic treatment, had the highest mortality risk. In my 
study, I found no evidence to indicate that dose had an independent 




This study had several strengths. SLAM is close to being a monopoly mental 
health care provider for its geographic catchment (Stewart et al. 2009; Perera 
et al. 2016). Therefore, I was able to capture a large cohort of patients with 
SMI giving me the statistical power to adjust for a number of well-known and 
other potential confounders, such as smoking and antipsychotic dose, that 
other research has been unable to examine.  
 
At present, there is no ‘gold standard’ for calculating equivalent doses (Patel 
et al. 2013); therefore I chose to use two different methods of calculating 
dose. Percentage out of the maximum BNF recommended dose has been 
recommended by the Royal College of Psychiatrists (Royal College of 
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Psychiatrists 2014) as one method of choice for calculating high dose 
prescribing in polypharmacy. Olanzapine equivalence dose method has 
gained popularity in recent years (Gardner et al. 2010; Gisev et al. 2014; Patel 
et al. 2013) in this field and is currently preferred to chlorpromazine 
equivalence. Furthermore, using two different approaches allowed me to test 
the effect of dose more rigorously and also demonstrate that existing 
evidence in this field needs to be interpreted with caution, as findings are 
dependent on the method that is used.  
 
8.5.5 Limitations  
 
There were several potential limitations in this study. Given the marginally 
significant results in relation to long-term antipsychotic polypharmacy 
prescribing with all-cause; and natural-causes of death, it is possible that I did 
not have sufficient statistical power to detect a consistently significant effect. 
However, the width of the confidence intervals did not suggest that there were 
particularly strong effects that were missed.  
 
Furthermore, despite adjusting for multiple confounders, it is possible that 
some residual confounding may have occurred. I employed propensity scores 
as both a covariate and in a sensitivity analysis, where I restricted the analysis 
to patients at risk of being prescribed monotherapy and polypharmacy. 
Although this limited the chance for confounding by indication, it cannot be 
completely ruled out. In relation to confounders, the role of smoking as a 
covariate does need to be considered with some caution. Firstly, I did not 
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have data on the frequency of smoking to include in the models (only smoking 
status), so there may have been residual confounding as a consequence. 
Furthermore, adjustment for smoking presupposes a situation where people 
who go on to receive polypharmacy have more unhealthy lifestyles, including 
smoking, which account for any raised mortality in this group. However, it is 
possible that an effect of polypharmacy may be to maintain smoking 
behaviour, if this is used to counteract perceived or actual adverse effects of 
medication (Goff et al. 1992). Inclusion of smoking status as a covariate in this 
circumstance would represent an over-adjustment as it could be on the causal 
pathway between antipsychotic polypharmacy and mortality. Unfortunately it 
was not possible to tease out the timing of polypharmacy in relation to 
smoking status, and therefore these different pathways have yet to be 
distinguished.  
 
Despite the potentially specific effects that certain antipsychotics, such as 
clozapine or groups of antipsychotics such as FGA, could have had on the 
overall association, examining specific combinations of antipsychotics was 
beyond the scope of the study. However, it is possible that the risk of death 
differs across certain combinations of antipsychotics (Kiviniemi et al. 2013; 
Hayes et al. 2014; Montout et al. 2002; Tenback et al. 2012).  
 
I chose to compare polypharmacy with monotherapy treatment with a 
minimum duration of six months, as the reference group, therefore ensuring 
that all patients that qualified for the study were known to services for a 
minimum of six months. However, it is still possible that some survival bias 
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may have occurred in selecting the patients with a first episode of 
polypharmacy, as patients needed to have survived long enough to go from 
monotherapy to long-term antipsychotic polypharmacy. Furthermore it is 
possible that as a result of selecting patients who have had either 
antipsychotic regimen for six or more months, I was unable to detect acute 
outcomes that occurred within the six months prior to the patient entering the 
cohort. This could have possibly resulted in immortal time bias, as the patients 
had to survive long enough in order to enter either of the exposure groups. An 
additional limitation was that I was unable to determine the antipsychotic 
regimen at the time of death. Therefore, I was unable to determine how long 
patients were prescribed the antipsychotic regimens prior to their death. 
 
8.5.6 Possible mechanisms  
 
In seeking alternative mechanisms that could explain the mortality gap 
between patients with SMI and the general population, it is possible that 
polypharmacy regimen has an indirect effect on mortality. For example, there 
is some existing research that indicates that antipsychotic polypharmacy 
increases the risk for adverse drug reactions such as QTc prolongation, 
parkinsonian symptoms, hyperprolactinemia, dyslipidaemia and other 
metabolic problems such as weight gain and diabetes (Barbui et al. 2016; 
Gallego et al. 2012). Furthermore, antipsychotic polypharmacy has been 
associated with pre-metabolic syndrome (the presence of visceral fat obesity 
in addition to either elevated blood glucose or lipid abnormalities or elevated 
blood pressure), after adjusting for a number of confounders, indicating that 
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polypharmacy may act as a mediator on the causal pathway to mortality in 
individuals with SMI (Misawa et al. 2011). Further evidence also suggests that 
dose can also mediate this relationship (Barbui et al. 2016; Centorrino et al. 
2004). Therefore, it is possible that the increased risk for death in people with 
SMI is a by-product of a complex interplay between different treatment factors 
and their side effects (not to mention consequences of side effects on lifestyle 
choices such as smoking behaviour, as previously mentioned). However, 
research investigating this remains too sparse to draw firm conclusions. 
Future research should aim to investigate causal pathways to mortality, 
including adverse drug reactions to general antipsychotic medications use 
and more specifically to polypharmacy. 
 
8.5.7 Conclusion and implications  
 
To date, despite the widespread practice of regimens such as antipsychotic 
polypharmacy, little is known about the long-term effects of its prescribing. 
Findings to date have been mixed and limited by methodological problems 
such as measuring antipsychotic polypharmacy of short duration, investigating 
small and homogeneous samples and difficulties with excluding residual 
confounding. The study described here is one of the first mortality studies to 
look specifically at the effects of long-term polypharmacy prescribing in a 
large clinical cohort that is representative of the population seen by secondary 
mental health care services, and considering a broad range of potential 
confounders. My findings suggest that the effect of long-term antipsychotic 
polypharmacy on mortality is not a clear-cut one. The effect of this regimen on 
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all-cause and natural causes of death was small and did not reach 
significance in most models. This has potential implications for further 
research. It is possible that if there is any effect on mortality, this is driven by 
specific antipsychotic medication combinations. Therefore, perhaps future 
research could focus on examining common antipsychotic combinations and 
their effect on particular cause of death, such as for example cardiovascular 
death, which from previous research, we know is particularly elevated in SMI 
population (Raedler 2010).  
 
It is imperative to consider my findings and their implications within the wider 
context of antipsychotic polypharmacy treatment. Although I found that long-
term antipsychotic polypharmacy does not increase the risk for death, in 
prescribing this regimen, it is important to bear in mind that polypharmacy 
continues to be associated with more severe side effects (Barbui et al. 2016; 
Gallego et al. 2012; Correll et al. 2007; Langan & Shajahan 2010). 
Furthermore, the notion that more is better, in relation to adding additional 
antipsychotics and increasing treatment dose, has been consistently rejected 
by empirical research (Lochmann van Bennekom et al. 2013; Taylor 2010), 
indicating that once an optimal dose and response is reached, adding 
additional treatments makes little difference. In certain circumstances 
increasing dose and/or adding an additional antipsychotic can be associated 
with lowering certain side effects (Taylor 2010; Joo-Cheol et al. 2007); 
however this needs to be done with caution. Lastly, evidence remains that 
polypharmacy is often prescribed in favour to clozapine monotherapy, despite 
research indicating that clozapine is effective in treating treatment- resistant 
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symptoms (Taylor et al. 2011). Although I was not able to assess reasons for 
not initiating clozapine prior to antipsychotic polypharmacy prescribing, 
previous research suggests that premature antipsychotic polypharmacy 
prescribing is likely to reflect a prescribing culture rather than evidence-based 
treatment (Howes et al. 2012). Therefore, the need to target this on prescriber 
and service level remains (Mace & Taylor 2015; Paton et al. 2008).  
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9.1 Aim  
The aim of this chapter is to discuss the findings of this thesis within the 
context of previous research but also in consideration of the wider patient, 
clinical, and treatment context. Furthermore, I also examine possible 
implications and directions for further research.  
 
9.2 Summary of findings  
The aims of the thesis were to: 
1) To identify cases on long-term antipsychotic polypharmacy (≥ 6 
months) prescribing in South London and Maudsley electronic health 
records (EHR).  
 
2) To identify factors that predict long-term antipsychotic polypharmacy 
prescribing for SMI patients in secondary mental health care.  
 
3) To investigate whether outcomes such as hospital readmission and 
mortality are associated with long-term antipsychotic polypharmacy 
prescribing in secondary mental health care.  
 
Overall, this thesis provides evidence that EHRs can be successfully used to 
derive information on long-term antipsychotic polypharmacy prescribing in 
secondary mental health care with high precision (Chapter 5). Using SLAM 
de-identified health records (CRIS), I identified that being younger, residing in 
an area with a greater socioeconomic deprivation, having significant problems 
with clinical symptoms (positive psychotic symptoms), and greater previous 
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service use (prior outpatient contact, prior use of clozapine and/or long-acting 
injectables) were significant, independent predictors of long-term 
antipsychotic polypharmacy initiation (Chapter 6). Furthermore, patients 
prescribed antipsychotic polypharmacy at discharge were at increased risk for 
clinical outcomes such as hospital readmission into secondary mental health 
care (Chapter 7). Lastly, I found insufficient evidence to indicate that 
antipsychotic polypharmacy prescribing increases the risk for all-cause and 
cause-specific mortality. In addition, antipsychotic dose appeared to have little 
effect on mortality risk (Chapter 8).  
 
9.3 How has this thesis advanced knowledge in this field?  
 
9.3.1 Detecting antipsychotic polypharmacy prescribing using 
electronic health records  
 
Existing literature examining antipsychotic polypharmacy has predominantly 
derived information from medical insurance databases (Boaz et al. 2013; 
Clark et al. 2002; Ganguly et al. 2004; Katona et al. 2014; Morrato et al. 2007; 
Ortiz et al. 2016). Although this has enabled researchers to examine large 
population samples, these datasets often do not contain detailed contextual 
information, such as that on patient symptoms and response to treatment, 
which is also regularly updated. Therefore, studies have examined fewer 
confounders, such as antipsychotic dose, leading to possible residual 
confounding (Suokas et al. 2012; Ortiz et al. 2016; Ganguly et al. 2004; 
Gallego et al. 2012; Faries et al. 2005; Clark et al. 2002; Katona et al. 2014; 
Tiihonen et al. 2012). Conversely, studies that have used text-rich databases 
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such as clinical records (Barbui et al. 2006; Moilanen et al. 2016; Centorrino 
et al. 2004) have examined smaller patient samples, due to the time and 
labour constraints of manually examining a large volume of documents and 
searching for relevant information. Furthermore, such studies have often 
focused on specific patient samples, such as inpatients (Waddington et al. 
1998; Centorrino et al. 2004), thus limiting the generalizability of their findings 
to wider and more diverse patient populations. In this thesis, I successfully 
used a combination of NLP and a bespoke algorithm to extract antipsychotic 
polypharmacy data from a large, but nevertheless information-rich dataset, 
including free-text clinical notes. Mental health professionals often write some 
of the most relevant information in free text. In addition these fields often 
receive entries from different professionals and tend to contain the most up-
to-date information (Perera et al. 2016). Therefore, from a data-derivation 
point of view, this thesis demonstrates the utility of using a novel way of 
extracting and examining medication data, where information can be derived 
from both structured and free-text fields. The migration from paper to 
electronic records has already begun in UK health services and 
internationally, in countries such as Sweden, Finland and Denmark. 
Therefore, this tool has the potential to be applied in similarly structured 
clinical datasets where a large proportion of medications data is held in free-
text format. Furthermore, using similar methods across research to derive 
medication prescription information has the potential to overcome some of the 
most significant methodological problems that existing research has faced, 
such as assessing and measuring long-term antipsychotic polypharmacy. At 
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present, it is almost impossible to compare findings across studies due to 
significant differences in defining and measuring antipsychotic polypharmacy.   
 
9.3.2 Who is prescribed antipsychotic polypharmacy?  
 
Prior research has predominantly considered characteristics of patients 
prescribed antipsychotic polypharmacy (Suokas et al. 2012; Santone et al. 
2011; Kreyenbuhl et al. 2007; Kreyenbuhl et al. 2006), rather than predictors 
of this regimen, mainly due to difficulties with determining prior episode of 
polypharmacy prescribing (Ganguly et al. 2004; Morrato et al. 2007) and the 
use of cross-sectional methods to investigate this (Suokas et al. 2012; 
Santone et al. 2011; Ortiz et al. 2016). Furthermore, studies to date have 
examined a limited number of possible predictors (Suokas et al. 2012; Ortiz et 
al. 2016; Ganguly et al. 2004; Gallego et al. 2012); therefore for example 
relatively little is known about the socioeconomic predictors, such as social 
deprivation. In this thesis (Chapter 6), I measured a number of socio-
demographic, socioeconomic, clinical and service use factors, and was able 
to measure these over periods prior to the initiation of long-term antipsychotic 
polypharmacy. Therefore, I was able to ascertain predictors rather than 
characteristics of antipsychotic polypharmacy prescribing.  
 
Overall, the results from the studies described in this thesis indicated that 
patients prescribed antipsychotic polypharmacy were more likely to be 
younger, to be homeless, to experience more psychotic symptoms, and to 
have had more previous service use (prior outpatient contact, prior community 
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treatment orders, prior clozapine and/or LAI use) (see Chapter 6). The studies 
described in Chapter 7 and 8, further indicated that patients on polypharmacy 
were more likely to have problems with hallucinations and delusions, and 
more previous contact with services (as measured by time known to SLAM 
services; and inpatient and outpatient contact), in comparison to patients 
prescribed monotherapy. This suggests that certain patient groups are at a 
particular risk of receiving antipsychotic polypharmacy prescription. The 
implications of this finding are discussed in more detail in section 9.6 of this 
chapter.   
 
The results largely support previous research which has indicated that prior 
service use, such as more frequent outpatient contact (Kreyenbuhl et al. 
2007; Ganguly et al. 2004), previous use of LAI, and clozapine (Ganguly et al. 
2004), are associated with an increased risk for longer term antipsychotic 
polypharmacy. However, contrary to some previous reports, I found no 
evidence to suggest that polypharmacy initiation is predicted by the number of 
days spent as an inpatient or number of different antipsychotics used (Barbui 
et al. 2006; Ganguly et al. 2004; Morrato et al. 2007) in the previous six 
months. It is possible that these discrepancies are due to differences in 
measuring antipsychotic polypharmacy (60 days or more in previous research 
as compared to six months or more in my studies). Furthermore, the 
aforementioned studies did not account for the effect of previous use of this 
regimen. Consequently, in previous research it has been difficult to establish 
with confidence whether the reported correlates were predictors or products of 
polypharmacy prescribing. An additional important issue to consider is that 
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studies conducted in the US that have investigated medication insurance 
databases (Ganguly et al. 2004; Morrato et al. 2007) may be limited by 
sampling bias. More specifically, as access to services is not uniform across 
hospitals in different states, and individuals pay to receive care, it is possible 
that identified patients from some hospitals are not representative of their 
catchment populations, and thus have limited generalizability. 
 
My results also generated some novel findings. Deprivation level of area of 
residence emerged as the sole socioeconomic factor that predicted initiating 
long-term antipsychotic polypharmacy. This is in contrast with previous 
research in this field, which has predominately examined employment status 
(Barbui et al. 2006; Biancosino et al. 2005; Santone et al. 2011) and has 
found mixed results. Therefore, the role of socioeconomic factors such as 
deprivation warrants further investigation. Furthermore, this thesis has shed 
further light on the role of clinical symptoms in antipsychotic polypharmacy 
prescribing. The presence of significant hallucinations and/or delusions, as 
rated on the respective HoNOS sub-scale, emerged as the sole symptomatic 
predictor of long-term antipsychotic polypharmacy initiation. Previous 
research in this field has been mixed, with some studies reporting no 
associations between general psychopathology and long-term antipsychotic 
polypharmacy (Barbui et al. 2006; Gallego et al. 2012), whereas research 
examining inpatient samples (Biancosino et al. 2005) indicating an association 
with positive symptoms. Overall previous research has generally examined 
small population samples (Barbui et al. 2006; Biancosino et al. 2005; 
Moilanen et al. 2016), thus limiting the statistical power to detect an effect and 
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the generalizability of their findings. In contrast, I was able to examine clinical 
factors in a large, diverse and representative patient sample.  
 
9.3.3 What are the effects of antipsychotic polypharmacy prescribing?  
 
The studies described in this thesis are some of the first to investigate both 
clinical and health outcomes (Chapter 7 and 8) using EHRs for a large and 
diverse cohort, taking into account a range of possible confounders. The 
studies have generated findings which are more representative of patients 
with SMI, and that can be generalised beyond the context of this study (this 
potential strength is further discussed in section 9.4 under Strengths).  
 
Overall, previous research investigating outcomes of polypharmacy has been 
of varying quality. Studies examining antipsychotic duration of 60 days (that 
can possibly include cross-titration) have risked possible misclassification 
(Katona et al. 2014; Boaz et al. 2013). In addition, studies have only 
investigated limited potential confounders (Katona et al. 2014; Tiihonen et al. 
2012), such as antipsychotic dose, as a result of having access to limited 
contextual information, thus possibly risking residual confounding (Katona et 
al. 2014; Tiihonen et al. 2012). While some smaller studies that examined 
polypharmacy of unspecified duration have been able to account for more 
contextual factors (Waddington et al. 1998; Joukama et al. 2006), smaller 
samples increase the likelihood of making a type II error and increase the 
likelihood that the findings are spurious.  
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The results of this thesis suggest that polypharmacy has significant clinical 
repercussions in comparison to monotherapy. More specifically, patients 
discharged on antipsychotic polypharmacy were more likely to be readmitted 
into hospital within six months in comparison to those discharged on 
monotherapy. The results appeared robust and remained after adjusting for a 
multitude of potential confounders, after carrying out sensitivity analyses, and 
after using propensity score methods to address confounding by indication. 
Overall, previous research in this field has been sparse and has provided 
mixed evidence of the role of polypharmacy in hospital readmissions. My 
results support findings from studies that have used clinical records to 
examine hospitalization [(Kreyenbuhl et al. 2007)(investigated antipsychotic 
polypharmacy of unspecified duration and therefore did not qualify for the 
literature review in this thesis)]. On the other hand, research using medical 
insurance databases have indicated that polypharmacy is associated with 
either a decrease in hospital readmissions (Katona et al. 2014) or is not 
associated with future hospital readmissions; rather readmission was 
associated with patients being insufficiently stable at the point of initial 
discharge (Boaz et al. 2013). Clinical severity in patients prescribed 
antipsychotic polypharmacy (Correll & Gallego 2012; Ganguly et al. 2004; 
Kreyenbuhl et al. 2007) is one possible explanation proposed for the higher 
level of readmission in comparison to patients on antipsychotic monotherapy. 
However, it is also possible that findings from insurance databases are 
subject to residual confounding, due to limited number of factors examined 
(Katona et al. 2014)(such as dose or smoking) and sampling bias as a result 
of inequality in access to services (Boaz et al. 2013). Furthermore, an 
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important caveat in the latter studies (Katona et al. 2014; Boaz et al. 2013) is 
that misclassification of polypharmacy cannot be completely ruled out as a 
result of examining antipsychotic polypharmacy with a duration of 60 or more 
days.  
 
I found modest evidence to suggest that antipsychotic polypharmacy is 
associated with higher all-cause mortality. This finding does not clearly 
contradict or support previous studies. Research that has examined 
antipsychotic polypharmacy of unspecified duration in clinical records has 
reported that antipsychotic polypharmacy significantly increased the risk of 
mortality (Waddington et al. 1998; Joukama et al. 2006). On the other hand, 
results from larger and more diverse cohorts have indicated that antipsychotic 
polypharmacy either decreases the risk for mortality (Katona et al. 2014), or 
has no association with all cause and natural cause of death (Baandrup et al. 
2010; Tiihonen et al. 2009; Tiihonen et al. 2012). However, the lack of 
contextual data available to examine potential confounders in more recent 
research (Tiihonen et al. 2012; Katona et al. 2014) has left a doubt  over 
whether this holds true. Therefore, in the study described in Chapter 8, I 
sought to adjust for a range of factors such as socio-demographic, 
socioeconomic, and service use. In addition, by using propensity score 
methods, I sought to address confounding by indication to some extent.  
 
This thesis has generated several novel findings in relation to antipsychotic 
polypharmacy and mortality. In line with evidence from previous descriptive 
research, patients receiving antipsychotic polypharmacy were more likely to 
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receive a higher combined antipsychotic dose (Gisev et al. 2014; Grech & 
Taylor 2012; Roh et al. 2013; Roh et al. 2015). However, there has been no 
previous research that has adjusted for dose in examining the association 
between long-term antipsychotic polypharmacy and mortality. I found no 
evidence to suggest that antipsychotic dose had a direct effect on mortality. 
Although this is at odds with previous research examining the association 
between antipsychotic dose and mortality (Torniainen et al. 2015; Ray et al. 
2009; Osborn et al. 2014), it is important to note that the methods used to 
measure dose appeared to play a pivotal role in the final results. More 
specifically, in my study, the effect of dose was only evident when I examined 
dose as percentage of the maximum BNF recommended dose, and this was 
not sustained for olanzapine equivalent dose. Although I cannot definitively 
conclude that antipsychotic dose does not have an effect on mortality, given 
previous research, it is imperative to consider the limitations of existing 
methods used to measure dose. For example, methods such as BNF dose 
and defined daily dose calculate dose by using the upper licensed dose range 
of antipsychotics (Patel et al. 2013).  This poses a problem for antipsychotics 
that reach their maximum efficacy at a lower dose range, such as risperidone, 
and thus are rarely prescribed at maximum or above maximum recommended 
dose. Furthermore, over the years, there have been reductions to the 
recommended maximum doses for some antipsychotics. Thus it is difficult to 
compare findings from different studies across time. An alternative 
explanation for differences in findings across studies is the possibility of 
residual confounding. For example, although Torniainen et al. (Torniainen et 
al. 2015) used age and gender matched case and controls, the Cox model did 
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not account for any other factors that may affect mortality such as smoking, 
which is associated with significant risk for death in people with SMI (Goff et 
al. 2005; Brown et al. 2000) although, as discussed previously, there may be 
issues of over-adjustment in instances where smoking behaviour is a 
consequence of prescribing practices. This study highlights an important issue 
around measuring antipsychotic dose and investigating its role in the 
association between polypharmacy and death. Future research in this field 
would greatly benefit from a ‘gold standard’ method of dose equivalence and 
measurement, thus facilitating across-study comparisons.  
 
9.4 Strengths 
The studies described in this thesis had several strengths, most of which are 
also mentioned in the respective chapters. SLAM is close to being a 
monopoly mental health care provider for its geographic catchment. 
Therefore, routinely collected EHRs capture a range of populations, such as 
patients in different clinical settings (e.g. inpatients/ outpatients). In addition, 
CRIS is based on an ‘opt out’ system and to date only three patients (Perera 
et al. 2016) have asked for their records to be removed from the search 
system, and as a result the coverage is close to 100%. Furthermore, routine 
mortality tracing and linkages with the Office of National Statistics national 
mortality ensures that if a death occurs within the UK, even if it is outside 
SLAM catchment, this information will be fed back to the service. 
Consequently, I was able to capture and follow-up a large cohort of patients 
with SMI, which was representative of patients seen by secondary care 
(Stewart et al. 2009; Perera et al. 2016). 
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EHRs contain rich and diverse contextual information, much of which may be 
embedded in free-text fields. Thus, in comparison to previous research 
(Suokas et al. 2012; Ortiz et al. 2016; Ganguly et al. 2004), I was able to 
incorporate relatively detailed information on socio-demographic, 
socioeconomic, clinical and service use factors, some of which have been 
previously under-represented and/or under-investigated, such as ethnicity and 
level of deprivation. Furthermore, the size of the sample I investigated gave 
me the statistical power to adjust for multiple potential confounders in the 
analysis, thus limiting residual confounding. In addition, having rich contextual 
information (such as socioeconomic factors and antipsychotic dose), allowed 
me to distinguish with a better precision between different types of 
antipsychotic polypharmacy, thus limiting potential misclassification (Chapter 
4 and 5), a problem that a large proportion of previous research has been 
unable to avoid (Centorrino et al. 2004; Joukama et al. 2006; Ito et al. 2005; 
Misawa et al. 2011; Sim et al. 2004; Janssen et al. 2005). Misclassification 
was further reduced by using a combination of NLP and the novel algorithm 
described in Chapter 5. This allowed me to extract information available in 
structured fields and free text. In instances where structured fields are poorly 
populated or incomplete, using supplementary information available in free-
text fields provides more detailed and complete data on treatments. A further 
advantage of NLP is its ability to take into account the linguistic context 
around terminology of interest. I was able to identify and exclude negation 
statements, past rather than current prescribing, speculations about future 
prescribing and instances in the text where the drug is mentioned as being 
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taken by a person other than the patient, thus further increasing the precision 
of identifying antipsychotic polypharmacy.   
 
EHRs reflect real-life clinical practice and have an advantage over 
randomised control trials and clinical cohort studies, which often suffer from 
poor response rates and loss to follow-up. Furthermore, randomised 
controlled trials are often restrictive in their inclusion criteria (e.g. comorbid 
diagnoses); operate in idealized environment (e.g. number of clinical 
contacts); and have short follow-up period, making it hard to investigate rare 
outcomes such as mortality that require longer follow-up. Therefore, EHRs 
offer an invaluable tool for investigating trends in medication prescribing and 
the impact of medications under real-world circumstances that are not 
necessarily captured by clinical trials. As a result, EHRs have the potential to 
provide valuable information that can inform prescribing guidelines.  
 
The historic nature of EHRs allows longitudinal research, where medication 
profiles can be examined in relation to multiple predictors and outcomes. 
Although EHRs provide historical information, recall bias is rarely an issue, as 
records are entered close to the time the events occur. For example, in 
Chapter 6, measuring predictors prior to antipsychotic polypharmacy initiation 
allowed me to separate the exposures and outcome in time, thereby reducing 
the potential for reverse causality. 
 
At present, there is no ‘gold standard’ for calculating equivalent antipsychotic 
doses (Patel et al. 2013), therefore I chose to use two different methods in 
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Chapter 8. Percentage of the maximum BNF recommended dose has been 
recommended by the Royal College of Psychiatrist (Royal College of 
Psychiatrists 2014) as one method of choice for calculating high dose 
prescribing in polypharmacy. However, the olanzapine equivalence dose 
method has gained popularity in recent years (Gardner et al. 2010; Gisev et 
al. 2014; Patel et al. 2013) in this field, and is currently preferred to 
chlorpromazine equivalence. Furthermore, using two different approaches 
allowed me to test the effect of dose more rigorously and also demonstrate 
that existing evidence in this field needs to be interpreted with caution, as 
findings are possibly dependent on the method that is used.  
 
I chose to compare antipsychotic polypharmacy to monotherapy treatment 
with a minimum duration of six months, as the reference group, therefore 
ensuring that all patients that qualified for the study were known to services 
for a minimum period. In Chapter 8, as well as using the propensity score 
method (discussed above), I carried out extra analysis to ensure that I had 
chosen the most appropriate reference group. In an addition to the main 
analysis, I compared the polypharmacy group: to patients with an episode of 
monotherapy in 2010 (appendix C); and to the rest of the sample (patients 
who did not qualify for the polypharmacy group)(appendix D).  
 
 
9.5 Limitations  
There were several potential limitations faced by the studies described in this 
thesis, also described in respective chapters. Despite adjusting for multiple 
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confounders, it is possible that some residual confounding may have occurred 
in studies described in Chapters 6, 7 and 8. For example, I was unable to 
measure factors such as duration of illness or stages of treatment as patients 
entered the observation period. In addition, I was unable to measure clinician 
related factors such as prescriber experience of initiating antipsychotic 
polypharmacy (Correll et al. 2011; Correll & Gallego 2012; Gee et al. 2014). 
Although I employed propensity score as both a covariate and in a sensitivity 
analysis in Chapters 7 and 8, where I restricted the analysis to patients that 
could have been prescribed either monotherapy or polypharmacy, 
confounding by indication cannot be completely ruled out. Interaction with 
calendar time was not measured in Chapter 7 and Chapter 8. Therefore it is 
possible that risk may have varied over calendar time. 
 
Despite examining a large and diverse clinical cohort, the possibility of not 
having sufficient power to examine rare outcomes such as mortality remains. 
In Chapter 8, I observed a modest effect of long-term antipsychotic 
polypharmacy on all-cause and natural causes of death. This association was 
significant in only some models. However the effect size changed little across 
the different models which may suggest that non-significance in some models 
may have been due to lack of power rather than confounding.  
 
In contrast to previous research where standardised symptomatic 
assessments have been used (e.g. PANSS, BPRS), symptom assessment in 
Chapter 6 and 7 was limited to individual HoNOS items, measured at one 
point in time. This scale has received some previous criticism with regards to 
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its measurement of symptoms (Stein 1999; Bebbington et al. 1999), and I was 
only able to analyse a composite measure of psychotic symptoms. It is 
possible that true associations may have been concealed, and further 
research is required into the role of observed and recorded symptomatology 
in clinical decision-making.  
 
Despite examining the specific effects that certain antipsychotics, such as 
clozapine or groups of antipsychotics such as FGAs, could have had on the 
overall associations of interest, examining the effects of a broad range of 
specific combinations of antipsychotics was beyond the scope of the studies 
(Chapter 7 and 8). It is therefore possible that the risk for detrimental 
outcomes such as mortality, differs across certain combinations of 
antipsychotics (Kiviniemi et al. 2013; Hayes et al. 2014; Montout et al. 2002; 
Tenback et al. 2012).  
 
There were several limitations specific to the use of EHRs. For example, as a 
secondary dataset, I was not able to insert variables that I may have wanted 
to investigate; rather I had to work with the data that were available. In 
addition, the completion of certain information by clinicians is beyond the 
control of the researchers. Therefore some variables had a large proportion of 
missing values and could not be included in the analysis. Furthermore, in the 
analysis I was unable to account for unmeasured/ unrecorded confounding 
factors.  For example, it is possible that there is a systematic bias in record 
keeping across the EHRs, where oral and depot medication are recorded 
differently. Outpatients receiving a combination of oral and depot medication 
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may not be identified as antipsychotic polypharmacy. Although for depot 
injections the patients are often required to return to the outpatient clinic to 
have it administered, they can obtain repeat prescriptions for oral medications 
by their GP. Therefore, as CRIS reflects secondary care records, I potentially 
may have only been able to detect the administration of depot and therefore 
misclassify the patient as receiving monotherapy.  
 
9.6 Implications  
The results from Chapter 6, 7 and 8 suggest that patients prescribed 
antipsychotic polypharmacy are likely to be already experiencing significant 
burden prior to and as a result of antipsychotic polypharmacy. For example, 
patients initiated on antipsychotic polypharmacy are more likely to be from a 
more deprived area and more specifically homeless (based on area 
socioeconomic deprivation index), to experience significant problems with 
positive clinical symptoms and to have had more previous mental health 
service use. At present there is little evidence to indicate that antipsychotic 
polypharmacy is more effective than monotherapy regimens (Galling et al. 
2017). In fact, the high level of inpatient readmission (Chapter 7) can be 
interpreted as an indicator that polypharmacy is not effective in managing 
mental health symptoms in the community. In addition previous research has 
indicated that antipsychotic polypharmacy is associated with more side 
effects, and side effects of greater severity (Barbui et al. 2016; Gallego et al. 
2012; Correll et al. 2007; Langan & Shajahan 2010) than antipsychotic 
monotherapy; therefore, further contributing to treatment burden experienced 
by this group of patients.  
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My findings that certain patient groups are at an increased risk for long-term 
antipsychotic polypharmacy initiation have important treatment implications. 
For example, clinicians can pay particular attention to factors that are known 
to predict antipsychotic polypharmacy (Chapter 6) earlier on in the treatment 
process, and perhaps employ a broader range of interventions in addition to 
pharmacotherapy, to reduce the risk of antipsychotic polypharmacy 
prescribing in the future. Mace and Taylor (Mace & Taylor 2015) indicated that 
antipsychotic high doses and polypharmacy can be reduced through regular 
patient reviews and collaborative work between clinicians and pharmacists. 
Their quality improvement programme managed to successfully reduce the 
rate of polypharmacy from 57% to 16% in inpatient settings and intensive care 
units. This was clearly a substantial decrease and suggests that even though 
some patients may be more likely to be prescribed polypharmacy, this is not 
necessarily a long-term treatment management strategy and can be 
successfully transitioned to monotherapy.  
 
My findings further indicate that only a third of the patients initiated on 
antipsychotic polypharmacy had previously been trialled on clozapine 
(Chapter 6). This has been previously suggested (Howes et al. 2012; Nielsen 
et al. 2012), and highlights that prescribing guidelines (e.g. that antipsychotic 
polypharmacy should only be considered after trials of two individual agents 
followed by clozapine) are not consistently applied in ‘real-world’ clinical 
practice. However, it is important to note I was unable to establish reasons for 
not prescribing clozapine and therefore it is possible that a proportion of 
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patients could have refused this treatment. In cases where antipsychotic 
polypharmacy has been initiated prior to the clinician considering clozapine 
Barnes and Paton (Barnes & Paton 2011a) have suggested that to modify 
premature polypharmacy prescribing, services may need to implement a 
combination of treatment algorithms, educational outreach, standardised 
assessments of symptoms and adverse effects and examine specific local 
barriers to change.  
 
My findings also have important service implications. The high prevalence of 
hospital readmissions amongst patients discharged on antipsychotic 
polypharmacy supports previous research which has indicated that 
antipsychotic polypharmacy is associated with significantly increased service 
costs due to higher bed occupancy and length of inpatient stay, as well as the 
extra costs associated with multiple medication prescribing (Baandrup et al. 
2012; Gilmer et al. 2007; Valuck et al. 2007). Therefore, reducing 
antipsychotic polypharmacy prescribing may have benefits at both the patient 
and service level.   
 
9.7 Possible mechanisms and future research  
 
9.7.1 Adverse drug reactions   
 
Approximately sixty per cent of the excess mortality in patients with 
schizophrenia is attributed to physical illnesses (Barnes et al. 2007). 
Antipsychotic pharmacotherapy has been associated with a number of 
physical health problems such as weight gain, diabetes, metabolic syndrome, 
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dyslipidaemia and prolonged QT and PR intervals (Auquier et al. 2006; 
Raedler 2010; Suzuki et al. 2014; Pramyothin and Khaodhiar 2010 ). These 
findings are most prominent for atypical antipsychotics. For example, 
olanzapine has been linked to an increased risk for weight gain and 
consequently metabolic problems (Leucht et al. 2009). Although some 
research suggests that this is most evident in young, treatment-naive patients 
(Pramyothin & Khaodhiar 2010), research using such samples is sparse; 
therefore this cannot be supported conclusively (Reynolds & Kirk 2010). 
Clozapine has been associated with diabetes mellitus (Newcomer 2014), 
pulmonary embolism (Hägg et al. 2000) and myocarditis (Killian et al. 1999).  
 
In Chapter 6, I described how antipsychotic polypharmacy prescribing is likely 
to be a by-product of a complex interplay between a number of different 
patient, treatment and contextual factors. It is possible that similarly, the 
relationship between long-term antipsychotic polypharmacy treatment and 
death in patients with SMI is complex and subject to an interplay between a 
number of different factors.  More specifically, it is possible that antipsychotic 
regimens, and more specifically polypharmacy, could increase the risk of 
certain side effects, which in turn can increase the risk of death. However, this 
needs further examination by future research 
 
Research examining the effect of polypharmacy on physical health outcomes 
has been limited. However, there is some evidence to indicate that, for 
example, risperidone and clozapine polypharmacy has been associated with 
elevated prolactin levels (Ganguly et al. 2004; Galling et al. 2016). Combining 
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atypical antipsychotics has also been related to arrhythmia, asthma and 
complicated diabetes (Ganguly et al. 2004), whereas cross-generation 
polypharmacy has been associated with myocardial infarction (Ganguly et al. 
2004). Furthermore, there is evidence which indicates that atypical drugs may 
have an additive side-effect profile (Freudenreich & Goff 2002). For example, 
a Danish longitudinal cohort study (Kessing et al. 2010) found that the 
incidence of diabetes increased with the number of antipsychotics co-
prescribed. However, at present there have been no studies that have 
investigated side effects of long-term antipsychotic polypharmacy and 
mortality; therefore, it is not possible to draw firm conclusions. It is also 
important to bear in mind evidence that does not support the above 
mechanism, indicating that antipsychotic treatment has no direct effect on 
physical health (Brown et al. 2000). Kuo and colleagues (Kuo et al. 2011) 
concluded that patients with SMI have a genetic predisposition for obesity and 
metabolic problems, which precedes the effects of antipsychotic medication. 
Furthermore, Correll and colleagues (Correll et al. 2007) found that 
polypharmacy was not independently correlated with metabolic abnormalities, 
which were instead associated with demographic, clinical and anthropometric 
factors. Therefore, future research should aim to investigate causal pathways 
to mortality, including physical illness and adverse drug reactions in relation to 





9.7.2 Concomitant non-antipsychotic medication use  
 
SMI patients have an increased risk for comorbid diagnoses such as 
substance use, depression and personality disorder (Kreyenbuhl et al. 2007; 
Ganguly et al. 2004). Furthermore, as mentioned earlier in this section, this 
population also has high physical health comorbidities (Auquier et al. 2006; 
Raedler 2010; Suzuki et al. 2014; Pramyothin & Khaodhiar 2010). Therefore it 
is likely that comorbid medication use may have some effect; possibly not so 
much on clinical outcomes such as readmission, but more so on physical 
health outcomes such as mortality.  
 
A large Danish cohort study examining long-term antipsychotic polypharmacy 
and benzodiazepines has indicated that current use of benzodiazepines with 
a long elimination half-life (24hrs or more) is associated with increased risk of 
natural death in patients with schizophrenia (Baandrup et al. 2010). Similarly, 
a large Finnish study (Tiihonen et al. 2012) also indicated that benzodiazepine 
use is associated with all-cause mortality, and for suicidal and non-suicidal 
deaths in this population. Furthermore, the latter study also indicated that the 
concomitant use of antipsychotic polypharmacy with benzodiazepine and 
antidepressants is associated with increased risk for mortality in SMI. There 
has been some further evidence from one large US Medicaid study (Ganguly 
et al. 2004) and a meta-analysis (Gallego et al. 2012) investigating over 147 
studies and over a million participants, that have indicated that mood 
stabilisers such as lithium and antidepressants are both associated with 
antipsychotic polypharmacy prescribing. Finally, the latter two studies have 
also indicated that anticholinergic agents (Gallego et al. 2012) and drugs for 
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physical health problems such as tuberculosis, hyperlipidaemia and cancer 
(Ganguly et al. 2004) are also associated with long-term antipsychotic 
polypharmacy prescribing.  Therefore, it is possible that the other non-
antipsychotic concomitant medication use could have a confounding effect on 
the association between long-term antipsychotic polypharmacy and mortality. 
To better understand the risk of mortality in SMI, we may need to investigate 
medications used for physical illness and other psychotropic medications in 
addition to antipsychotics.    
 
9.7.3 Effects of individual antipsychotics or specific antipsychotic 
combinations    
 
Although in this thesis I did not have the ability to investigate all antipsychotic 
combinations individually, I tested for the effect of specific antipsychotic (e.g. 
clozapine) and/or combinations (e.g. FGAs) where possible (see Chapter 7 
Table 7.4 and Chapter 8 section 8.7). As previously discussed, antipsychotics 
such as clozapine have been associated with reduced hospitalisation and 
mortality, whereas most FGAs, whether as part of polypharmacy or not, have 
been associated with higher risk for mortality (Chapter 7, section 7.2; Chapter 
1 section 1.3). Although evidence on SGAs have been mixed, antipsychotics 
such as olanzapine have also been associated with increased mortality, 
especially from natural causes (e.g. cardiovascular)(see Chapter 1 section 
1.3). As a result, it is possible that specific antipsychotics and/or combinations 
may exhibit different effects on outcomes such as hospital readmission into 
secondary mental health care and mortality. Therefore, future research could 
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focus in more detail on examining common antipsychotic combinations and 
their effect on clinical and health outcomes in the SMI population.   
 
9.8 Conclusions  
The studies described in this thesis are, I believe, some of the first to 
investigate both predictors and outcomes of long-term antipsychotic 
polypharmacy prescribing in secondary mental health care in patients with 
SMI. More specifically, I examined an array of possible predictors (Chapter 6) 
and both clinical and health outcomes (Chapter 7 and 8) extracted from EHRs 
for a large, diverse and representative cohort, thus increasing the 
generalizability of my findings. In addition, I measured and adjusted for a 
multitude of possible confounders, thus reducing residual confounding.  
 
Overall, this thesis provides evidence that EHRs, such as SLAM de-identified 
health records (CRIS), can be successfully used to derive information on long-
term antipsychotic polypharmacy prescribing in secondary mental health care 
with high precision (Chapter 5). My findings further indicated that certain sub-
groups in the SMI population, such as patients who are younger, homeless, 
having significant problems with clinical symptoms, and greater previous 
service use, could be at increased risk of receiving long-term antipsychotic 
polypharmacy treatment. As discussed in section 9.6 of this chapter, these 
findings could have important treatment implications, specifically for 
unwarranted cases of polypharmacy (such as those where clozapine has not 
been previously trialled) by increasing clinicians’ awareness to pre-empt 
antipsychotic polypharmacy prescribing.  
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In addition, my results indicated that patients prescribed long-term 
antipsychotic polypharmacy at discharge were at increased risk for clinical 
outcomes such as hospital readmission into secondary mental health care 
(Chapter 7). Lastly, I found insufficient evidence to indicate that antipsychotic 
polypharmacy prescribing is associated with statistically significant increase in 
the risk for all-cause mortality for patients with SMI (Chapter 8). Overall, it is 
likely that patients prescribed antipsychotic polypharmacy suffer considerable 
burden, whether or not this is directly caused by this regimen. As discussed in 
section 9.6 of this chapter, this has clinical and treatment implications. More 
specifically, although a proportion of these patients under the guidance of 
existing recommendations, would require antipsychotic polypharmacy, the 
justification behind the prescription of this regimen where it is unwarranted, 
needs specific attention. A recent clinical programme in SLAM (Mace & Taylor 
2015) indicated that antipsychotic polypharmacy can be successfully reduced 
by clinicians and pharmacists closely collaborating and reviewing cases of 
polypharmacy. Therefore, similar programmes need to become a priority, in 
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Appendix C was discussed on page 254 under ‘Additional analyses’ in 
Chapter 8. This table examines an alternative reference group for the 
analysis, where first episode of long-term polypharmacy was compared to a 
long-term monotherapy episode that occurred at or after the midpoint of the 




Supplementary Table: Sample characteristics of patients prescribed 
monotherapy and antipsychotic polypharmacy (n=9,085).  
 
 






Total  6561 (72.22) 2,524(27.78) 
Deaths 345  162  
Socio-demographic and 
socioeconomic factors  
  
Age                                               
Mean (SD)  
41.28 (14.93) 38.07 (13.47) 
Gender   
Female 2,873 (43.79) 1,054 (41.76) 
Male 3,688 (56.21) 1,470 (58.24) 
Ethnicity group   
British 2,364 (36.03) 838 (33.20) 
Other White 579 (8.82) 184 (7.29) 
Asian 449 (6.84) 159 (6.30) 
Caribbean 863 (13.15) 354 (14.03) 
Black African  1,798 (27.40) 813 (32.21) 
Other 508 (7.74) 176 (6.97) 
Employment    
Not in paid employment  6,363 (96.98) 2,461 (97.50) 
Paid employment  198 (3.02) 63 (2.50) 
Relationship status    
No relationship 5,607 (85.46) 2,303 (91.24) 
Relationship  954 (14.54) 221 (8.76) 
Deprivation level    
Low level  2,132 (32.65) 805 (32.21) 
Medium level  2,156 (33.02) 808 (32.33) 
High level  2,143 (32.82) 821 (32.85) 
Homelessness 98 (1.50) 65 (2.60) 
Clinical factors    
ICD-10: F20 4,637 (70.68) 1,950 (77.26) 
ICD-10: F25 492 (7.50) 235 (9.31) 
ICD-10: F31 1,432 (21.83) 339 (13.43) 
Comorbid Depression   




Yes 751 (11.45) 379 (15.02) 
Comorbid Substance Use   
Yes 827 (12.60) 272 (10.78) 
Time known to SLAM   
Mean (SD)  1641.46 (1191.24) 2223.98 (1468.95) 
Smoking   




Appendix D was discussed on page 254 under ‘Additional analyses’ in 
Chapter 8. This table examines an alternative reference group for the 
analysis, where first episode of long-term polypharmacy was compared to 
everyone else in the sample who did not qualify for the long-term 
antipsychotic polypharmacy group. This reference group included patients 
who were on long-term monotherapy and all other patients who were known 
to SLAM services for six or more months and that did not qualify for the 
polypharmacy group.   
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Supplementary Table: Sample characteristics of patients prescribed 
antipsychotic polypharmacy and those have not been prescribed 
polypharmacy. (n=16,871) 
 






Number (%) 14,347  2,524 
Deaths 1,434 162  
Socio-demographic and 
socioeconomic factors  
  
Age   Mean (SD)  42.25 (15.95) 38.07 (13.47) 
Gender   
Female 6,738 (46.96) 1,054 (41.76) 
Male 7,609 (53.04) 1,470 (58.24) 
Ethnicity group   
British 5,979 (41.67) 838 (33.20) 
Other White 1,491 (10.39) 184 (7.29) 
Asian 850 (5.92) 159 (6.30) 
Caribbean 1,536 (10.71) 354 (14.03) 
Black African  3,138 (21.87) 813 (32.21) 
Other 1,353 (9.43) 176 (6.97) 
Employment    
Not in paid employment  13,820 (96.33) 2,461 (97.50) 
Paid employment  527 (3.67) 63 (2.50) 
Relationship status    
No relationship 12,170 (84.83) 2,303 (91.24) 
Relationship  2,177 (15.17) 221 (8.76) 
Deprivation level in area of 
residence   
  
Low level  4,639 (32.83) 805 (32.21) 
Medium level  4,649 (32.90) 808 (32.33) 
High level  4,587 (32.46) 821 (32.85) 
Homelessness 257 (1.82) 65 (2.60) 
Clinical factors    
Comorbid Depression   




Yes 1,140 (7.95) 379 (15.02) 
Comorbid Substance Use   
Yes 1,217 (8.48) 272 (10.78) 
Time known to SLAM   
Mean (SD) 1181.26 (1291.13) 2223.98 (1468.95) 
Smoking   
Have smoked ever  7,240 (50.46) 2,150 (85.18) 
